,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,180,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
1,192,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,200,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
3,206,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
4,210,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
5,212,1,1,,75249,5757,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
6,220,1,1,,75249,5757,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
7,228,1,1,,75249,5757,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
8,248,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
9,256,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
10,264,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
11,268,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice,Other,,
12,296,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
13,328,1,1,,75249,5757,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
14,421,1,3,,17389898,5757,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
15,422,1,5,,17405066,5757,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
16,426,1,2,,17389898,5757,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
17,427,1,1,,17389898,5757,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
18,429,1,5,,17405066,5757,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
19,429,1,5,,17405066,5757,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
20,433,1,1,,17389898,5757,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
21,434,1,2,,17389898,5757,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
22,435,1,2,,17389898,5757,Inconclusive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
23,436,2,1,,17405066,5757,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
24,445,3,1,,17389898,5757,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
25,485,1,8,,8139865,5757,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
26,530,1,1,,17389898,5757,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
27,540,1,1,,17389898,5757,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
28,541,1,1,,17389898,5757,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
29,542,1,1,,17389898,5757,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
30,543,1,1,,17389898,5757,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
31,544,2,1,,17389898,5757,Inconclusive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
32,545,1,1,,17389898,5757,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
33,546,1,1,,17389898,5757,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
34,547,1,4,,17405066,5757,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
35,568,1,7,,8139865,5757,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
36,568,1,7,,8139865,5757,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
37,583,2,6,,8139865,5757,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
38,584,1,3,,17389898,5757,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
39,585,1,4,,17389898,5757,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
40,595,1,3,,17389898,5757,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
41,596,1,2,,17389898,5757,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
42,598,1,4,,8139865,5757,Active,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
43,602,1,4,,8139865,5757,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
44,603,1,2,,17389898,5757,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
45,605,1,2,,17389898,5757,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
46,606,1,3,,8139865,5757,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
47,606,1,3,,8139865,5757,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
48,618,2,6,,8139865,5757,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
49,620,2,5,,8139865,5757,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
50,629,1,3,,8139865,5757,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
51,630,1,1,,8139865,5757,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
52,631,1,4,,8139865,5757,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
53,631,1,4,,8139865,5757,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
54,633,1,3,,8139865,5757,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
55,639,1,2,,8139865,5757,Active,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
56,648,1,3,,8139865,5757,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
57,654,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
58,655,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
59,656,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
60,657,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
61,658,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
62,659,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
63,660,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
64,661,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
65,662,1,1,,17389898,5757,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
66,663,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
67,664,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
68,665,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
69,666,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
70,667,1,1,,17389898,5757,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
71,687,1,17,,8139865,5757,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
72,694,1,1,,17405066,5757,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
73,701,1,17,,8139865,5757,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
74,719,1,3,,8139865,5757,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
75,731,1,5,,8139865,5757,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
76,731,1,5,,8139865,5757,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
77,732,1,2,,17405066,5757,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
78,750,1,3,,8139865,5757,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
79,757,1,4,,8139865,5757,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
80,758,1,4,,8139865,5757,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
81,759,1,4,,8139865,5757,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
82,760,1,4,,8139865,5757,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
83,761,1,4,,8139865,5757,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
84,764,1,4,,8139865,5757,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
85,775,1,3,,8139865,5757,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
86,781,1,1,,8139865,5757,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
87,782,1,2,,8139865,5757,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
88,782,1,2,,8139865,5757,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
89,793,1,2,,8139865,5757,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
90,797,1,1,,8139865,5757,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
91,798,2,12,,8139865,5757,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
92,799,1,5,,8139865,5757,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
93,800,2,11,,8139865,5757,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
94,803,1,4,,8139865,5757,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
95,804,1,3,,8139865,5757,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
96,817,1,1,,8139865,5757,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
97,818,1,2,,8139865,5757,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
98,827,1,2,,8139865,5757,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
99,828,1,5,,8139865,5757,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
100,834,1,3,,8139865,5757,Inactive,,,,,C. albicans biofilm killing,Screening,,
101,841,1,1,,8139865,5757,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
102,861,1,1,,8139865,5757,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
103,862,1,2,,8139865,5757,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
104,868,1,3,,8139865,5757,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
105,871,1,2,,8139865,5757,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
106,873,1,13,,8139865,5757,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
107,875,1,2,,17389898,5757,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
108,878,1,2,,8139865,5757,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
109,879,1,2,,17389898,5757,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
110,879,1,2,,17389898,5757,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
111,880,2,1,,8139865,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
112,880,2,1,,8139865,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
113,880,2,1,,17389898,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
114,880,2,1,,17389898,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
115,880,2,1,,26753050,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
116,880,2,1,,26753050,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
117,880,2,1,,26753051,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
118,880,2,1,,26753051,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
119,880,2,1,,29215116,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
120,880,2,1,,29215116,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
121,880,2,1,,50105619,5757,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
122,880,2,1,,50105619,5757,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
123,881,2,2,,17389898,5757,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
124,881,2,2,,29215116,5757,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
125,884,1,2,,17389898,5757,Inactive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
126,885,1,2,,17389898,5757,Inconclusive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
127,886,1,2,,17389898,5757,Inconclusive,122921310.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
128,886,1,2,,17389898,5757,Inconclusive,122921311.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
129,887,1,2,,17389898,5757,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
130,889,1,3,,17389898,5757,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
131,892,1,2,,17389898,5757,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
132,893,1,2,,17389898,5757,Inactive,122921310.0,,19.9526,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
133,893,1,2,,17389898,5757,Inactive,122921311.0,,19.9526,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
134,894,2,1,,8139865,5757,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
135,894,2,1,,17389898,5757,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
136,894,2,1,,29215116,5757,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
137,894,2,1,,50105619,5757,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
138,895,1,2,,17389898,5757,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
139,898,1,1,,8139865,5757,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
140,900,1,3,,17389898,5757,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
141,901,1,2,,17389898,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
142,902,1,2,,17389898,5757,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
143,912,1,2,,17389898,5757,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
144,917,1,3,,17389898,5757,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
145,918,1,3,,17389898,5757,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
146,920,1,2,,8139865,5757,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
147,921,1,2,,17389898,5757,Inconclusive,,,63.0957,Potency,Cell Viability - LYMP2-001,Confirmatory,,
148,923,1,2,,17389898,5757,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
149,924,1,2,,17389898,5757,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
150,925,1,2,,17389898,5757,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
151,926,1,2,,17389898,5757,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
152,927,1,3,,17389898,5757,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
153,928,1,2,,17389898,5757,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
154,932,1,4,,8139865,5757,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
155,938,1,2,,17389898,5757,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
156,940,1,2,,8139865,5757,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
157,940,1,2,,17405066,5757,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
158,943,1,2,,17389898,5757,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
159,944,1,2,,17389898,5757,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
160,945,1,4,,17389898,5757,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
161,946,1,2,,17389898,5757,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
162,947,1,2,,17389898,5757,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
163,948,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
164,950,1,1,,8139865,5757,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
165,951,1,1,,8139865,5757,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
166,952,1,1,,8139865,5757,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
167,954,1,2,,17389898,5757,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
168,955,1,2,,17389898,5757,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
169,957,1,2,,17389898,5757,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
170,958,1,2,,17389898,5757,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
171,959,1,4,,17389898,5757,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
172,960,1,2,,17389898,5757,Inconclusive,,,19.9526,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
173,961,1,2,,17389898,5757,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
174,962,1,2,,17389898,5757,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
175,963,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
176,964,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
177,965,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
178,966,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
179,967,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
180,968,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
181,969,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
182,970,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
183,971,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
184,972,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
185,973,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
186,974,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
187,975,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
188,976,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
189,977,1,2,,17389898,5757,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-002,Confirmatory,,
190,978,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
191,979,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
192,980,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
193,981,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
194,982,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
195,983,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
196,984,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
197,985,1,2,,17389898,5757,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-018,Confirmatory,,
198,986,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
199,987,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
200,988,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
201,989,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
202,992,1,3,,17389898,5757,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
203,993,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
204,994,1,2,,17389898,5757,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
205,995,1,2,,17389898,5757,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
206,997,1,2,,17389898,5757,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
207,998,1,2,,17389898,5757,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
208,1001,2,2,,8139865,5757,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
209,1006,1,6,,8139865,5757,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
210,1007,1,1,,8139865,5757,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
211,1008,1,2,,8139865,5757,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
212,1009,1,2,,8139865,5757,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
213,1012,1,4,,8139865,5757,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
214,1016,1,4,,8139865,5757,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
215,1018,2,5,,8139865,5757,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
216,1019,1,4,,8139865,5757,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
217,1020,1,5,,8139865,5757,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
218,1021,1,1,,8139865,5757,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
219,1022,1,1,,8139865,5757,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
220,1027,1,3,,8139865,5757,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
221,1030,2,1,,8139865,5757,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
222,1030,2,1,,17389898,5757,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
223,1030,2,1,,26753050,5757,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
224,1030,2,1,,26753051,5757,Inconclusive,30582681.0,216.0,37.6505,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
225,1030,2,1,,29215116,5757,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
226,1030,2,1,,50105619,5757,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
227,1032,1,2,,8139865,5757,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
228,1032,1,2,,8139865,5757,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
229,1040,1,2,,8139865,5757,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
230,1046,1,6,,8139865,5757,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
231,1048,1,1,,8139865,5757,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
232,1048,1,1,,8139865,5757,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
233,1049,1,1,,8139865,5757,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
234,1049,1,1,,8139865,5757,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
235,1051,1,1,,8139865,5757,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
236,1051,1,1,,8139865,5757,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
237,1063,1,1,,8139865,5757,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
238,1066,1,2,,8139865,5757,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
239,1085,1,1,,8139865,5757,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
240,1135,1,3,,8139865,5757,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
241,1136,1,3,,8139865,5757,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
242,1189,1,5,,48413728,5757,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
243,1194,1,3,,48413728,5757,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
244,1195,1,2,,48415956,5757,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
245,1199,1,3,,48413728,5757,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
246,1203,1,3,,8139865,5757,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
247,1204,1,2,,48421871,5757,Active,,,,,DSSTox (NCTRER) National Center for Toxicological Research Estrogen Receptor Binding Database,Screening,,
248,1209,2,2,,8139865,5757,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
249,1214,1,4,,8139865,5757,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
250,1216,1,5,,8139865,5757,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
251,1217,1,4,,8139865,5757,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
252,1220,2,2,,8139865,5757,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
253,1222,1,6,,8139865,5757,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
254,1229,1,3,,8139865,5757,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
255,1236,1,1,,8139865,5757,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
256,1239,1,3,,8139865,5757,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
257,1239,1,3,,8139865,5757,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
258,1242,1,1,,8139865,5757,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
259,1251,1,1,,8139865,5757,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
260,1273,1,1,,8139865,5757,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
261,1274,1,2,,8139865,5757,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
262,1276,1,1,,8139865,5757,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
263,1285,1,1,,8139865,5757,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
264,1296,1,1,,8139865,5757,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
265,1304,1,2,,8139865,5757,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
266,1321,1,2,,8139865,5757,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
267,1325,1,2,,8139865,5757,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
268,1326,1,4,,8139865,5757,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
269,1332,1,1,,49698496,5757,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
270,1359,1,4,,8139865,5757,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
271,1362,1,2,,8139865,5757,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
272,1376,1,2,,8139865,5757,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
273,1377,1,1,,8139865,5757,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
274,1379,1,2,,8139865,5757,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
275,1379,1,2,,29215116,5757,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
276,1379,1,2,,50105619,5757,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
277,1381,1,1,,8139865,5757,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
278,1385,2,2,,8139865,5757,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
279,1415,1,2,,8139865,5757,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
280,1415,1,2,,8139865,5757,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
281,1416,1,2,,8139865,5757,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
282,1422,1,1,,8139865,5757,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
283,1422,1,1,,17405066,5757,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
284,1423,1,2,,8139865,5757,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
285,1423,1,2,,8139865,5757,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
286,1424,1,1,,8139865,5757,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
287,1430,1,1,,8139865,5757,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
288,1434,2,3,,8139865,5757,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
289,1434,2,3,,8139865,5757,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
290,1439,1,1,,8139865,5757,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
291,1439,1,1,,8139865,5757,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
292,1440,1,1,,8139865,5757,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
293,1440,1,1,,8139865,5757,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
294,1441,1,1,,8139865,5757,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
295,1441,1,1,,8139865,5757,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
296,1443,1,3,,8139865,5757,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
297,1445,1,1,,8139865,5757,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
298,1446,1,3,,8139865,5757,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
299,1448,1,3,,8139865,5757,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
300,1452,1,1,,8139865,5757,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
301,1452,1,1,,17389898,5757,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
302,1452,1,1,,29215116,5757,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
303,1454,1,1,,50105619,5757,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
304,1456,1,1,,8139865,5757,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
305,1457,1,1,,8139865,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
306,1457,1,1,,17389898,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
307,1457,1,1,,26753050,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
308,1457,1,1,,26753051,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
309,1457,1,1,,29215116,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
310,1457,1,1,,50105619,5757,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
311,1458,1,1,,8139865,5757,Inactive,10937869.0,6607.0,0.7943,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
312,1458,1,1,,17389898,5757,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
313,1458,1,1,,26753050,5757,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
314,1458,1,1,,26753051,5757,Inconclusive,10937869.0,6607.0,0.0014,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
315,1458,1,1,,50105619,5757,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
316,1459,1,1,,50105619,5757,Inconclusive,27436948.0,4000.0,3.5481,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
317,1460,1,3,,8139865,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
318,1460,1,3,,26753050,5757,Inconclusive,92096784.0,4137.0,1.9953,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
319,1460,1,3,,26753051,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
320,1460,1,3,,29215116,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
321,1460,1,3,,50105619,5757,Inconclusive,92096784.0,4137.0,19.9526,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
322,1461,1,2,,8139865,5757,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
323,1461,1,2,,50105619,5757,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
324,1463,1,1,,8139865,5757,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
325,1463,1,1,,26753050,5757,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
326,1463,1,1,,26753051,5757,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
327,1463,1,1,,29215116,5757,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
328,1463,1,1,,50105619,5757,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
329,1465,1,1,,8139865,5757,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
330,1466,1,2,,8139865,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
331,1467,1,3,,29215116,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
332,1467,1,3,,50105619,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
333,1468,1,1,,8139865,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
334,1468,1,1,,26753050,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
335,1468,1,1,,26753051,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
336,1468,1,1,,29215116,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
337,1468,1,1,,50105619,5757,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
338,1469,1,1,,8139865,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
339,1469,1,1,,17389898,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
340,1469,1,1,,26753050,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
341,1469,1,1,,26753051,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
342,1469,1,1,,29215116,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
343,1469,1,1,,29215117,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
344,1469,1,1,,50105619,5757,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
345,1471,2,1,,17389898,5757,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
346,1471,2,1,,26753050,5757,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
347,1471,2,1,,26753051,5757,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
348,1471,2,1,,29215116,5757,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
349,1476,2,1,,8139865,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
350,1476,2,1,,17389898,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
351,1476,2,1,,29215116,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
352,1476,2,1,,50105619,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
353,1477,1,1,,8139865,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
354,1477,1,1,,17389898,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
355,1477,1,1,,26753050,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
356,1477,1,1,,26753051,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
357,1477,1,1,,29215116,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
358,1477,1,1,,29215117,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
359,1477,1,1,,50105619,5757,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
360,1478,2,1,,8139865,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
361,1478,2,1,,17389898,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
362,1478,2,1,,29215116,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
363,1478,2,1,,50105619,5757,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
364,1479,1,2,,8139865,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
365,1479,1,2,,17389898,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
366,1479,1,2,,26753050,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
367,1479,1,2,,26753051,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
368,1479,1,2,,29215116,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
369,1479,1,2,,29215117,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
370,1479,1,2,,50105619,5757,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
371,1481,1,2,,8139865,5757,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
372,1486,1,3,,8139865,5757,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
373,1487,1,1,,8139865,5757,Inconclusive,27436948.0,4000.0,6.3096,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
374,1487,1,1,,29215116,5757,Inconclusive,27436948.0,4000.0,4.4668,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
375,1487,1,1,,50105619,5757,Inconclusive,27436948.0,4000.0,12.5893,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
376,1490,2,1,,8139865,5757,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
377,1490,2,1,,26753050,5757,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
378,1490,2,1,,26753051,5757,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
379,1490,2,1,,29215116,5757,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
380,1490,2,1,,29215117,5757,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
381,1496,1,4,,8139865,5757,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
382,1496,1,4,,8139865,5757,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
383,1509,1,2,,8139865,5757,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
384,1510,1,3,,8139865,5757,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
385,1511,1,3,,8139865,5757,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
386,1515,1,2,,8139865,5757,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
387,1519,1,3,,50105619,5757,Inconclusive,,,1.5849,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
388,1527,1,3,,8139865,5757,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
389,1529,1,1,,8139865,5757,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
390,1530,1,1,,8139865,5757,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
391,1531,1,1,,8139865,5757,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
392,1532,1,1,,8139865,5757,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
393,1554,1,1,,8139865,5757,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
394,1556,1,4,,8139865,5757,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
395,1565,2,2,,8139865,5757,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
396,1566,2,3,,8139865,5757,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
397,1576,1,1,,57244067,5757,Active,,,,,DSSTox (KIERBL) EPA Estrogen Receptor Ki Binding Study (Laws et al.) Database,Other,,
398,1578,3,2,,8139865,5757,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
399,1619,1,2,,8139865,5757,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
400,1621,1,2,,8139865,5757,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
401,1626,1,2,,8139865,5757,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
402,1631,3,1,,8139865,5757,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
403,1634,3,1,,8139865,5757,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
404,1654,2,2,,8139865,5757,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
405,1656,2,2,,8139865,5757,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
406,1662,1,2,,8139865,5757,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
407,1663,1,2,,8139865,5757,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
408,1672,1,3,,8139865,5757,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
409,1688,1,1,,8139865,5757,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
410,1688,1,1,,29215116,5757,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
411,1700,1,2,,8139865,5757,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
412,1705,1,2,,50105619,5757,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
413,1706,1,2,,8139865,5757,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
414,1707,1,3,,50105619,5757,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
415,1708,1,3,,50105619,5757,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
416,1721,1,2,,8139865,5757,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
417,1722,1,2,,8139865,5757,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
418,1766,1,1,,8139865,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
419,1766,1,1,,8139865,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
420,1766,1,1,,29215116,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
421,1766,1,1,,29215116,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
422,1766,1,1,,29215117,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
423,1766,1,1,,29215117,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
424,1766,1,1,,50105619,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
425,1766,1,1,,50105619,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
426,1768,1,1,,8139865,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
427,1768,1,1,,8139865,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
428,1768,1,1,,29215116,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
429,1768,1,1,,29215116,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
430,1768,1,1,,29215117,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
431,1768,1,1,,29215117,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
432,1768,1,1,,50105619,5757,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
433,1768,1,1,,50105619,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
434,1775,1,2,,8139865,5757,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
435,1776,1,2,,8139865,5757,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
436,1777,3,2,,8139865,5757,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
437,1778,3,3,,8139865,5757,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
438,1779,2,2,,8139865,5757,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
439,1789,1,2,,8139865,5757,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
440,1800,1,2,,8139865,5757,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
441,1811,3,2,,46393010,5757,Active,10120873.0,,,,Experimentally measured binding affinity data derived from PDB,Other,,
442,1811,3,2,,46394036,5757,Active,82408297.0,,,,Experimentally measured binding affinity data derived from PDB,Other,16221673.0,
443,1811,3,2,,53812544,5757,Active,10120874.0,,,,Experimentally measured binding affinity data derived from PDB,Other,11278577.0,
444,1813,1,2,,8139865,5757,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
445,1814,1,2,,8139865,5757,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
446,1815,1,1,,50105619,5757,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
447,1816,1,1,,50105619,5757,Inconclusive,,,15.8489,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
448,1817,2,2,,8139865,5757,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
449,1822,1,3,,8139865,5757,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
450,1825,1,1,,8139865,5757,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
451,1828,2,1,,50105619,5757,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
452,1832,2,1,,8139865,5757,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
453,1845,1,2,,8139865,5757,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
454,1850,2,1,,8139865,5757,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
455,1861,2,1,,8139865,5757,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
456,1862,1,4,,8139865,5757,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
457,1863,2,1,,8139865,5757,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
458,1865,1,1,,8139865,5757,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
459,1865,1,1,,26753050,5757,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
460,1865,1,1,,26753051,5757,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
461,1865,1,1,,29215116,5757,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
462,1865,1,1,,50105619,5757,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
463,1867,1,4,,8139865,5757,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
464,1868,1,4,,8139865,5757,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
465,1870,1,4,,8139865,5757,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
466,1873,1,4,,8139865,5757,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
467,1875,2,1,,8139865,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
468,1876,1,1,,50105619,5757,Inconclusive,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
469,1877,1,1,,50105619,5757,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
470,1882,1,1,,50105619,5757,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
471,1883,1,1,,50105619,5757,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
472,1885,2,1,,8139865,5757,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
473,1886,1,1,,50105619,5757,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
474,1887,1,4,,8139865,5757,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
475,1899,1,3,,8139865,5757,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
476,1903,2,3,,8139865,5757,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
477,1906,1,3,,8139865,5757,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
478,1910,1,2,,8139865,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
479,1947,1,2,,8139865,5757,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
480,1948,1,1,,17389898,5757,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
481,1948,1,1,,29215116,5757,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
482,1948,1,1,,50105619,5757,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
483,1950,1,3,,8139865,5757,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
484,1956,1,1,,8139865,5757,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
485,1961,2,2,,8139865,5757,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
486,1962,1,2,,8139865,5757,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
487,1967,1,1,,50105619,5757,Inconclusive,4505907.0,5376.0,67.4555,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
488,1974,1,2,,8139865,5757,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
489,1979,1,1,,8139865,5757,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
490,1984,1,3,,8139865,5757,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
491,1986,1,2,,8139865,5757,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
492,1987,1,2,,8139865,5757,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
493,2006,3,2,,8139865,5757,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
494,2006,3,2,,8139865,5757,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
495,2006,3,2,,8139865,5757,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
496,2012,3,2,,8139865,5757,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
497,2013,2,2,,8139865,5757,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
498,2014,3,2,,8139865,5757,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
499,2016,1,3,,8139865,5757,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
500,2023,1,3,,8139865,5757,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
501,2025,1,3,,8139865,5757,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
502,2029,1,3,,8139865,5757,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
503,2052,2,1,,8139865,5757,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
504,2057,1,2,,8139865,5757,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
505,2058,3,2,,8139865,5757,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
506,2066,1,4,,8139865,5757,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
507,2071,2,2,,8139865,5757,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
508,2073,2,3,,8139865,5757,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
509,2073,2,3,,8139865,5757,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
510,2094,1,2,,8139865,5757,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
511,2094,1,2,,8139865,5757,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
512,2094,1,2,,8139865,5757,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
513,2097,1,2,,8139865,5757,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
514,2098,1,1,,8139865,5757,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
515,2099,1,1,,8139865,5757,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
516,2100,1,1,,8139865,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
517,2101,1,1,,8139865,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
518,2101,1,1,,17389898,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
519,2101,1,1,,26753050,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
520,2101,1,1,,26753051,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
521,2101,1,1,,29215116,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
522,2101,1,1,,29215117,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
523,2101,1,1,,50105619,5757,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
524,2107,1,1,,8139865,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
525,2107,1,1,,17389898,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
526,2107,1,1,,26753050,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
527,2107,1,1,,26753051,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
528,2107,1,1,,29215116,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
529,2107,1,1,,29215117,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
530,2107,1,1,,50105619,5757,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
531,2112,1,1,,8139865,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
532,2112,1,1,,17389898,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
533,2112,1,1,,26753050,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
534,2112,1,1,,26753051,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
535,2112,1,1,,29215116,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
536,2112,1,1,,29215117,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
537,2112,1,1,,50105619,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
538,2120,1,1,,17389898,5757,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
539,2129,1,2,,8139865,5757,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
540,2130,1,3,,8139865,5757,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
541,2147,1,1,,8139865,5757,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
542,2147,1,1,,50105619,5757,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
543,2156,2,2,,8139865,5757,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
544,2174,1,3,,8139865,5757,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
545,2177,1,3,,8139865,5757,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
546,2205,1,1,,8139865,5757,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
547,2216,1,3,,8139865,5757,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
548,2221,1,2,,8139865,5757,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
549,2227,1,2,,8139865,5757,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
550,2234,1,2,,8139865,5757,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
551,2235,1,2,,8139865,5757,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
552,2237,1,2,,8139865,5757,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
553,2239,1,2,,8139865,5757,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
554,2240,1,1,,85788274,5757,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
555,2241,1,1,,85788274,5757,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
556,2242,1,1,,8139865,5757,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
557,2247,1,2,,8139865,5757,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
558,2275,1,1,,85788274,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
559,2280,2,3,,8139865,5757,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
560,2288,1,1,,8139865,5757,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
561,2289,1,1,,8139865,5757,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
562,2300,1,3,,8139865,5757,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
563,2313,1,1,,85788274,5757,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
564,2314,1,2,,8139865,5757,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
565,2314,1,2,,8139865,5757,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
566,2314,1,2,,29215116,5757,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
567,2314,1,2,,29215116,5757,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
568,2314,1,2,,29215117,5757,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
569,2314,1,2,,29215117,5757,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
570,2315,1,2,,8139865,5757,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
571,2315,1,2,,8139865,5757,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
572,2315,1,2,,29215116,5757,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
573,2315,1,2,,29215116,5757,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
574,2315,1,2,,29215117,5757,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
575,2315,1,2,,29215117,5757,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
576,2322,1,1,,85788274,5757,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
577,2323,1,1,,50105619,5757,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
578,2326,1,1,,8139865,5757,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
579,2326,1,1,,50105619,5757,Inactive,194352380.0,,7.9433,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
580,2330,1,1,,85788274,5757,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
581,2353,1,3,,50105619,5757,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
582,2364,1,2,,50105619,5757,Inconclusive,4557365.0,641.0,0.0224,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
583,2380,1,2,,8139865,5757,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
584,2391,1,1,,8139865,5757,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
585,2417,1,1,,8139865,5757,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
586,2435,1,2,,8139865,5757,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
587,2441,1,1,,50105619,5757,Active,,,10.0,Potency,Cell cycle validation with wells to cells screening paradigm,Confirmatory,,
588,2445,1,2,,8139865,5757,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
589,2451,1,2,,8139865,5757,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
590,2451,1,2,,29215116,5757,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
591,2451,1,2,,29215117,5757,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
592,2451,1,2,,50105619,5757,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
593,2462,1,1,,8139865,5757,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
594,2462,1,1,,8139865,5757,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
595,2472,1,2,,8139865,5757,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
596,2472,1,2,,29215116,5757,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
597,2472,1,2,,29215117,5757,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
598,2517,2,1,,8139865,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
599,2517,2,1,,17389898,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
600,2517,2,1,,26753050,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
601,2517,2,1,,26753051,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
602,2517,2,1,,29215117,5757,Inactive,6980812.0,,0.0032,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
603,2517,2,1,,50105619,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
604,2517,2,1,,144204699,5757,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
605,2520,1,4,,8139865,5757,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
606,2521,1,3,,8139865,5757,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
607,2523,1,1,,8139865,5757,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
608,2524,1,2,,8139865,5757,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
609,2528,1,2,,8139865,5757,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
610,2528,1,2,,29215116,5757,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
611,2528,1,2,,29215117,5757,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
612,2528,1,2,,50105619,5757,Inconclusive,4557365.0,641.0,0.0224,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
613,2540,1,2,,8139865,5757,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
614,2544,1,2,,8139865,5757,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
615,2546,1,1,,8139865,5757,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
616,2546,1,1,,17389898,5757,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
617,2546,1,1,,29215116,5757,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
618,2546,1,1,,29215117,5757,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
619,2549,1,1,,8139865,5757,Active,282403581.0,,31.6228,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
620,2549,1,1,,17389898,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
621,2549,1,1,,26753050,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
622,2549,1,1,,26753051,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
623,2549,1,1,,29215116,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
624,2549,1,1,,29215117,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
625,2549,1,1,,50105619,5757,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
626,2550,1,3,,8139865,5757,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
627,2551,1,1,,8139865,5757,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
628,2551,1,1,,17389898,5757,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
629,2551,1,1,,29215116,5757,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
630,2551,1,1,,29215117,5757,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
631,2553,1,2,,8139865,5757,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
632,2557,1,3,,8139865,5757,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
633,2563,1,1,,8139865,5757,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
634,2599,1,2,,8139865,5757,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
635,2606,1,2,,8139865,5757,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
636,2629,1,1,,8139865,5757,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
637,2629,1,1,,56422158,5757,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
638,2642,1,2,,8139865,5757,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
639,2648,1,2,,8139865,5757,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
640,2650,2,1,,8139865,5757,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
641,2660,1,1,,90341590,5757,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
642,2661,1,1,,8139865,5757,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
643,2662,2,1,,8139865,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
644,2662,2,1,,29215116,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
645,2662,2,1,,50105619,5757,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
646,2666,1,1,,90341590,5757,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
647,2667,1,1,,90341590,5757,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
648,2668,1,1,,90341590,5757,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
649,2674,1,1,,8139865,5757,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
650,2675,1,1,,8139865,5757,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
651,2675,1,1,,50105619,5757,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
652,2676,1,2,,8139865,5757,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
653,2685,1,1,,8139865,5757,Inconclusive,,,20.5962,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
654,2690,1,2,,8139865,5757,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
655,2706,1,1,,8139865,5757,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
656,2716,1,1,,8139865,5757,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
657,2716,1,1,,56422158,5757,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
658,2717,1,2,,8139865,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
659,2718,1,1,,8139865,5757,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
660,2732,1,1,,8139865,5757,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
661,2732,1,1,,17405066,5757,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
662,2751,2,2,,8139865,5757,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
663,2774,1,3,,92303967,5757,Inactive,,,,,LOPAC Circadian Assay,Screening,,
664,2796,1,4,,8139865,5757,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
665,2797,1,2,,8139865,5757,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
666,2805,2,2,,8139865,5757,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
667,2806,2,2,,8139865,5757,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
668,2825,1,2,,8139865,5757,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
669,7783,3,4,,103189263,5757,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
670,8002,5,2,,103189263,5757,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
671,15714,3,4,,103189263,5757,Unspecified,,,,,CLog P was determined,Other,12565971.0,
672,19262,5,1,,103189263,5757,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
673,19424,3,4,,103189263,5757,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
674,19427,3,3,,103189263,5757,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
675,22293,4,4,,103189263,5757,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
676,24236,3,3,,103189263,5757,Unspecified,,,,,Partition coefficient (logP),Other,7684451.0,
677,26304,4,4,,103189263,5757,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
678,26380,3,3,,103189263,5757,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
679,27580,3,3,,103189263,5757,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
680,28233,3,3,,103189263,5757,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
681,28235,3,3,,103189263,5757,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
682,28236,3,3,,103189263,5757,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
683,29360,4,3,,103189263,5757,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
684,29421,3,3,,103189263,5757,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
685,29423,3,4,,103189263,5757,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
686,29811,4,3,,103189263,5757,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
687,29925,5,2,,103189263,5757,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
688,35536,3,10,,103189263,5757,Unspecified,120044.0,24177.0,,,"Binding affinity against Alphafetoprotein (AFP), in rodents.",Other,1701833.0,
689,35537,3,10,,103189263,5757,Unspecified,120044.0,24177.0,,,Relative binding affinity for Alphafetoprotein,Other,7684451.0,
690,39012,8,8,,103189263,5757,Inconclusive,1018618719.0,367.0,,,Binding affinity for human Androgen receptor; ND = Not determined,Other,8627601.0,
691,39320,4,7,,103189263,5757,Unspecified,,,,,Relative binding affinity for androgen receptor of prostate of rat at 2 hr,Other,2897467.0,
692,39451,4,8,,103189263,5757,Unspecified,,,,,Binding affinity against cytosolic androgen receptor from ventral prostate of rats using [3H]MIB competitive binding assay (relative to dihydro testosterone),Other,15239655.0,
693,42279,5,2,,103189263,5757,Inconclusive,,,,,Inhibition of proliferation of BT-20 cells in presence of 10e-5 TPE concentration; nm = not measuable,Other,2769681.0,
694,42280,3,4,,103189263,5757,Unspecified,,,,,Percent of inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.,Other,2769681.0,
695,42634,3,4,,103189263,5757,Unspecified,,,,,Percent of compound bound to bone mineral hydroxylapatite was determined in vivo,Other,,
696,45078,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent change in 17-beta-estradiol mediated transcriptional activation in CHO cells expressing human estrogen receptor alpha at 10e-7 M,Other,12877579.0,
697,51048,3,7,,103189263,5757,Unspecified,,,,,In silico binding affinity to human corticosteriod binding globulin,Other,9379435.0,
698,51049,3,7,,103189263,5757,Unspecified,,,,,Binding affinity against corticosteroid-binding globulin,Other,8474098.0,
699,51052,3,7,,103189263,5757,Unspecified,,,,,In silico binding affinity to corticosteroid binding globulin (CBG),Other,9435904.0,
700,51054,3,7,,103189263,5757,Unspecified,,,,,Binding affinity for corticosteroid binding globulin is expressed as log(1/k),Other,8667357.0,
701,51055,4,1,,103189263,5757,Active,,,10.0,Ki,Binding affinity to human CBG receptor (corticosteroid-binding globulins),Confirmatory,15139751.0,
702,51056,3,7,,103189263,5757,Unspecified,,,,,Binding affinity to the corticosteroid-binding globulin (CBG) receptor.,Other,10966742.0,
703,51058,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards corticosteroid-binding globulin (CBG),Other,12672239.0,
704,51061,3,8,,103189263,5757,Unspecified,,,,,Compound was tested for Corticosteroid binding globulin affinity,Other,9651159.0,
705,51062,3,8,,103189263,5757,Unspecified,,,,,In silico steroid binding affinity to transport protein corticosteroid binding globulin,Other,8057280.0,
706,68711,9,5,,103189263,5757,Active,544257.0,2099.0,0.0009960000000000001,EC50,Affinity for estrogen receptor,Confirmatory,8627615.0,
707,68711,9,5,,103189263,5757,Active,6166154.0,2100.0,0.0009960000000000001,EC50,Affinity for estrogen receptor,Confirmatory,8627615.0,
708,68712,10,5,,103189263,5757,Active,544257.0,2099.0,0.0038,EC50,Affinity estrogen receptor of MCF-7 human mammary cancer cells,Confirmatory,8627615.0,
709,68712,10,5,,103189263,5757,Active,6166154.0,2100.0,0.0038,EC50,Affinity estrogen receptor of MCF-7 human mammary cancer cells,Confirmatory,8627615.0,
710,68714,9,5,,103189263,5757,Active,544257.0,2099.0,0.00018,EC50,Affinity for estrogen receptor of human MCF-7 cells,Confirmatory,9371241.0,
711,68714,9,5,,103189263,5757,Active,6166154.0,2100.0,0.00018,EC50,Affinity for estrogen receptor of human MCF-7 cells,Confirmatory,9371241.0,
712,68744,9,2,,103189263,5757,Active,,,0.0016,IC50,"Binding affinity for estrogen receptor, by competition with [3H]estradiol",Confirmatory,8784443.0,
713,68749,9,5,,103189263,5757,Active,544257.0,2099.0,0.003,IC50,Displacement of [3H]-estradiol from estrogen receptor (ER),Confirmatory,2909731.0,
714,68749,9,5,,103189263,5757,Active,6166154.0,2100.0,0.003,IC50,Displacement of [3H]-estradiol from estrogen receptor (ER),Confirmatory,2909731.0,
715,68750,7,5,,103189263,5757,Active,544257.0,2099.0,0.003,IC50,Displacement of [3H]estradiol from Estrogen receptor in MCF-7 cells,Confirmatory,1548683.0,
716,68750,7,5,,103189263,5757,Active,6166154.0,2100.0,0.003,IC50,Displacement of [3H]estradiol from Estrogen receptor in MCF-7 cells,Confirmatory,1548683.0,
717,68899,3,8,,103189263,5757,Unspecified,,,,,Estrogen receptor (ER) binding affinity,Other,9357533.0,
718,68900,7,5,,103189263,5757,Active,544257.0,2099.0,0.00037999999999999997,Ki,Binding affinity for human estrogen receptor,Confirmatory,8627601.0,
719,68900,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00037999999999999997,Ki,Binding affinity for human estrogen receptor,Confirmatory,8627601.0,
720,68905,7,5,,103189263,5757,Active,544257.0,2099.0,0.000113,Ki,Apparent inhibition constant for estrogen receptor in Human Breast cancer cytosol in 2.5%DMF,Confirmatory,9216828.0,
721,68905,7,5,,103189263,5757,Active,6166154.0,2100.0,0.000113,Ki,Apparent inhibition constant for estrogen receptor in Human Breast cancer cytosol in 2.5%DMF,Confirmatory,9216828.0,
722,68906,7,5,,103189263,5757,Active,544257.0,2099.0,0.000138,Ki,Inhibition of estradiol binding to estrogen receptor in Human Breast cancer cytosol (3.3% ethanol),Confirmatory,9216828.0,
723,68906,7,5,,103189263,5757,Active,6166154.0,2100.0,0.000138,Ki,Inhibition of estradiol binding to estrogen receptor in Human Breast cancer cytosol (3.3% ethanol),Confirmatory,9216828.0,
724,68908,7,5,,103189263,5757,Active,544257.0,2099.0,0.000181,Ki,Apparent inhibition constant for estrogen receptor in Human uterine cytosol in 2.5%DMF,Confirmatory,9216828.0,
725,68908,7,5,,103189263,5757,Active,6166154.0,2100.0,0.000181,Ki,Apparent inhibition constant for estrogen receptor in Human uterine cytosol in 2.5%DMF,Confirmatory,9216828.0,
726,68909,7,5,,103189263,5757,Active,544257.0,2099.0,0.00011999999999999999,Ki,Apparent inhibition constant for estrogen receptor in Human uterine cytosol in 3.3%ethanol,Confirmatory,9216828.0,
727,68909,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00011999999999999999,Ki,Apparent inhibition constant for estrogen receptor in Human uterine cytosol in 3.3%ethanol,Confirmatory,9216828.0,
728,68913,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative affinity constant for cytosolic estrogen receptor,Other,9216841.0,
729,68913,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative affinity constant for cytosolic estrogen receptor,Other,9216841.0,
730,69055,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Displacement of [3H]17-beta-estradiol from estrogen receptor of MCF-7 cell lysates relative to 17-beta-estradiol,Other,10098655.0,
731,69055,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Displacement of [3H]17-beta-estradiol from estrogen receptor of MCF-7 cell lysates relative to 17-beta-estradiol,Other,10098655.0,
732,69056,3,7,,103189263,5757,Unspecified,,,,,In vitro relative binding affinity by competition with [3H]17-beta-estradiol for estrogen receptor in MCF-7 cell lysate,Other,9003514.0,
733,69058,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent relative binding affinity (RBA) for estrogen receptor compared to estradiol,Other,8201601.0,
734,69058,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Percent relative binding affinity (RBA) for estrogen receptor compared to estradiol,Other,8201601.0,
735,69059,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity (RBA) for the estrogen receptor,Other,9371241.0,
736,69059,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity (RBA) for the estrogen receptor,Other,9371241.0,
737,69060,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for estrogen receptor compared to estradiol,Other,8627615.0,
738,69060,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for estrogen receptor compared to estradiol,Other,8627615.0,
739,69061,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for MCF-7 human breast cancer cell lysates compared to estradiol by displacement of [3H]-estradiol,Other,,
740,69061,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for MCF-7 human breast cancer cell lysates compared to estradiol by displacement of [3H]-estradiol,Other,,
741,69063,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity(RBA) of estradiol with respect to compound (using estrogen receptor preparations),Other,8627615.0,
742,69063,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity(RBA) of estradiol with respect to compound (using estrogen receptor preparations),Other,8627615.0,
743,69067,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 2.5%DMF compared to estradiol,Other,9216828.0,
744,69067,4,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 2.5%DMF compared to estradiol,Other,9216828.0,
745,69068,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative affinity for estrogen receptor of Human Breast cancer or normal uterine cytosol (3.3%ethanol) compared to estradiol,Other,9216828.0,
746,69068,4,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative affinity for estrogen receptor of Human Breast cancer or normal uterine cytosol (3.3%ethanol) compared to estradiol,Other,9216828.0,
747,69070,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 3.3%ethanol compared to estradiol,Other,9216828.0,
748,69070,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 3.3%ethanol compared to estradiol,Other,9216828.0,
749,69072,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 2.5%DMF compared to estradiol,Other,9216828.0,
750,69072,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative Binding Affinity for estrogen receptor in Human Breast cancer or normal uterine cytosol in 2.5%DMF compared to estradiol,Other,9216828.0,
751,69074,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells compared to estradiol,Other,8627615.0,
752,69074,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells compared to estradiol,Other,8627615.0,
753,69075,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Binding affinity for Estrogen receptor in MCF-Cells relative to estradiol,Other,1548683.0,
754,69075,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Binding affinity for Estrogen receptor in MCF-Cells relative to estradiol,Other,1548683.0,
755,69077,3,8,,103189263,5757,Unspecified,,,,,Affinity against estrogen receptor in MCF-7 cell lysate by competitive displacement of [3H]estradiol,Other,,
756,69081,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for estrogen receptor in MCF-7 cell cytosol extract,Other,8164266.0,
757,69081,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for estrogen receptor in MCF-7 cell cytosol extract,Other,8164266.0,
758,69086,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Binding affinity for lamb uterine estrogen receptor,Other,10395487.0,
759,69086,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Binding affinity for lamb uterine estrogen receptor,Other,10395487.0,
760,69224,3,7,,103189263,5757,Unspecified,,,,,Relative binding affinity ( relative to estradiol) to mouse estrogen receptor.,Other,9632359.0,
761,69237,4,11,,103189263,5757,Unspecified,119599.0,13982.0,,,Binding affinity for mouse uterine cytosol estrogen receptor,Other,,
762,69237,4,11,,103189263,5757,Unspecified,380865470.0,13983.0,,,Binding affinity for mouse uterine cytosol estrogen receptor,Other,,
763,69238,6,4,,103189263,5757,Unspecified,,,,,Displacement of [3H]estradiol from estrogen receptor in immature rabbit,Other,2738897.0,
764,69240,7,2,,103189263,5757,Active,,,0.0005,IC50,Displacement of [3H]17-beta-estradiol from Estrogen receptor of rabbit uterine tissue,Confirmatory,11738564.0,
765,69241,7,2,,103189263,5757,Active,,,0.0007,IC50,Inhibitory activity against Estrogen receptor by displacement of [3H]17-beta-estradiol in ER-rich cytosol from rabbit uterine tissue,Confirmatory,11055361.0,
766,69242,7,2,,103189263,5757,Active,,,0.0007,IC50,Binding affinity for estrogen receptor of rabbit uterine skeletal muscle tissue,Confirmatory,10714509.0,
767,69243,3,9,,103189263,5757,Unspecified,,,,,Relative binding affinity for rabbit uterine estrogen receptor compared to estradiol,Other,15203171.0,
768,69364,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Percent affinity for estrogen receptor binding relative to d-estradiol,Other,8126710.0,
769,69364,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Percent affinity for estrogen receptor binding relative to d-estradiol,Other,8126710.0,
770,69367,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Non specific binding to estrogen receptor in rat uterine cytosol using unlabeled ligand,Other,3385736.0,
771,69367,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Non specific binding to estrogen receptor in rat uterine cytosol using unlabeled ligand,Other,3385736.0,
772,69369,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Specific binding to estrogen receptor in rat uterine cytosol using [3H]estradiol,Other,3385736.0,
773,69369,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Specific binding to estrogen receptor in rat uterine cytosol using [3H]estradiol,Other,3385736.0,
774,69371,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for estrogen receptor in rat uterine cytosol extract,Other,8164266.0,
775,69371,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for estrogen receptor in rat uterine cytosol extract,Other,8164266.0,
776,69375,6,8,,103189263,5757,Unspecified,119600.0,24890.0,,,Displacement of [3H]-estradiol from estrogen receptor in mature rat,Other,2738897.0,
777,69375,6,8,,103189263,5757,Unspecified,6166156.0,25149.0,,,Displacement of [3H]-estradiol from estrogen receptor in mature rat,Other,2738897.0,
778,69377,7,5,,103189263,5757,Active,119600.0,24890.0,0.0057,EC50,In vitro displacement of [3H]estradiol from estrogen receptor of rat uterine cystol,Confirmatory,3385736.0,
779,69377,7,5,,103189263,5757,Active,6166156.0,25149.0,0.0057,EC50,In vitro displacement of [3H]estradiol from estrogen receptor of rat uterine cystol,Confirmatory,3385736.0,
780,69381,4,6,,103189263,5757,Unspecified,,,,,Compound was evaluated in vivo for estrogenic receptor potency relative to ethynylestradiol in rat.,Other,2738897.0,
781,69382,7,5,,103189263,5757,Active,119600.0,24890.0,0.0018,IC50,Displacement of [3H]- Estradiol from Estrogen receptor of rat uterine cytosol,Confirmatory,8941399.0,
782,69382,7,5,,103189263,5757,Active,6166156.0,25149.0,0.0018,IC50,Displacement of [3H]- Estradiol from Estrogen receptor of rat uterine cytosol,Confirmatory,8941399.0,
783,69383,7,5,,103189263,5757,Active,119600.0,24890.0,0.000354,IC50,Inhibition of estradiol binding to estrogen receptor,Confirmatory,9685230.0,
784,69383,7,5,,103189263,5757,Active,6166156.0,25149.0,0.000354,IC50,Inhibition of estradiol binding to estrogen receptor,Confirmatory,9685230.0,
785,69389,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Nonspecific binding affinity (NSB) for estrogen receptor,Other,7684451.0,
786,69389,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Nonspecific binding affinity (NSB) for estrogen receptor,Other,7684451.0,
787,69390,3,7,,103189263,5757,Unspecified,,,,,Binding affinity against estrogen receptor was determined by using [3H]estradiol as radioligand in competitive radiometric binding assay,Other,9873709.0,
788,69391,3,7,,103189263,5757,Unspecified,,,,,Binding affinity against estrogen receptor was determined by using [3H]estradiol as radioligand in competitive radiometric binding assay,Other,9873709.0,
789,69393,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Binding affinity against estrogen receptor at 0C,Other,1701833.0,
790,69393,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Binding affinity against estrogen receptor at 0C,Other,1701833.0,
791,69395,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Binding affinity against estrogen receptor at 25 degree C,Other,1701833.0,
792,69395,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Binding affinity against estrogen receptor at 25 degree C,Other,1701833.0,
793,69511,3,7,,103189263,5757,Unspecified,,,,,Relative binding affinity (RBA) towards estrogen receptor.,Other,7990116.0,
794,69518,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,In vitro relative binding affinity for estrogen receptor in rat uterine cytosol by displacement of [3H]estradiol,Other,3385736.0,
795,69518,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,In vitro relative binding affinity for estrogen receptor in rat uterine cytosol by displacement of [3H]estradiol,Other,3385736.0,
796,69536,4,6,,103189263,5757,Unspecified,,,,,Relative binding affinity evaluated from the ability to displace [3H]estradiol from estrogen receptor in rat uterine cytosol preparation.,Other,1995907.0,
797,69538,4,8,,103189263,5757,Unspecified,,,,,Relative binding affinity for uterine cytosol 17-beta-estradiol receptor obtained from immature Charles Foster rats,Other,6834394.0,
798,69541,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity against Estrogen receptor as inhibition of [3H]estradiol binding in rat uterus,Other,6891404.0,
799,69541,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity against Estrogen receptor as inhibition of [3H]estradiol binding in rat uterus,Other,6891404.0,
800,69542,3,8,,103189263,5757,Unspecified,,,,,Relative binding affinity against estrogen receptor of rat uterine tissue was determined relative to estradiol,Other,,
801,69543,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for estrogen receptor from immature rat uterus,Other,2033587.0,
802,69543,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for estrogen receptor from immature rat uterus,Other,2033587.0,
803,69672,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for rat uterine estrogen receptor at 0C,Other,2258901.0,
804,69672,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for rat uterine estrogen receptor at 0C,Other,2258901.0,
805,69673,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for rat uterine estrogen receptor at 25 degree C,Other,2258901.0,
806,69673,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for rat uterine estrogen receptor at 25 degree C,Other,2258901.0,
807,69675,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for estrogen receptor(ER),Other,2258906.0,
808,69675,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for estrogen receptor(ER),Other,2258906.0,
809,69676,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for estrogen receptor at 0C,Other,7684451.0,
810,69676,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for estrogen receptor at 0C,Other,7684451.0,
811,69677,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for estrogen receptor at 25 degree C,Other,7684451.0,
812,69677,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for estrogen receptor at 25 degree C,Other,7684451.0,
813,69682,3,7,,103189263,5757,Unspecified,,,,,Binding affinity against Estrogen receptor with relative to E2,Other,12723952.0,
814,69684,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Binding affinity for rat uterine estrogen receptor,Other,,
815,69684,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Binding affinity for rat uterine estrogen receptor,Other,,
816,69689,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative affinity constant for lamb cytosolic estrogen receptor binding compared to [3H]estradiol,Other,7608900.0,
817,69689,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative affinity constant for lamb cytosolic estrogen receptor binding compared to [3H]estradiol,Other,7608900.0,
818,69690,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,"Relative affinity constant for [3H]-estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 20 hr at 20 degree C",Other,8411015.0,
819,69690,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,"Relative affinity constant for [3H]-estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 20 hr at 20 degree C",Other,8411015.0,
820,69691,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,"Relative affinity constant for [3H]estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 28 hr at 0C",Other,8411015.0,
821,69691,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,"Relative affinity constant for [3H]estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 28 hr at 0C",Other,8411015.0,
822,69692,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,"Relative affinity constant for [3H]estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 4 hr at 0C",Other,8411015.0,
823,69692,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,"Relative affinity constant for [3H]estradiol binding to cytosol (2 mg protein/mL, pH 7.0) after 4 hr at 0C",Other,8411015.0,
824,69701,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Association constant for estrogen receptor,Other,8254621.0,
825,69701,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Association constant for estrogen receptor,Other,8254621.0,
826,69703,4,3,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for sheep uterine estrogen receptor by displacement of [3H]estradiol,Other,11708930.0,
827,69703,4,3,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for sheep uterine estrogen receptor by displacement of [3H]estradiol,Other,11708930.0,
828,69704,3,12,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for sheep uterine estrogen receptor relative to estradiol as Ka(compound)/Ka(estradiol) x 100,Other,6251218.0,
829,69704,3,12,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for sheep uterine estrogen receptor relative to estradiol as Ka(compound)/Ka(estradiol) x 100,Other,6251218.0,
830,69705,4,9,,103189263,5757,Unspecified,1706709.0,443228.0,,,"Binding affinity towards uterine estrogen receptor relative to that of estradiol expressed by RAC x 100, which is the ratio of association constants (Ka compound/Ka estradiol) x 100.",Other,7411555.0,
831,69705,4,9,,103189263,5757,Unspecified,13124234.0,443066.0,,,"Binding affinity towards uterine estrogen receptor relative to that of estradiol expressed by RAC x 100, which is the ratio of association constants (Ka compound/Ka estradiol) x 100.",Other,7411555.0,
832,69706,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 0 degree Celsius relative to estradiol,Other,7629815.0,
833,69706,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 0 degree Celsius relative to estradiol,Other,7629815.0,
834,69834,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 25 degree Celsius relative to estradiol,Other,7629815.0,
835,69834,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 25 degree Celsius relative to estradiol,Other,7629815.0,
836,69838,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for estrogen receptor in lamb uterus cytosol relative to estradiol,Other,9089332.0,
837,69838,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for estrogen receptor in lamb uterus cytosol relative to estradiol,Other,9089332.0,
838,69839,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for lamb uterine estrogen receptor by displacement of [3H]estradiol,Other,8254621.0,
839,69839,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for lamb uterine estrogen receptor by displacement of [3H]estradiol,Other,8254621.0,
840,69840,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.,Other,7853335.0,
841,69840,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.,Other,7853335.0,
842,69841,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.,Other,7853335.0,
843,69841,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.,Other,7853335.0,
844,69844,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for estrogen receptor of lamb uterus at 0C,Other,2258901.0,
845,69844,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for estrogen receptor of lamb uterus at 0C,Other,2258901.0,
846,69846,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity for lamb uterine estrogen receptor relative to 17-beta-estradiol,Other,9934476.0,
847,69846,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative binding affinity for lamb uterine estrogen receptor relative to 17-beta-estradiol,Other,9934476.0,
848,69850,3,9,,103189263,5757,Unspecified,,,,,Binding affinity against estrogen receptor relative to [3H]estradiol,Other,,
849,69854,7,2,,103189263,5757,Active,,,0.001,EC50,Displacement of [3H]estradiol from estrogen receptor-ligand binding domain,Confirmatory,10476873.0,
850,69855,3,8,,103189263,5757,Unspecified,,,,,Relative binding affinity for estrogen receptor compared to estradiol,Other,10328289.0,
851,69857,3,8,,103189263,5757,Unspecified,,,,,Percent relative binding affinity for estrogen receptor ligand binding domain expressed in BL21 cells at 2C,Other,12825929.0,
852,69858,3,8,,103189263,5757,Unspecified,,,,,Percent relative binding affinity for estrogen receptor ligand binding domain expressed in BL21 cells at 25 degree C,Other,12825929.0,
853,69859,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Binding of [3H]E2 alkyl ester to human estrogen receptor alpha ligand binding domain expressed in Escherichia coli,Other,12723952.0,
854,69870,8,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity for human estrogen receptor alpha,Confirmatory,12954056.0,
855,69872,8,5,,103189263,5757,Active,544257.0,2099.0,0.1,Ki,Binding affinity for human estrogen receptor alpha by displacement of [3H]estradiol,Confirmatory,12954056.0,
856,70017,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Binding of [3H]E2 alkyl ester to human estrogen receptor beta ligand binding domain expressed in Escherichia coli,Other,12723952.0,
857,70020,5,6,,103189263,5757,Active,6166154.0,2100.0,0.0008,EC50,Agonist effect on transcriptional activation of T47D cells expressing human estrogen receptor beta,Confirmatory,12459017.0,
858,70021,7,2,,103189263,5757,Active,,,3.9e-05,EC50,Transcriptional potency (EC50) at Human estrogen receptor Beta,Confirmatory,11708925.0,
859,70026,3,11,,103189263,5757,Inactive,6166154.0,2100.0,,,In vitro inhibition of 1 nM 17-beta-estradiol induced transcriptional activation in T47D cells expressing estrogen receptor beta; Inactive at 10e-4 M,Other,12459017.0,
860,70031,7,2,,103189263,5757,Active,,,0.024,IC50,Inhibitory concentration against estrogen receptor 2 using radioligand binding assay.,Confirmatory,12825935.0,
861,70034,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity for human estrogen receptor beta,Confirmatory,12954056.0,
862,70035,5,3,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for human estrogen receptor beta by displacement of [3H]estradiol,Other,11708930.0,
863,70037,8,5,,103189263,5757,Active,6166154.0,2100.0,0.1,Ki,Relative binding affinity for human estrogen receptor beta compared to [3H]-estradiol,Confirmatory,12954056.0,
864,70166,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Inhibition of estrogen receptor beta mediated transcriptional activation; Not determined,Other,12825935.0,
865,70170,4,7,,103189263,5757,Unspecified,,,,,Relative binding affinity (RBA) at human estrogen receptor beta (radiometric binding assay with [3H]estradiol using full-length human ER Beta),Other,11708925.0,
866,70174,4,7,,103189263,5757,Unspecified,,,,,Relative estrogenic potency at Human estrogen receptor Beta (EC50 (Estradiol) / EC50 (ligand)),Other,11708925.0,
867,70175,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Percent of maximal transcriptional activation in T47D cells expressing estrogen receptor beta compared to 17-beta-estradiol,Other,12459017.0,
868,70179,4,6,,103189263,5757,Unspecified,,,,,ChEMBL 67344,Other,12459017.0,
869,70185,4,8,,103189263,5757,Active,,,0.00047999999999999996,EC50,Ability to activate estrogen receptor 1-mediated transcription.,Confirmatory,15081034.0,
870,70186,7,1,,103189263,5757,Active,,,2e-05,EC50,Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.,Confirmatory,11906280.0,
871,70188,6,6,,103189263,5757,Active,544257.0,2099.0,7.000000000000001e-06,EC50,Agonist effect on transcriptional activation in MCF-7 cells expressing estrogen receptor alpha,Confirmatory,10673099.0,
872,70190,5,6,,103189263,5757,Active,544257.0,2099.0,7e-05,EC50,Agonist effect on transcriptional activation in T47D cells expressing estrogen receptor alpha,Confirmatory,12459017.0,
873,70191,7,2,,103189263,5757,Active,,,0.024,EC50,Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor alpha.,Confirmatory,11906280.0,
874,70192,8,1,,103189263,5757,Active,,,0.0073,ED50,Affinity of compound towards human estrogen receptor alpha,Confirmatory,14584960.0,
875,70194,5,3,,103189263,5757,Active,544257.0,2099.0,4.56e-06,ED50,Functional ERalpha receptor activity in transcriptional activation assay in MCF-7 cells,Confirmatory,12824043.0,
876,70195,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Fold selectivity for estrogen receptor alpha,Other,12824043.0,
877,70197,3,12,,103189263,5757,Inactive,544257.0,2099.0,,,In vitro inhibition of 1 nM 17-beta-estradiol induced transcriptional activation in T47D cells expressing estrogen receptor alpha; Inactive at 10e-4 M,Other,12459017.0,
878,70199,7,2,,103189263,5757,Active,,,0.0013,IC50,Binding affinity against human estrogen receptor alpha in competitive binding assay,Confirmatory,15006374.0,
879,70200,7,2,,103189263,5757,Active,,,0.011000000000000001,IC50,Binding affinity towards estrogen receptor alpha by [3H]17-beta-estradiol displacement.,Confirmatory,15081034.0,
880,70202,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity for human estrogen receptor alpha,Confirmatory,15203155.0,
881,70203,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity for human estrogen receptor alpha,Confirmatory,15203156.0,
882,70319,7,2,,103189263,5757,Active,,,0.0032,IC50,Binding affinity towards human estrogen receptor alpha(ERalpha),Confirmatory,12824043.0,
883,70320,7,2,,103189263,5757,Active,,,0.0013,IC50,Binding affinity towards human recombinant Estrogen receptor alpha was determined,Confirmatory,15084115.0,
884,70321,8,5,,103189263,5757,Active,544257.0,2099.0,0.003,IC50,Displacement of [3H]17-beta-estradiol from human Estrogen receptor alpha,Confirmatory,10673099.0,
885,70325,8,7,,103189263,5757,Inactive,544257.0,2099.0,,,Antagonist effect on transcriptional activation in MCF-7 cells expressing estrogen receptor alpha; Not active means no effect at < 1000 nM,Other,10673099.0,
886,70330,8,5,,103189263,5757,Active,544257.0,2099.0,0.002,IC50,In vitro binding affinity for estrogen receptor alpha,Confirmatory,12749898.0,
887,70337,7,5,,103189263,5757,Active,544257.0,2099.0,0.0015,IC50,Inhibition of [3H]E2 binding to estrogen receptor alpha in MCF-7 cell lysate,Confirmatory,14971899.0,
888,70337,7,5,,103189263,5757,Active,6166154.0,2100.0,0.0015,IC50,Inhibition of [3H]E2 binding to estrogen receptor alpha in MCF-7 cell lysate,Confirmatory,14971899.0,
889,70339,7,2,,103189263,5757,Active,,,0.027999999999999997,IC50,Inhibitory concentration against estrogen receptor alpha using radioligand binding assay.,Confirmatory,12825935.0,
890,70341,8,5,,103189263,5757,Active,544257.0,2099.0,0.0059,IC50,Displacement of [3H]17-beta-estradiol from human estrogen receptor alpha,Confirmatory,10447957.0,
891,70345,7,2,,103189263,5757,Active,,,0.0022,Ki,Ability to displace [3H]17-beta-estradiol from Estrogen receptor alpha by scintillation proximity assay.,Confirmatory,11459665.0,
892,70481,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Inhibition of estrogen receptor alpha mediated transcriptional activation; Not determined,Other,12825935.0,
893,70486,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for human Estrogen receptor alpha compared to estradiol (E2),Other,11392537.0,
894,70489,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity ratio for binding to estrogen receptor alpha compared to estrogen receptor beta,Other,12749898.0,
895,70489,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity ratio for binding to estrogen receptor alpha compared to estrogen receptor beta,Other,12749898.0,
896,70490,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Binding affinity for human Estrogen receptor alpha,Other,10395487.0,
897,70491,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent of maximal transcriptional activation in T47D cells expressing estrogen receptor alpha compared to 17-beta-estradiol,Other,12459017.0,
898,70498,4,1,,103189263,5757,Inconclusive,,,,,Irreversible inhibition of [3H]estradiol binding to Estrogen receptor alpha; '-' indicates decrease in estradiol binding,Other,10691688.0,
899,70499,7,3,,103189263,5757,Active,,,0.0034,IC50,Displacement of radioligand from Estrogen receptor alpha,Confirmatory,11965371.0,
900,70502,3,9,,103189263,5757,Unspecified,,,,,Binding affinity against estrogen receptor alpha relative to E2,Other,15177442.0,
901,70504,4,7,,103189263,5757,Active,,,0.00067,EC50,Ability to activate estrogen receptor 2-mediated transcription.,Confirmatory,15081034.0,
902,70505,7,1,,103189263,5757,Active,,,7e-05,EC50,Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.,Confirmatory,11906280.0,
903,70506,5,6,,103189263,5757,Active,6166154.0,2100.0,0.0001,EC50,Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta,Confirmatory,11906280.0,
904,70507,7,2,,103189263,5757,Active,,,0.024,EC50,Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor beta.,Confirmatory,11906280.0,
905,70508,8,1,,103189263,5757,Active,,,0.011000000000000001,ED50,Affinity of compound towards human estrogen receptor beta,Confirmatory,14584960.0,
906,70510,5,3,,103189263,5757,Active,6166154.0,2100.0,0.0047,ED50,Functional Estrogen receptor beta activity by metallothionein induction in SAOS-2 cells,Confirmatory,12824043.0,
907,70511,3,8,,103189263,5757,Unspecified,,,,,Fold selectivity for estrogen receptor beta(ERbeta),Other,12824043.0,
908,70514,7,2,,103189263,5757,Active,,,0.0011,IC50,Binding affinity against human estrogen receptor beta (ER beta) in competitive binding assay,Confirmatory,15006374.0,
909,70515,7,2,,103189263,5757,Active,,,0.019,IC50,Binding affinity towards estrogen receptor beta by [3H]17-beta-estradiol displacement.,Confirmatory,15081034.0,
910,70516,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding affinity for human estrogen receptor beta,Confirmatory,15203155.0,
911,70517,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding affinity for human estrogen receptor beta,Confirmatory,15203156.0,
912,70520,7,2,,103189263,5757,Active,,,0.0036,IC50,Binding affinity towards human estrogen receptor beta (ERbeta),Confirmatory,12824043.0,
913,70644,7,2,,103189263,5757,Active,,,0.0011,IC50,Binding affinity towards human recombinant Estrogen receptor beta was determined,Confirmatory,15084115.0,
914,70645,8,5,,103189263,5757,Active,6166154.0,2100.0,0.004,IC50,Displacement of [3H]17-beta-estradiol from human Estrogen receptor beta,Confirmatory,10673099.0,
915,70650,8,5,,103189263,5757,Active,6166154.0,2100.0,0.002,IC50,In vitro binding affinity for estrogen receptor beta,Confirmatory,12749898.0,
916,70656,7,2,,103189263,5757,Active,,,0.0035,Ki,Ability to displace [3H]17-beta-estradiol from Estrogen receptor beta by scintillation proximity assay.,Confirmatory,11459665.0,
917,70665,4,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for human Estrogen receptor beta compared to estradiol (E2),Other,11392537.0,
918,70666,4,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Binding affinity for human ER(estrogen receptor)beta,Other,10395487.0,
919,70667,3,7,,103189263,5757,Unspecified,,,,,Relative binding affinity calculated as the ratio of molar concentration of Estrogen receptor beta and the triarylpropenones (TAP's) required to decrease [3H]E2 binding by 50%.,Other,3981542.0,
920,70670,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity(RBA) for Estrogen receptor,Other,3373496.0,
921,70670,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity(RBA) for Estrogen receptor,Other,3373496.0,
922,70672,7,2,,103189263,5757,Active,,,0.002,IC50,Binding to Estrogen receptor- alpha (ER alpha) receptor,Confirmatory,12270167.0,
923,70673,7,2,,103189263,5757,Active,,,0.002,IC50,Binding to Estrogen receptor- beta (ER beta) receptor,Confirmatory,12270167.0,
924,70820,7,1,,103189263,5757,Unspecified,,,84.0,IC50,Estrone sulfatase activity against homogenized human JEG-3 cells was determined by measuring the [3H]E1 obtained from [3H]E1S,Confirmatory,9873454.0,
925,70969,4,8,,103189263,5757,Unspecified,,,,,Tested by protection experiments to demonstrate the inactivation of estradiol dehydrogenase and the kinetic parameter Kapp was reported at a concentration of 20 uM,Other,2391679.0,
926,70975,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity(RBA) as displacement of [3H]17-beta-estradiol from MCF-7 cell lysate,Other,11495597.0,
927,70975,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity(RBA) as displacement of [3H]17-beta-estradiol from MCF-7 cell lysate,Other,11495597.0,
928,70981,6,4,,103189263,5757,Unspecified,,,,,Displacement of [3H]estradiol from estrogen receptor in squirrel monkey,Other,2738897.0,
929,70983,3,11,,103189263,5757,Unspecified,13124247.0,281146.0,,,Relative binding affinity for estrogen receptor by displacement of [3H]estradiol,Other,6323712.0,
930,70983,3,11,,103189263,5757,Unspecified,55584164.0,407238.0,,,Relative binding affinity for estrogen receptor by displacement of [3H]estradiol,Other,6323712.0,
931,70988,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards calf uterine estrogen receptor using [3H]17-beta-estradiol as radioligand,Other,2066987.0,
932,71121,3,11,,103189263,5757,Unspecified,13124247.0,281146.0,,,Relative binding affinity (RBA) to Estrogen receptor of calf uterine cytosol,Other,12139447.0,
933,71121,3,11,,103189263,5757,Unspecified,55584164.0,407238.0,,,Relative binding affinity (RBA) to Estrogen receptor of calf uterine cytosol,Other,12139447.0,
934,71132,3,11,,103189263,5757,Unspecified,13124247.0,281146.0,,,Relative binding affinity was measured on calf uterus estrogen receptor after 5 hr at 25C.,Other,1738150.0,
935,71132,3,11,,103189263,5757,Unspecified,55584164.0,407238.0,,,Relative binding affinity was measured on calf uterus estrogen receptor after 5 hr at 25C.,Other,1738150.0,
936,71133,3,7,,103189263,5757,Unspecified,,,,,"Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 2 hours at 0 degree Centigrade.",Other,2769681.0,
937,71134,3,7,,103189263,5757,Unspecified,,,,,"Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 5 hours at 25 degree Centigrade.",Other,2769681.0,
938,74221,8,8,,103189263,5757,Inconclusive,121069.0,2908.0,,,Binding affinity for human glucocorticoid receptor(hGR); ND = Not determined,Other,8627601.0,
939,74373,4,6,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr,Other,2897467.0,
940,74374,4,6,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr,Other,2897467.0,
941,74375,4,6,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr,Other,2897467.0,
942,74376,4,6,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr,Other,2897467.0,
943,74377,4,7,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr,Other,2897467.0,
944,74378,4,7,,103189263,5757,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr,Other,2897467.0,
945,82021,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Transcriptional activation in human endometrial carcinoma (HEC-1) cells expressing estrogen receptor alpha in presence of 1 nM estradiol,Other,11392537.0,
946,82026,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Transcriptional activation in human endometrial carcinoma (HEC-1) cells expressing estrogen receptor beta in presence of 1 nM estradiol,Other,11392537.0,
947,91474,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Stimulatory activity against estrogen-dependent alkaline phosphatase expression in Ishikawa cells relative to E2,Other,12723952.0,
948,91474,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Stimulatory activity against estrogen-dependent alkaline phosphatase expression in Ishikawa cells relative to E2,Other,12723952.0,
949,91481,4,7,,103189263,5757,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
950,91597,4,4,,103189263,5757,Active,,,1e-05,EC50,Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells,Confirmatory,8201587.0,
951,91598,3,4,,103189263,5757,Unspecified,,,,,Maximum stimulation of alkaline phosphatase activity expressed as a percent of the maximum induced by 10 nM estradiol,Other,8201587.0,
952,101590,4,4,,103189263,5757,Inconclusive,,,,IC50,Inhibition of MCF-7 cancer cell proliferation; ND=No data,Confirmatory,15203155.0,
953,101591,8,2,,103189263,5757,Inconclusive,,,,,Inhibition of MCF-7 cancer cell proliferation; ND=No data,Other,15203156.0,
954,101600,6,2,,103189263,5757,Active,,,32.0,IC50,Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay,Confirmatory,12565971.0,
955,101612,4,4,,103189263,5757,Active,,,0.00032,IC50,Effect on estradiol-stimulated MCF-7 cell proliferation,Confirmatory,8941399.0,
956,101784,3,8,,103189263,5757,Unspecified,,,,,Displacement of tritiated [3H]raloxifene binding in MCF-7 cell lysate,Other,,
957,101818,6,2,,103189263,5757,Unspecified,,,100.0,IC50,Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay,Confirmatory,12565971.0,
958,101914,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Induction of pS2 gene expression in human MCF-7 cells,Other,9371241.0,
959,101914,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Induction of pS2 gene expression in human MCF-7 cells,Other,9371241.0,
960,102407,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells compared to estradiol,Other,12749898.0,
961,102407,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells compared to estradiol,Other,12749898.0,
962,102435,4,4,,103189263,5757,Active,,,2e-05,EC50,Effective dose for [3H]- estradiol against proliferation of MCF-7 cells,Confirmatory,2769681.0,
963,102436,4,12,,103189263,5757,Active,544257.0,2099.0,1e-05,EC50,Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells,Confirmatory,12749898.0,
964,102436,4,12,,103189263,5757,Active,6166154.0,2100.0,1e-05,EC50,Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells,Confirmatory,12749898.0,
965,102449,5,2,,103189263,5757,Inconclusive,,,,,Inhibition of proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]- estradiol (E2); nm = not measuable,Other,2769681.0,
966,102585,8,8,,103189263,5757,Inactive,544257.0,2099.0,,,Antagonist effect as inhibition of estrogen stimulated MCF-7 cell proliferation; Inactive,Other,,
967,102585,8,8,,103189263,5757,Inactive,6166154.0,2100.0,,,Antagonist effect as inhibition of estrogen stimulated MCF-7 cell proliferation; Inactive,Other,,
968,102598,4,12,,103189263,5757,Active,544257.0,2099.0,1e-05,IC50,In vitro inhibition of estrogen-stimulated MCF-7 cell proliferation,Confirmatory,10098655.0,
969,102598,4,12,,103189263,5757,Active,6166154.0,2100.0,1e-05,IC50,In vitro inhibition of estrogen-stimulated MCF-7 cell proliferation,Confirmatory,10098655.0,
970,102623,3,5,,103189263,5757,Unspecified,,,,,Percent of inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]estradiol (E2).,Other,2769681.0,
971,102624,3,5,,103189263,5757,Unspecified,,,,,Percent of inhibitory activity versus 0.1 nm [3H]estradiol against proliferation of MCF-7 cells.,Other,2769681.0,
972,102626,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximal effective dose for 50% inhibition of estrogen stimulated MCF-7 cell proliferation,Other,,
973,102626,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximal effective dose for 50% inhibition of estrogen stimulated MCF-7 cell proliferation,Other,,
974,102627,3,4,,103189263,5757,Unspecified,,,,,Stimulation of MCF-7 cell proliferation at 10 nM,Other,14584960.0,
975,102629,5,2,,103189263,5757,Inconclusive,,,,,Stimulation of MCF-7 cell proliferation at 100 nM; not tested,Other,14584960.0,
976,102631,5,2,,103189263,5757,Inconclusive,,,,,Stimulation of MCF-7 cell proliferation at 1000 nM; not tested,Other,14584960.0,
977,102768,3,5,,103189263,5757,Unspecified,,,,,Percent of effective dose for [3H]estradiol against proliferation of MCF-7 cells.,Other,2769681.0,
978,103074,7,6,,103189263,5757,Active,544257.0,2099.0,0.00049,EC50,Agonist activity in transcriptional activation assay in MCF-7-2a cells compared to estradiol E2,Confirmatory,12139447.0,
979,103075,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent relative activation of luciferase expression in MCF-7-2a cells at a concentration of 1 uM,Other,12139447.0,
980,103077,7,1,,103189263,5757,Active,544257.0,2099.0,8e-05,EC50,Concentration required to activate luciferase expression in MCF-7-2a cells,Confirmatory,14761193.0,
981,103078,3,8,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative transcriptional potency required to activate luciferase expression in MCF-7-2a cells relative to estradiol (E2),Other,14761193.0,
982,103079,3,8,,103189263,5757,Unspecified,544257.0,2099.0,,,Activation of luciferase expression in MCF-7-2a cells relative to estradiol (E2),Other,14761193.0,
983,103375,10,1,,103189263,5757,Active,,,1e-05,EC50,Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.,Confirmatory,12825935.0,
984,103378,3,5,,103189263,5757,Unspecified,,,,,Inhibition of MCF-7 breast tumor cell proliferation; Not determined,Other,12825935.0,
985,103380,3,5,,103189263,5757,Unspecified,,,,,Percent agonistic activity in MCF-7 breast tumor cells using MCF-7 assay,Other,12825935.0,
986,103384,3,5,,103189263,5757,Inactive,,,,,Inhibition of 17-beta-estradiol induced MCF-7 cell proliferation; NA=not active,Other,11495597.0,
987,103550,4,3,,103189263,5757,Inactive,,,,,Inhibition of MCF-7 cell proliferation stimulated by 10e-12 M estradiol: Not active,Other,,
988,103551,6,8,,103189263,5757,Active,544257.0,2099.0,3.01e-05,EC50,Induction of pS2 Gene expression in human MCF-7 cells,Confirmatory,9371241.0,
989,103551,6,8,,103189263,5757,Active,6166154.0,2100.0,3.01e-05,EC50,Induction of pS2 Gene expression in human MCF-7 cells,Confirmatory,9371241.0,
990,103552,6,8,,103189263,5757,Active,544257.0,2099.0,9.96e-05,EC50,Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells,Confirmatory,8627615.0,
991,103552,6,8,,103189263,5757,Active,6166154.0,2100.0,9.96e-05,EC50,Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells,Confirmatory,8627615.0,
992,103553,5,9,,103189263,5757,Active,544257.0,2099.0,0.000292,EC50,Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells,Confirmatory,8627615.0,
993,103553,5,9,,103189263,5757,Active,6166154.0,2100.0,0.000292,EC50,Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells,Confirmatory,8627615.0,
994,103554,6,2,,103189263,5757,Active,,,1.52e-06,EC50,Growth response in cultures of MCF-7 (human breast cancer cell line) cells,Confirmatory,9357533.0,
995,103555,4,4,,103189263,5757,Active,,,0.0007,EC50,Stimulation of MCF-7 cell proliferation,Confirmatory,8941399.0,
996,103600,3,4,,103189263,5757,Unspecified,,,,,Agonistic activity in MCF-7 cell proliferation.,Other,1738150.0,
997,103753,3,4,,103189263,5757,Unspecified,,,,,Inhibition of MCF-7 cell proliferation at 5 uM,Other,2909731.0,
998,103754,3,5,,103189263,5757,Unspecified,,,,,Cytostatic activity against MCF-7 cell proliferation.,Other,1738150.0,
999,103889,8,2,,103189263,5757,Inactive,,,,,Inhibition of MCF-7 cell proliferation stimulated by 10e-11 M 17-beta-estradiol; Not active at the doses tested,Other,9003514.0,
1000,105943,3,8,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogenicity of compound for maximal induction of MVLN cell luciferase activity in the absence of E2 (estradiol).,Other,9089332.0,
1001,105943,3,8,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogenicity of compound for maximal induction of MVLN cell luciferase activity in the absence of E2 (estradiol).,Other,9089332.0,
1002,110097,3,11,,103189263,5757,Inactive,119599.0,13982.0,,,Anti-uterotropic effect as inhibition of 0.06 ug/injection estrone-induced uterine weight gain in mice at 10 ug/injection dose; No,Other,,
1003,110097,3,11,,103189263,5757,Inactive,380865470.0,13983.0,,,Anti-uterotropic effect as inhibition of 0.06 ug/injection estrone-induced uterine weight gain in mice at 10 ug/injection dose; No,Other,,
1004,124015,3,11,,103189263,5757,Active,119599.0,13982.0,,,Uterotrophic effect in mice at 10 ug/injection dose; Yes,Other,,
1005,124015,3,11,,103189263,5757,Active,380865470.0,13983.0,,,Uterotrophic effect in mice at 10 ug/injection dose; Yes,Other,,
1006,126435,4,7,,103189263,5757,Unspecified,,,,,Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr,Other,2897467.0,
1007,127349,3,3,,103189263,5757,Inactive,,,,,Binding affinity against human monoclonal antibody (mAb)-11E6,Other,12109909.0,
1008,127350,3,3,,103189263,5757,Inactive,,,,,Binding affinity against human monoclonal antibody (mAb)-1B3,Other,12109909.0,
1009,127351,3,3,,103189263,5757,Inactive,,,,,Binding affinity against human monoclonal antibody (mAb)-5C2,Other,12109909.0,
1010,127352,3,3,,103189263,5757,Inactive,,,,,Binding affinity against human monoclonal antibody (mAb)-7F2,Other,12109909.0,
1011,135326,5,2,,103189263,5757,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
1012,140821,4,7,,103189263,5757,Unspecified,,,,,In vivo uterotrophic activity (uterine weight) in immature mice.,Other,3981542.0,
1013,162274,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,"Estrogen-related induction of progesterone receptor expression in MCF-7 cells, control without estrogen",Other,3172132.0,
1014,162274,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,"Estrogen-related induction of progesterone receptor expression in MCF-7 cells, control without estrogen",Other,3172132.0,
1015,162275,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-10 M,Other,3172132.0,
1016,162275,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-10 M,Other,3172132.0,
1017,162276,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-11 M,Other,3172132.0,
1018,162276,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-11 M,Other,3172132.0,
1019,162278,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-7 M,Other,3172132.0,
1020,162278,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-7 M,Other,3172132.0,
1021,162279,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-8 M,Other,3172132.0,
1022,162279,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-8 M,Other,3172132.0,
1023,162280,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-9 M,Other,3172132.0,
1024,162280,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Estrogen-related induction of progesterone receptor expression in MCF-7 cells at 10e-9 M,Other,3172132.0,
1025,162590,8,8,,103189263,5757,Inconclusive,90110048.0,5241.0,,,Binding affinity for human Progesterone receptor A isoform; ND = Not determined,Other,8627601.0,
1026,162613,4,8,,103189263,5757,Unspecified,,,,,Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr,Other,2897467.0,
1027,164970,3,12,,103189263,5757,Unspecified,125552.0,24680.0,,,The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+],Other,1738150.0,
1028,164970,3,12,,103189263,5757,Unspecified,54037692.0,24681.0,,,The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+],Other,1738150.0,
1029,164970,3,12,,103189263,5757,Unspecified,55977078.0,25023.0,,,The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+],Other,1738150.0,
1030,164971,4,9,,103189263,5757,Unspecified,125552.0,24680.0,,,Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].,Other,1738150.0,
1031,164971,4,9,,103189263,5757,Unspecified,54037692.0,24681.0,,,Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].,Other,1738150.0,
1032,164971,4,9,,103189263,5757,Unspecified,55977078.0,25023.0,,,Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].,Other,1738150.0,
1033,164972,3,5,,103189263,5757,Unspecified,,,,,Percent stimulation or inhibition of protein kinase C III activity for protamine sulfate in the presence of EGTA.,Other,1738150.0,
1034,168222,3,4,,103189263,5757,Unspecified,,,,,Activity of alkaline phosphatase (ALP) tested in serum of rat when 18 ug/kg of compound was administered intramuscularly,Other,12467635.0,
1035,169006,3,3,,103189263,5757,Unspecified,,,,,Compound was tested in male rats for its effect on the seminal vesicle weight,Other,7990122.0,
1036,169651,3,3,,103189263,5757,Unspecified,,,,,Compound is tested in male rats for its effect on the pituitary weight,Other,7990122.0,
1037,169652,3,4,,103189263,5757,Unspecified,,,,,Compound is tested in male rats for its effect on the prostate weight,Other,7990122.0,
1038,170307,3,9,,103189263,5757,Inconclusive,,,,,Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing serum cholesterol levels as end points: significant decrease at dose <10 mg/kg,Other,,
1039,170313,3,11,,103189263,5757,Inconclusive,119600.0,24890.0,,,Effect on uterine eosinophil peroxidase activity as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at 0.1 mg/kg dose,Other,,
1040,170313,3,11,,103189263,5757,Inconclusive,6166156.0,25149.0,,,Effect on uterine eosinophil peroxidase activity as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at 0.1 mg/kg dose,Other,,
1041,170315,3,11,,103189263,5757,Inconclusive,119600.0,24890.0,,,Effect on uterine weight as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at <=10 mg/kg dose,Other,,
1042,170315,3,11,,103189263,5757,Inconclusive,6166156.0,25149.0,,,Effect on uterine weight as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at <=10 mg/kg dose,Other,,
1043,171525,6,1,,103189263,5757,Unspecified,,,,,Activity tested for the content of calcium in serum of rat when 18 ug/kg of compound was administered intramuscularly when compared to prednisone,Other,12467635.0,
1044,171531,3,4,,103189263,5757,Unspecified,,,,,Percentage content of calcium in femur tested in the compound using male ICR rats when compared to vehicle,Other,12467635.0,
1045,171777,3,7,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic activity in rats,Other,3373496.0,
1046,171777,3,7,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic activity in rats,Other,3373496.0,
1047,172456,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,In vivo estrogenic activity in immature rat uterine weight assay at 2 mg/kg subcutaneous dose,Other,15006374.0,
1048,172456,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,In vivo estrogenic activity in immature rat uterine weight assay at 2 mg/kg subcutaneous dose,Other,15006374.0,
1049,172991,4,3,,103189263,5757,Unspecified,,,,,In vivo for antifertility potency in rat at 200 ug/Kg/day,Other,2738897.0,
1050,173467,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in rats,Other,15203155.0,
1051,173467,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in rats,Other,15203155.0,
1052,173468,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 0 ug subcutaneous dose,Other,3746826.0,
1053,173468,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 0 ug subcutaneous dose,Other,3746826.0,
1054,173469,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 0.05 ug subcutaneous dose,Other,3746826.0,
1055,173469,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 0.05 ug subcutaneous dose,Other,3746826.0,
1056,173470,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 0.1 ug subcutaneous dose,Other,3746826.0,
1057,173470,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 0.1 ug subcutaneous dose,Other,3746826.0,
1058,173471,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 0.2 ug subcutaneous dose,Other,3746826.0,
1059,173471,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 0.2 ug subcutaneous dose,Other,3746826.0,
1060,173472,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 0.5 ug subcutaneous dose,Other,3746826.0,
1061,173472,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 0.5 ug subcutaneous dose,Other,3746826.0,
1062,173473,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as percent of control at 1 ug subcutaneous dose,Other,3746826.0,
1063,173473,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as percent of control at 1 ug subcutaneous dose,Other,3746826.0,
1064,173735,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic potency in rats by subcutaneous dose,Other,2795603.0,
1065,173735,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic potency in rats by subcutaneous dose,Other,2795603.0,
1066,174673,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of LH 12 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1067,174674,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of LH 18 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1068,174675,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of LH 24 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1069,174676,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of estradiol 12 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1070,174677,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of estradiol 18 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1071,174678,3,3,,103189263,5757,Unspecified,,,,,Serum concentration of estradiol 24 days after intravenous administration in Orchidectomized rats,Other,3531516.0,
1072,175659,6,8,,103189263,5757,Unspecified,119600.0,24890.0,,,Displacement of [3H]estradiol from estrogen receptor in immature rat,Other,2738897.0,
1073,175659,6,8,,103189263,5757,Unspecified,6166156.0,25149.0,,,Displacement of [3H]estradiol from estrogen receptor in immature rat,Other,2738897.0,
1074,179333,3,7,,103189263,5757,Unspecified,119600.0,24890.0,,,Percent uterotrophic effect at 0.2 ug/day dose compared to estradiol,Other,2995668.0,
1075,179333,3,7,,103189263,5757,Unspecified,6166156.0,25149.0,,,Percent uterotrophic effect at 0.2 ug/day dose compared to estradiol,Other,2995668.0,
1076,179651,3,8,,103189263,5757,Unspecified,,,,,Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing serum cholesterol levels as end points,Other,,
1077,179988,6,1,,103189263,5757,Unspecified,,,,,In vivo prevention of bone loss in ovariectomised rats on oral administration,Other,9685230.0,
1078,179989,6,1,,103189263,5757,Unspecified,,,,,In vivo prevention of reduced serum cholesterol in ovariectomised rats on oral administration,Other,9685230.0,
1079,180230,3,8,,103189263,5757,Unspecified,119600.0,24890.0,,,Compound was evaluated in immature rats as assessed by uterine weight gain (subcutaneously),Other,6834394.0,
1080,180230,3,8,,103189263,5757,Unspecified,6166156.0,25149.0,,,Compound was evaluated in immature rats as assessed by uterine weight gain (subcutaneously),Other,6834394.0,
1081,183574,6,8,,103189263,5757,Inconclusive,119600.0,24890.0,,,"Inhibition of estradiol (0.004 mpk, sc) induced uterine growth in rats at 1 mg/kg/day subcutaneous dose for 3 days; ND=No data",Other,15203155.0,
1082,183574,6,8,,103189263,5757,Inconclusive,6166156.0,25149.0,,,"Inhibition of estradiol (0.004 mpk, sc) induced uterine growth in rats at 1 mg/kg/day subcutaneous dose for 3 days; ND=No data",Other,15203155.0,
1083,184497,3,3,,103189263,5757,Unspecified,,,,,Antiimplantation activity as minimum effective dose after subcutaneous administration.,Other,3373496.0,
1084,186064,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats at 0.2 ug/day dose,Other,2995668.0,
1085,186064,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats at 0.2 ug/day dose,Other,2995668.0,
1086,186404,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity as mean uterine weight in rats after 1 ug dose,Other,2258906.0,
1087,186404,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity as mean uterine weight in rats after 1 ug dose,Other,2258906.0,
1088,186920,3,3,,103189263,5757,Unspecified,,,,,The compound was tested for uterotropic activity in immature rats(Dosage 0.1 ug),Other,6431104.0,
1089,187204,3,4,,103189263,5757,Unspecified,,,,,Percentage content of phosphor in femur tested in the compound using male ICR rats,Other,12467635.0,
1090,187626,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative uterotrophic activity in immature female Sprague-Dawley rats,Other,8126710.0,
1091,187626,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative uterotrophic activity in immature female Sprague-Dawley rats,Other,8126710.0,
1092,187645,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in immature female Sprague-Dawley rats,Other,,
1093,187645,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in immature female Sprague-Dawley rats,Other,,
1094,189169,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for uterine cytosolic estrogen receptors of immature rats,Other,3746826.0,
1095,189169,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for uterine cytosolic estrogen receptors of immature rats,Other,3746826.0,
1096,191533,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,In vivo anti-uterotrophic effect in 0.2 ug estradiol benzoate stimulated immature rats,Other,3385723.0,
1097,191533,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,In vivo anti-uterotrophic effect in 0.2 ug estradiol benzoate stimulated immature rats,Other,3385723.0,
1098,191540,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 0.04 ug/day dose,Other,2995668.0,
1099,191540,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 0.04 ug/day dose,Other,2995668.0,
1100,191541,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 0.08 ug/day dose,Other,2995668.0,
1101,191541,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 0.08 ug/day dose,Other,2995668.0,
1102,191671,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 0.1 ug/day dose,Other,2995668.0,
1103,191671,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 0.1 ug/day dose,Other,2995668.0,
1104,191672,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 0.16 ug/day dose,Other,2995668.0,
1105,191672,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 0.16 ug/day dose,Other,2995668.0,
1106,191674,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 0.2 ug/day dose,Other,2995668.0,
1107,191674,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 0.2 ug/day dose,Other,2995668.0,
1108,191676,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 1 ug/day dose,Other,2995668.0,
1109,191676,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 1 ug/day dose,Other,2995668.0,
1110,191679,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic effect in rats uterine at 10 ug/day dose,Other,2995668.0,
1111,191679,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic effect in rats uterine at 10 ug/day dose,Other,2995668.0,
1112,192035,3,4,,103189263,5757,Unspecified,,,,,Weight of rat body tested after intramuscular administration of 18 ug/kg of compound when compared to prednisone,Other,12467635.0,
1113,192040,3,4,,103189263,5757,Unspecified,,,,,Weight of rat femur ash tested after intramuscular administration of 18 ug/kg of compound when compared to vehicle,Other,12467635.0,
1114,192044,3,4,,103189263,5757,Unspecified,,,,,Weight of rat femur tested after intramuscular administration of 18 ug/kg of compound when compared to vehicle,Other,12467635.0,
1115,194366,3,3,,103189263,5757,Unspecified,,,,,"Compound is evaluated for effect on serum estradiol, 14 days subsequent to a single intravenous dose determined by means of a radioimmunoassay",Other,7990122.0,
1116,194559,3,3,,103189263,5757,Unspecified,,,,,Activity to induce the elevation of HDL(High Density Lipoproteins)-Cholesterol in plasma lipids of male Wistar rats after the sc administration of 5 mg/kg/day,Other,3612689.0,
1117,194690,3,3,,103189263,5757,Unspecified,,,,,Activity to induce the elevation of alpha/beta cholesterol ratio in plasma lipids of male Wistar rats after the sc administration of 5 mg/kg/day,Other,3612689.0,
1118,194697,3,3,,103189263,5757,Unspecified,,,,,Activity to induce the elevation of phospholipids in plasma lipids of male Wistar rats after the sc administration of 5 mg/kg/day,Other,3612689.0,
1119,194704,3,3,,103189263,5757,Unspecified,,,,,Activity to induce the elevation of triglycerides in plasma lipids of male Wistar rats after the sc administration of 5 mg/kg/day,Other,3612689.0,
1120,195685,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Uterotrophic activity in rats relative to estradiol (E2 = 100%),Other,3746826.0,
1121,195685,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Uterotrophic activity in rats relative to estradiol (E2 = 100%),Other,3746826.0,
1122,197042,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0 ug subcutaneous dose,Other,3746826.0,
1123,197042,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0 ug subcutaneous dose,Other,3746826.0,
1124,197044,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose,Other,3746826.0,
1125,197044,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose,Other,3746826.0,
1126,197045,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.10 ug subcutaneous dose,Other,3746826.0,
1127,197045,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.10 ug subcutaneous dose,Other,3746826.0,
1128,197046,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.2 ug subcutaneous dose,Other,3746826.0,
1129,197046,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.2 ug subcutaneous dose,Other,3746826.0,
1130,197047,4,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose,Other,3746826.0,
1131,197047,4,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose,Other,3746826.0,
1132,197048,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 1 ug subcutaneous dose,Other,3746826.0,
1133,197048,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic activity in immature rats and assayed as uterine weight gain at 1 ug subcutaneous dose,Other,3746826.0,
1134,197235,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Oral estrogenic activity in uterotropic assay in rats at 400-4000ng dose,Other,7365751.0,
1135,197235,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Oral estrogenic activity in uterotropic assay in rats at 400-4000ng dose,Other,7365751.0,
1136,200434,3,10,,103189263,5757,Unspecified,134907.0,6462.0,,,Relative binding affinity against sex steroid binding protein (SBP),Other,7684451.0,
1137,203785,3,10,,103189263,5757,Unspecified,134907.0,6462.0,,,Binding affinity against Sex steroid binding protein(SBP) of human serum,Other,1701833.0,
1138,205268,4,7,,103189263,5757,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1139,205269,3,7,,103189263,5757,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
1140,205634,3,11,,103189263,5757,Unspecified,126886.0,25672.0,,,"Binding affinity to Steroid Hormone Receptor was determined using [1,2-3 H]aldosterone as radioligand",Other,7401101.0,
1141,205760,7,1,,103189263,5757,Unspecified,,,84.0,IC50,Inhibition of steroid sulfatase activity of JEG-3 cells,Confirmatory,11087571.0,
1142,212737,3,7,,103189263,5757,Unspecified,,,,,Binding affinity against testosterone-binding globulin (TeBG),Other,8474098.0,
1143,212919,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards testosterone binding globulin is expressed as log(1/k).,Other,8667357.0,
1144,212920,3,8,,103189263,5757,Unspecified,,,,,Binding affinity against transport protein testosterone binding globulin.,Other,8057280.0,
1145,212931,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards human testosterone binding globulin.,Other,9379435.0,
1146,213396,4,8,,103189263,5757,Unspecified,,,,,Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone,Other,2897467.0,
1147,213586,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Relative binding affinity for rat uterine estrogen receptor,Other,,
1148,213586,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Relative binding affinity for rat uterine estrogen receptor,Other,,
1149,213588,3,11,,103189263,5757,Unspecified,13124247.0,281146.0,,,The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand,Other,4009597.0,
1150,213588,3,11,,103189263,5757,Unspecified,55584164.0,407238.0,,,The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand,Other,4009597.0,
1151,220020,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards human corticosteroid binding globulin.,Other,8411009.0,
1152,220995,3,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative affinity constant (RAC) for lamb uterine estrogen receptor alpha by displacement of [3H]estradiol,Other,10691688.0,
1153,220995,3,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,Relative affinity constant (RAC) for lamb uterine estrogen receptor alpha by displacement of [3H]estradiol,Other,10691688.0,
1154,223389,5,3,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for human estrogen receptor alpha by displacement of [3H]-estradiol,Other,11708930.0,
1155,223390,7,2,,103189263,5757,Active,,,1.8e-05,EC50,Transcriptional potency (EC50) at Human estrogen receptor alpha,Confirmatory,11708925.0,
1156,223391,4,8,,103189263,5757,Unspecified,,,,,Relative binding affinity (RBA) at Human estrogen receptor alpha (radiometric binding assay with [3H]estradiol using full-length human ER alpha),Other,11708925.0,
1157,223392,4,8,,103189263,5757,Unspecified,,,,,Relative estrogenic potency at Human estrogen receptor alpha (EC50 (Estradiol) / EC50 (ligand)),Other,11708925.0,
1158,227715,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Binding selectivity index (BSI) as the relative affinity for estrogen receptor at 25 degree C and no-specific binding,Other,7684451.0,
1159,227715,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Binding selectivity index (BSI) as the relative affinity for estrogen receptor at 25 degree C and no-specific binding,Other,7684451.0,
1160,227718,7,1,,103189263,5757,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1161,228061,3,7,,103189263,5757,Unspecified,,,,,Binding affinity towards human testosterone binding globulin.,Other,8411009.0,
1162,229341,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity for estrogen receptor compared to estradiol,Other,2909731.0,
1163,229341,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for estrogen receptor compared to estradiol,Other,2909731.0,
1164,230360,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity as ratio of molar concentrations of E/Z-4-OHT to compound required to displace 50% [3H]E2 from MCF-7 cell lysates,Other,14971899.0,
1165,230360,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity as ratio of molar concentrations of E/Z-4-OHT to compound required to displace 50% [3H]E2 from MCF-7 cell lysates,Other,14971899.0,
1166,231319,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio of binding affinities at estrogen receptor subtypes alpha and beta.,Other,15081034.0,
1167,231319,4,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio of binding affinities at estrogen receptor subtypes alpha and beta.,Other,15081034.0,
1168,231433,4,11,,103189263,5757,Unspecified,1706709.0,443228.0,,,RAC ratio for estrogen receptor binding after 4 and 20 hr,Other,8411015.0,
1169,231433,4,11,,103189263,5757,Unspecified,13124234.0,443066.0,,,RAC ratio for estrogen receptor binding after 4 and 20 hr,Other,8411015.0,
1170,231465,4,8,,103189263,5757,Unspecified,,,,,Ratio between EC50 values of hER beta and ERalpha,Other,11708925.0,
1171,231651,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio of [3H]E2 alkyl ester binding to estrogen receptor alpha and beta ligand binding domains,Other,12723952.0,
1172,231651,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio of [3H]E2 alkyl ester binding to estrogen receptor alpha and beta ligand binding domains,Other,12723952.0,
1173,231690,4,8,,103189263,5757,Unspecified,,,,,Ratio between Relative estrogenic potency of hER beta and ERalpha,Other,11708925.0,
1174,231691,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio between Relative estrogenic potency of human ER beta and ERalpha,Other,11708925.0,
1175,231691,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio between Relative estrogenic potency of human ER beta and ERalpha,Other,11708925.0,
1176,232214,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity as ratio of IC50 for ER alpha to that of ER beta,Other,12459017.0,
1177,232214,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity as ratio of IC50 for ER alpha to that of ER beta,Other,12459017.0,
1178,232475,3,3,,103189263,5757,Unspecified,,,,,Selectivity ratio for antifertility and estrogenic potencies in rats,Other,2738897.0,
1179,233594,3,8,,103189263,5757,Unspecified,,,,,Selectivity as ratio of IC50 against ER beta receptor to IC50 against ER alpha receptor,Other,12270167.0,
1180,234055,3,9,,103189263,5757,Unspecified,,,,,Selectivity for estrogen receptor alpha over estrogen receptor beta; Average of 130 measurements,Other,15203155.0,
1181,234056,3,9,,103189263,5757,Unspecified,,,,,Selectivity for estrogen receptor alpha over estrogen receptor beta; Average of 130 measurements,Other,15203156.0,
1182,234090,3,7,,103189263,5757,Unspecified,,,,,Selectivity for relative binding affinity against estrogen receptor at 2 hrs and 5 hr in calf uterus cytosol,Other,2769681.0,
1183,235276,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Ratio of specific binding to non-specific binding at rat estrogen receptor,Other,3385736.0,
1184,235276,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Ratio of specific binding to non-specific binding at rat estrogen receptor,Other,3385736.0,
1185,235514,3,9,,103189263,5757,Unspecified,,,,,Selectivity was determined as ratio of IC50 against human ER alpha to that of human ER beta,Other,15006374.0,
1186,237575,3,3,,103189263,5757,Unspecified,,,,,Partition coefficient (logP),Other,15828819.0,
1187,237685,4,3,,103189263,5757,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
1188,238046,7,5,,103189263,5757,Active,544257.0,2099.0,0.00072,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 273 K,Confirmatory,15771445.0,
1189,238046,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00072,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 273 K,Confirmatory,15771445.0,
1190,238047,7,5,,103189263,5757,Active,544257.0,2099.0,0.00062,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 278 K,Confirmatory,15771445.0,
1191,238047,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00062,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 278 K,Confirmatory,15771445.0,
1192,238048,7,5,,103189263,5757,Active,544257.0,2099.0,0.00053,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 283 K,Confirmatory,15771445.0,
1193,238048,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00053,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 283 K,Confirmatory,15771445.0,
1194,238049,7,5,,103189263,5757,Active,544257.0,2099.0,0.00043,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 288 K,Confirmatory,15771445.0,
1195,238049,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00043,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 288 K,Confirmatory,15771445.0,
1196,238050,7,5,,103189263,5757,Active,544257.0,2099.0,0.00045,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 293K,Confirmatory,15771445.0,
1197,238050,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00045,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 293K,Confirmatory,15771445.0,
1198,238051,7,5,,103189263,5757,Active,544257.0,2099.0,0.00053,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 298 K,Confirmatory,15771445.0,
1199,238051,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00053,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 298 K,Confirmatory,15771445.0,
1200,238052,7,5,,103189263,5757,Active,544257.0,2099.0,0.00059,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 303 K,Confirmatory,15771445.0,
1201,238052,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00059,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 303 K,Confirmatory,15771445.0,
1202,238053,7,5,,103189263,5757,Active,544257.0,2099.0,0.00079,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 308 K,Confirmatory,15771445.0,
1203,238053,7,5,,103189263,5757,Active,6166154.0,2100.0,0.00079,Kd,Dissociation constant for [3H]estradiol at human estrogen receptor at 308 K,Confirmatory,15771445.0,
1204,238054,7,5,,103189263,5757,Active,544257.0,2099.0,0.0008699999999999999,Kd,Dissociation constant for [3H]-estradiol at human estrogen receptor at 310K,Confirmatory,15771445.0,
1205,238054,7,5,,103189263,5757,Active,6166154.0,2100.0,0.0008699999999999999,Kd,Dissociation constant for [3H]-estradiol at human estrogen receptor at 310K,Confirmatory,15771445.0,
1206,238121,6,2,,103189263,5757,Active,,,0.0005,Kd,Binding affinity for Estrogen receptor,Confirmatory,15482947.0,
1207,238122,5,3,,103189263,5757,Active,,,3e-06,Kd,Binding affinity for Estrogen receptor alpha,Confirmatory,15482947.0,
1208,239820,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Mean fluorescence intensity corrected to basal for GW-5638 selective peptide binding to human estrogen receptor alpha,Other,15771467.0,
1209,239828,3,8,,103189263,5757,Unspecified,,,,,Relative binding affinity for Estrogen receptor beta,Other,15828819.0,
1210,239829,3,9,,103189263,5757,Unspecified,,,,,Relative binding affinity for Estrogen receptor alpha,Other,15828819.0,
1211,239838,3,11,,103189263,5757,Unspecified,13124247.0,281146.0,,,Relative binding affinity for Estrogen receptor of Calf uterine cytosol,Other,15324884.0,
1212,239838,3,11,,103189263,5757,Unspecified,55584164.0,407238.0,,,Relative binding affinity for Estrogen receptor of Calf uterine cytosol,Other,15324884.0,
1213,239921,4,1,,103189263,5757,Active,6166154.0,2100.0,0.00316,Ki,Binding affinity for human estrogen receptor beta,Confirmatory,15771467.0,
1214,239927,4,1,,103189263,5757,Active,544257.0,2099.0,0.002,Ki,Binding affinity for human estrogen receptor alpha,Confirmatory,15771467.0,
1215,240014,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 273 K,Other,15771445.0,
1216,240014,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 273 K,Other,15771445.0,
1217,240015,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 278 K,Other,15771445.0,
1218,240015,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 278 K,Other,15771445.0,
1219,240016,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 283 K,Other,15771445.0,
1220,240016,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 283 K,Other,15771445.0,
1221,240017,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 288 K,Other,15771445.0,
1222,240017,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 288 K,Other,15771445.0,
1223,240018,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 293K,Other,15771445.0,
1224,240018,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 293K,Other,15771445.0,
1225,240019,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 298 K,Other,15771445.0,
1226,240019,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 298 K,Other,15771445.0,
1227,240020,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 303 K,Other,15771445.0,
1228,240020,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 303 K,Other,15771445.0,
1229,240021,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 308 K,Other,15771445.0,
1230,240021,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 308 K,Other,15771445.0,
1231,240022,5,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 310K,Other,15771445.0,
1232,240022,5,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Maximum binding of [3H]estradiol to human estrogen receptor at 310K,Other,15771445.0,
1233,240478,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding potency for human ER beta,Confirmatory,15225685.0,
1234,240479,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding potency for human ER beta,Confirmatory,15225686.0,
1235,240480,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding potency for human ER alpha,Confirmatory,15225685.0,
1236,240481,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding potency for human ER alpha,Confirmatory,15225686.0,
1237,240624,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Inhibition of human estrogen receptor beta,Confirmatory,15876535.0,
1238,240643,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Inhibition of human estrogen receptor alpha,Confirmatory,15876535.0,
1239,240821,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding affinity for human estrogen receptor beta,Confirmatory,15664843.0,
1240,240848,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity for human estrogen receptor alpha,Confirmatory,15664843.0,
1241,241337,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Inhibition of estrogen receptor beta,Confirmatory,15745820.0,
1242,241373,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Inhibition of estrogen receptor alpha,Confirmatory,15745820.0,
1243,241825,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Binding affinity for human Estrogen receptor beta,Confirmatory,15341953.0,
1244,241852,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Binding affinity for human Estrogen receptor alpha,Confirmatory,15341953.0,
1245,241865,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Inhibition of binding to recombinant human estrogen receptor beta,Confirmatory,15582421.0,
1246,241899,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Inhibition of bindign to recombinant human estrogen receptor alpha,Confirmatory,15582421.0,
1247,242043,8,5,,103189263,5757,Active,6166154.0,2100.0,0.024,IC50,Inhibition of [3H]estradiol binding to human estrogen receptor beta expressed in HeLa cells,Confirmatory,15658851.0,
1248,242068,8,5,,103189263,5757,Active,544257.0,2099.0,0.027999999999999997,IC50,Inhibition of [3H]estradiol binding to human estrogen receptor alpha expressed in HeLa cells,Confirmatory,15658851.0,
1249,242135,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor beta expressed in Escherichia coli,Confirmatory,15943471.0,
1250,242151,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha expressed in Escherichia coli,Confirmatory,15943471.0,
1251,242314,8,1,,103189263,5757,Active,6166156.0,25149.0,0.0017,IC50,Inhibition of [3H]17-beta-estradiol binding to rat ER beta expressed in Escherichia coli,Confirmatory,15456246.0,
1252,242327,8,1,,103189263,5757,Active,119600.0,24890.0,0.0019,IC50,Inhibition of [3H]17-beta-estradiol binding to rat ER alpha expressed in Escherichia coli,Confirmatory,15456246.0,
1253,242353,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Inhibitory concentration against human ER beta expressed in Escherichia coli was determined using [3H]17-beta-estradiol as radio ligand,Confirmatory,15456246.0,
1254,242354,8,1,,103189263,5757,Active,380865470.0,13983.0,0.0023,IC50,Inhibition of [3H]17-beta-estradiol binding to mouse ER beta expressed in Escherichia coli,Confirmatory,15456246.0,
1255,242369,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Inhibitory concentration against human ER alpha expressed in Escherichia coli was determined using [3H]17-beta-estradiol as radio ligand,Confirmatory,15456246.0,
1256,242370,8,1,,103189263,5757,Active,119599.0,13982.0,0.0022,IC50,Inhibition of [3H]17-beta-estradiol binding to mouse ER alpha expressed in Escherichia coli,Confirmatory,15456246.0,
1257,242498,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Inhibition of human estrogen receptor 2 using tritiated estradiol incubated for 3 hr,Confirmatory,15993065.0,
1258,242790,8,8,,103189263,5757,Inconclusive,6166154.0,2100.0,,,"Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay, not determined",Other,15658851.0,
1259,242793,8,8,,103189263,5757,Inconclusive,544257.0,2099.0,,,"Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay, not determined",Other,15658851.0,
1260,242959,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity ratio for binding to ER beta and ER alpha receptors,Other,15225685.0,
1261,242959,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity ratio for binding to ER beta and ER alpha receptors,Other,15225685.0,
1262,242960,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity ratio for ER beta to ER alpha receptor,Other,15225686.0,
1263,242960,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity ratio for ER beta to ER alpha receptor,Other,15225686.0,
1264,243052,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding to human estrogen receptor beta and alpha,Other,15876535.0,
1265,243052,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding to human estrogen receptor beta and alpha,Other,15876535.0,
1266,243059,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio of inhibitory activity against human estrogen receptors 2 and 1,Other,15993065.0,
1267,243059,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio of inhibitory activity against human estrogen receptors 2 and 1,Other,15993065.0,
1268,243114,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,IC50 ratio for binding to recombinant human estrogen receptors alpha and beta,Other,15582421.0,
1269,243114,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,IC50 ratio for binding to recombinant human estrogen receptors alpha and beta,Other,15582421.0,
1270,243121,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha and beta expressed in Escherichia coli,Other,15943471.0,
1271,243121,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha and beta expressed in Escherichia coli,Other,15943471.0,
1272,244155,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio of IC50 for binding to Estrogen receptor alpha and beta,Other,15341953.0,
1273,244155,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio of IC50 for binding to Estrogen receptor alpha and beta,Other,15341953.0,
1274,244177,4,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity fold for estrogen receptor beta over estrogen receptor alpha,Other,15456246.0,
1275,244177,4,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity fold for estrogen receptor beta over estrogen receptor alpha,Other,15456246.0,
1276,244199,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for Estrogen receptor alpha relative to beta (average of 130 measurement),Other,15745820.0,
1277,244199,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for Estrogen receptor alpha relative to beta (average of 130 measurement),Other,15745820.0,
1278,244507,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ishikawa cell alkaline phosphatase activity as percent maximal induction relative to 17 alpha-estradiol,Other,15771467.0,
1279,244507,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ishikawa cell alkaline phosphatase activity as percent maximal induction relative to 17 alpha-estradiol,Other,15771467.0,
1280,246379,4,6,,103189263,5757,Active,,,0.0097,EC50,In vitro agonist activity for estrogen receptor beta expressed in COS-1 cells,Confirmatory,15713407.0,
1281,246384,5,6,,103189263,5757,Active,544257.0,2099.0,0.0024,EC50,In vitro agonist activity for estrogen receptor alpha expressed in COS-1 cells,Confirmatory,15713407.0,
1282,246833,5,3,,103189263,5757,Active,119600.0,24890.0,5.9999999999999995e-05,ED50,Effective dose in immature rat uterotrophic growth assay,Confirmatory,15974584.0,
1283,246833,5,3,,103189263,5757,Active,6166156.0,25149.0,5.9999999999999995e-05,ED50,Effective dose in immature rat uterotrophic growth assay,Confirmatory,15974584.0,
1284,248429,8,8,,103189263,5757,Inconclusive,544257.0,2099.0,,,Inhibition of estrogen-mediated human breast adenocarcinoma (MCF-7) cell proliferation; not determined,Other,15658851.0,
1285,248429,8,8,,103189263,5757,Inconclusive,6166154.0,2100.0,,,Inhibition of estrogen-mediated human breast adenocarcinoma (MCF-7) cell proliferation; not determined,Other,15658851.0,
1286,249541,3,12,,103189263,5757,Inconclusive,544257.0,2099.0,,,pIC50 for 1 nM estradiol-induced Ishikawa cell proliferation; NT=Not tested,Other,15771467.0,
1287,249541,3,12,,103189263,5757,Inconclusive,6166154.0,2100.0,,,pIC50 for 1 nM estradiol-induced Ishikawa cell proliferation; NT=Not tested,Other,15771467.0,
1288,249793,4,3,,103189263,5757,Unspecified,,,,,Weight of mouse uterine when treated with compound at was determined,Other,15456246.0,
1289,249862,6,1,,103189263,5757,Unspecified,,,,,Total bone mineral density in ovariectomized rat when treated with compound at 2 ug/rat,Other,15456246.0,
1290,249864,6,1,,103189263,5757,Unspecified,,,,,Trabecular bone mineral density in ovariectomized rat when treated with compound at 2 ug/rat,Other,15456246.0,
1291,250247,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Antagonistic activity in vivo in rat uterine weight assay at 4 ug/kg,Other,15582421.0,
1292,250247,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Antagonistic activity in vivo in rat uterine weight assay at 4 ug/kg,Other,15582421.0,
1293,250279,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Inhibition of rat uterine growth (in absence of compound) at 1 mg/kg peroral dose,Other,15745820.0,
1294,250279,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Inhibition of rat uterine growth (in absence of compound) at 1 mg/kg peroral dose,Other,15745820.0,
1295,250367,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Fold activation of estrogen receptor beta at 100 nM in cell-based reporter gene assay,Other,15713377.0,
1296,250368,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Percent agonist activity against human breast adenocarcinoma (MCF-7) cell proliferation,Other,15658851.0,
1297,250368,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Percent agonist activity against human breast adenocarcinoma (MCF-7) cell proliferation,Other,15658851.0,
1298,250378,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Fold activation of estrogen receptor alpha at 100 nM in cell-based reporter gene assay,Other,15713377.0,
1299,250550,3,10,,103189263,5757,Unspecified,374095385.0,2103.0,,,Fold activation of estrogen-related receptor beta at 100 nM in cell-based reporter gene assay,Other,15713377.0,
1300,250587,3,10,,103189263,5757,Unspecified,215274146.0,2101.0,,,Fold activation of estrogen-related receptor alpha at 100 nM in cell-based reporter gene assay,Other,15713377.0,
1301,250588,3,10,,103189263,5757,Unspecified,50402102.0,2104.0,,,Fold activation of estrogen-related receptor gamma at 100 nM in cell-based reporter gene assay,Other,15713377.0,
1302,251168,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Transcriptional efficacy against human estrogen receptor beta at 10e-6 M,Other,15715479.0,
1303,251169,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Transcriptional efficacy against human estrogen receptor beta at 10e-8 M,Other,15715479.0,
1304,251170,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Transcriptional efficacy against human estrogen receptor alpha at 10e-6 M,Other,15715479.0,
1305,251171,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Transcriptional efficacy against human estrogen receptor alpha at 10e-8 M,Other,15715479.0,
1306,251418,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Percent serum cholesterol reduction in ovariectomised rats at 1.5 mg/kg/day (Average of 15 measurements at 0.6 mg/kg),Other,15745820.0,
1307,251418,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Percent serum cholesterol reduction in ovariectomised rats at 1.5 mg/kg/day (Average of 15 measurements at 0.6 mg/kg),Other,15745820.0,
1308,251711,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Estrogenic effect in rat uterine weight assay,Other,15664843.0,
1309,251711,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Estrogenic effect in rat uterine weight assay,Other,15664843.0,
1310,252867,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Percent agonism of estradiol effects in rat uterine tissue at 1 ug/kg,Other,15225685.0,
1311,252867,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Percent agonism of estradiol effects in rat uterine tissue at 1 ug/kg,Other,15225685.0,
1312,252868,3,11,,103189263,5757,Unspecified,119600.0,24890.0,,,Percent agonism of estradiol in rat uterine tissue at 4 ug/kg,Other,15225686.0,
1313,252868,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Percent agonism of estradiol in rat uterine tissue at 4 ug/kg,Other,15225686.0,
1314,254574,3,11,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity for human estrogen receptor beta using [3H]estradiol upon incubation at 0 degree C for 18-24 h; [RBA E2 = 100],Other,16190762.0,
1315,254575,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity towards human estrogen receptor alpha using [3H]estradiol upon incubation at 0 degree C for 18-24 h; [RBA E2 = 100],Other,16190762.0,
1316,254647,8,5,,103189263,5757,Active,6166154.0,2100.0,9.8e-05,EC50,Transcriptional activation of estrogen receptor beta in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT,Confirmatory,16162002.0,
1317,254648,8,5,,103189263,5757,Active,544257.0,2099.0,1.9e-05,EC50,Transcriptional activation of estrogen receptor alpha in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT,Confirmatory,16162002.0,
1318,254777,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Binding affinity for human Estrogen receptor beta,Confirmatory,16098741.0,
1319,254783,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Binding affinity for human Estrogen receptor alpha,Confirmatory,16098741.0,
1320,255163,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Ratio of relative binding affinity towards human ER beta to human ER alpha,Other,16190762.0,
1321,255163,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Ratio of relative binding affinity towards human ER beta to human ER alpha,Other,16190762.0,
1322,255211,8,1,,103189263,5757,Active,113832.0,24208.0,0.40738,IC50,Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881),Confirmatory,16134935.0,
1323,255235,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Transcriptional activation of estrogen receptor beta in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT,Other,16162002.0,
1324,255236,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Transcriptional activation of estrogen receptor alpha in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT,Other,16162002.0,
1325,255369,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity as ratio of IC50 against estrogen receptor alpha and beta,Other,16098741.0,
1326,255369,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity as ratio of IC50 against estrogen receptor alpha and beta,Other,16098741.0,
1327,255381,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Absolute ratio of relative binding affinity towards human ER beta to human ER alpha,Other,16190762.0,
1328,255381,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Absolute ratio of relative binding affinity towards human ER beta to human ER alpha,Other,16190762.0,
1329,255401,5,2,,103189263,5757,Unspecified,6166154.0,2100.0,,,Binding affinity towards human estrogen receptor beta in a competitive binding assay using fluorescently labelled estradiol; relative to 4-hydroxytamoxifen,Other,16162002.0,
1330,255402,5,2,,103189263,5757,Unspecified,544257.0,2099.0,,,Binding affinity towards human estrogen receptor alpha in a competitive binding assay using fluorescently labelled estradiol; relative to 4-hydroxytamoxifen,Other,16162002.0,
1331,255650,6,2,,103189263,5757,Active,,,8e-05,EC50,Effective concentration against human ER positive MCF-7 breast cancer cell line evaluated by luciferase assay,Confirmatory,16190777.0,
1332,256052,3,3,,103189263,5757,Unspecified,,,,,Serum estradiol level in nonestrus mouse BALB/c cell line; (n=2),Other,16190762.0,
1333,256053,3,3,,103189263,5757,Unspecified,,,,,Serum estradiol level in estrus estrogen receptor beta mouse; (n=3),Other,16190762.0,
1334,257299,8,5,,103189263,5757,Active,544257.0,2099.0,0.00075,IC50,Displacement of [3H]17beta-estradiol from recombinant human ERalpha expressed in 293T cells,Confirmatory,16219463.0,
1335,257300,8,5,,103189263,5757,Active,6166154.0,2100.0,0.00118,IC50,Displacement of [3H]17beta-estradiol from recombinant human ERbeta expressed in 293T cells,Confirmatory,16219463.0,
1336,257301,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for human ERbeta over human ERalpha,Other,16219463.0,
1337,257301,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for human ERbeta over human ERalpha,Other,16219463.0,
1338,257302,5,6,,103189263,5757,Active,544257.0,2099.0,1e-05,EC50,Effect on ERalpha in MCF7 cell line transfected with ER responsive luciferase reporter,Confirmatory,16219463.0,
1339,257303,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Activation of ERalpha in MCF7 cell line transfected with ER responsive luciferase reporter at 1 uM,Other,16219463.0,
1340,257304,5,6,,103189263,5757,Active,6166156.0,25149.0,0.00014,EC50,Effect on ERbeta in rat ovary granulosa cell line transfected with ER responsive luciferase reporter,Confirmatory,16219463.0,
1341,257305,3,11,,103189263,5757,Unspecified,6166156.0,25149.0,,,Activation of ERbeta in rat ovary granulosa cell line transfected with ER responsive luciferase reporter at 1 uM,Other,16219463.0,
1342,258224,3,8,,103189263,5757,Unspecified,,,,,Relative binding affinity for ER by a competitive [3H]estradiol binding assay,Other,16275069.0,
1343,258225,3,4,,103189263,5757,Unspecified,,,,,Cytotoxicity against human breast cancer MCF7 cell line expressing ER,Other,16275069.0,
1344,258226,3,4,,103189263,5757,Unspecified,,,,,Cytotoxicity against human breast cancer MDA-MB-231 cell line lacking ER,Other,16275069.0,
1345,260151,8,5,,103189263,5757,Active,544257.0,2099.0,0.0014,IC50,Binding affinity to human ERalpha,Confirmatory,16309907.0,
1346,260152,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity to human ERbeta,Confirmatory,16309907.0,
1347,260153,5,2,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for human ERbeta over ERalpha,Other,16309907.0,
1348,260153,5,2,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for human ERbeta over ERalpha,Other,16309907.0,
1349,260154,5,6,,103189263,5757,Active,544257.0,2099.0,0.00075,EC50,Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERalpha,Confirmatory,16309907.0,
1350,260155,5,6,,103189263,5757,Active,6166154.0,2100.0,0.0021,EC50,Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERbeta,Confirmatory,16309907.0,
1351,260156,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for transactivation of ALP gene expression in HEK293 cells transfected with hERbeta over hERalpha,Other,16309907.0,
1352,260156,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for transactivation of ALP gene expression in HEK293 cells transfected with hERbeta over hERalpha,Other,16309907.0,
1353,260157,8,5,,103189263,5757,Active,1018618719.0,367.0,0.0191,IC50,Inhibitory activity against AR,Confirmatory,16309907.0,
1354,260158,3,5,,103189263,5757,Unspecified,,,,,Selectivity for human ERbeta over AR,Other,16309907.0,
1355,262172,8,5,,103189263,5757,Active,544257.0,2099.0,0.00135,IC50,Binding affinity to ERalpha,Confirmatory,16412638.0,
1356,262173,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity to ERbeta,Confirmatory,16412638.0,
1357,262174,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for ERalpha over ERbeta,Other,16412638.0,
1358,262174,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for ERalpha over ERbeta,Other,16412638.0,
1359,262948,9,5,,103189263,5757,Active,6166154.0,2100.0,0.011000000000000001,IC50,Displacement of [3H]estrone from ER beta,Confirmatory,16610787.0,
1360,262950,9,5,,103189263,5757,Active,544257.0,2099.0,0.01,IC50,Displacement of [3H]estrone from ER alpha,Confirmatory,16610787.0,
1361,262952,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for ER beta over ER alpha,Other,16610787.0,
1362,262952,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for ER beta over ER alpha,Other,16610787.0,
1363,262953,5,6,,103189263,5757,Active,6166154.0,2100.0,0.00084,EC50,Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay,Confirmatory,16610787.0,
1364,262955,5,6,,103189263,5757,Active,6166154.0,2100.0,0.00059,EC50,Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM,Confirmatory,16610787.0,
1365,262957,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for ER beta over ER alpha-mediated transactivation of ERE in HeLa cell luciferase assay,Other,16610787.0,
1366,262957,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for ER beta over ER alpha-mediated transactivation of ERE in HeLa cell luciferase assay,Other,16610787.0,
1367,267730,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity to ERalpha by scintillation proximity assay,Confirmatory,16632357.0,
1368,267731,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity to ERbeta by scintillation proximity assay,Confirmatory,16632357.0,
1369,267732,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for human ERbeta over ERalpha,Other,16632357.0,
1370,267732,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for human ERbeta over ERalpha,Other,16632357.0,
1371,268961,8,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Displacement of [3H]estradiol from human ERalpha,Confirmatory,16884312.0,
1372,268962,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Displacement of [3H]estradiol from human ERbeta,Confirmatory,16884312.0,
1373,269184,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity to human ERalpha,Confirmatory,16730987.0,
1374,269185,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity to human ERbeta,Confirmatory,16730987.0,
1375,269186,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for human ERbeta over ERalpha,Other,16730987.0,
1376,269186,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for human ERbeta over ERalpha,Other,16730987.0,
1377,270404,8,5,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Binding affinity to human recombinant ERalpha by scintillation proximity assay,Confirmatory,16777408.0,
1378,270405,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0011,IC50,Binding affinity to human recombinant ERbeta by scintillation proximity assay,Confirmatory,16777408.0,
1379,270406,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,"Selectivity, IC50 for ERbeta over IC50 for ERalpha",Other,16777408.0,
1380,270406,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,"Selectivity, IC50 for ERbeta over IC50 for ERalpha",Other,16777408.0,
1381,271176,8,5,,103189263,5757,Active,544257.0,2099.0,0.046,IC50,Binding affinity to ERalpha L384M/M421G mutant,Confirmatory,16942012.0,
1382,271177,8,5,,103189263,5757,Active,544257.0,2099.0,0.0016,IC50,Binding affinity to human ER alpha,Confirmatory,16942012.0,
1383,271179,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0014,IC50,Binding affinity to human ER beta,Confirmatory,16942012.0,
1384,271188,3,12,,103189263,5757,Inactive,544257.0,2099.0,,,Activity at ERalpha L384M/M421G/G521R mutant in HeLa cells assessed as activation of SEAP reporter gene upto 10 uM,Other,16942012.0,
1385,274383,8,5,,103189263,5757,Active,544257.0,2099.0,0.0012,IC50,Displacement of [3H]E2 from human recombinant ERalpha LBD by SPA,Confirmatory,17149865.0,
1386,274384,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0014,IC50,Displacement of [3H]E2 from human recombinant ERbeta LBD by SPA,Confirmatory,17149865.0,
1387,274385,3,12,,103189263,5757,Unspecified,544257.0,2099.0,,,Selectivity for recombinant human ERbeta over ERalpha,Other,17149865.0,
1388,274385,3,12,,103189263,5757,Unspecified,6166154.0,2100.0,,,Selectivity for recombinant human ERbeta over ERalpha,Other,17149865.0,
1389,274505,3,9,,103189263,5757,Unspecified,134907.0,6462.0,,,Displacement of [3H]DHT from human SHBG relative to testosterone,Other,17149875.0,
1390,274506,9,5,,103189263,5757,Active,134907.0,6462.0,0.05,IC50,Displacement of [3H]DHT from human SHBG,Confirmatory,17149875.0,
1391,275284,6,2,,103189263,5757,Inconclusive,,,,EC50,Reduction of PrPSC accumulation in ScN2a cells,Confirmatory,17201410.0,
1392,275285,8,1,,103189263,5757,Inconclusive,,,,LD50,Cytotoxicity against ScN2a cells,Confirmatory,17201410.0,
1393,275286,6,2,,103189263,5757,Unspecified,,,,,Solubility in phosphate buffer at pH 6.5 at 500 uM,Other,17201410.0,
1394,275287,3,4,,103189263,5757,Inconclusive,,,,,Permeability across DOPC lipid membrane by PAMPA,Other,17201410.0,
1395,276364,3,3,,103189263,5757,Active,,,,,Bone resorption activity assessed as inhibition of PGE2-stimulated pit formation in ddY mouse osteoclasts,Other,16945531.0,
1396,282030,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DOX-TEG-TAM uptake in ER expressing Rtx6 cells at 20 nM,Other,15588086.0,
1397,282037,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DOX-TEG-TAM uptake in ER expressing Rtx6 cells,Other,15588086.0,
1398,282038,3,5,,103189263,5757,Inactive,,,,,Inhibition of DOX-TEG-TAM uptake in MDA-MB-435 cells,Other,15588086.0,
1399,282836,3,4,,103189263,5757,Unspecified,,,,,Cytotoxicity against human HL60 cells,Other,16279782.0,
1400,283561,3,4,,103189263,5757,Active,,,,,Effect on modulation in uptake of [3H]progesterone in Escherichia coli AG102 with marR1 mutation,Other,17210767.0,
1401,284776,3,4,,103189263,5757,Unspecified,,,,,Increase in cell growth of estrogen-starved ER expressing T47D cells at 10 nM relative to control after 10 days,Other,17110114.0,
1402,284781,3,4,,103189263,5757,Unspecified,,,,,Increase in cell growth of estrogen-starved ER expressing MCF7 cells at 10 nM relative to control after 10 days,Other,17110114.0,
1403,287683,3,4,,103189263,5757,Active,,,,,Down regulation of estrogen receptor expression in MCF7 cells at 1 nM after 24 hrs,Other,17275315.0,
1404,291679,3,3,,103189263,5757,Unspecified,,,,,"Increase in body weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1405,291680,8,1,,103189263,5757,Unspecified,,,,,"Effect on serum ALP lavel in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1406,291681,9,1,,103189263,5757,Unspecified,,,,,"Effect on serum calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1407,291682,9,1,,103189263,5757,Unspecified,,,,,"Effect on serum phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1408,291683,3,4,,103189263,5757,Unspecified,,,,,"Effect on dry weight of femurs in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1409,291684,3,4,,103189263,5757,Unspecified,,,,,"Effect on femur ash weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1410,291685,3,4,,103189263,5757,Unspecified,,,,,"Effect on femur length in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1411,291686,3,3,,103189263,5757,Unspecified,,,,,"Effect on calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1412,291687,3,3,,103189263,5757,Unspecified,,,,,"Effect on phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1413,291688,3,3,,103189263,5757,Unspecified,,,,,"Effect on mineral content in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1414,291689,3,3,,103189263,5757,Unspecified,,,,,"Effect on lung weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1415,291690,3,3,,103189263,5757,Unspecified,,,,,"Effect on liver weight in ovariectomized mouse at 0.110 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1416,291691,3,4,,103189263,5757,Unspecified,,,,,"Effect on spleen weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1417,291692,3,4,,103189263,5757,Unspecified,,,,,"Effect on uterus weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks",Other,17571867.0,
1418,291719,3,4,,103189263,5757,Unspecified,,,,,"Effect on dry weight of femurs in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1419,291720,3,4,,103189263,5757,Unspecified,,,,,"Effect on femur ash weight in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1420,291721,3,4,,103189263,5757,Unspecified,,,,,"Effect on lenght of femur in mouse at 0.110 mmol/kg, po",Other,17571867.0,
1421,291722,3,3,,103189263,5757,Unspecified,,,,,"Effect on calcium level in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1422,291723,3,3,,103189263,5757,Unspecified,,,,,"Effect on phosphorus level in mouse at 0.110 mmol/kg, po",Other,17571867.0,
1423,291724,3,3,,103189263,5757,Unspecified,,,,,"Effect on mineral content in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1424,291725,3,4,,103189263,5757,Unspecified,,,,,"Effect on serum calcium level in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1425,291726,3,3,,103189263,5757,Unspecified,,,,,"Effect on serum phosphorous Concentration in mouse at 0.110 mmol/kg, po",Other,17571867.0,
1426,291727,8,1,,103189263,5757,Unspecified,,,,,"Effect on serum ALP level in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1427,291728,3,3,,103189263,5757,Unspecified,,,,,"Effect on lung weight in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1428,291729,3,3,,103189263,5757,Unspecified,,,,,"Effect on liver weight in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1429,291730,3,4,,103189263,5757,Unspecified,,,,,"Effect on spleen weight in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1430,291731,3,4,,103189263,5757,Unspecified,,,,,"Effect on uterus weight in mouse at 0.1103 mmol/kg, po",Other,17571867.0,
1431,292714,8,5,,103189263,5757,Active,544257.0,2099.0,0.0036,IC50,Inhibition of human LBD of of ERalpha,Confirmatory,17049855.0,
1432,292715,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0032,IC50,Inhibition of human LBD of ERbeta,Confirmatory,17049855.0,
1433,293384,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0036,IC50,Inhibition of human ERbeta by radioligand binding assay,Confirmatory,17188490.0,
1434,293385,8,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Inhibition of human ERalpha by radioligand binding assay,Confirmatory,17188490.0,
1435,293386,3,3,,103189263,5757,Unspecified,,,,,Selectivity for human ER beta over human ER alpha,Other,17188490.0,
1436,293387,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Upregulation of ERalpha-mediated human keratin 19 mRNA expression in human LNCaPLN3 cells at 1 uM,Other,17188490.0,
1437,293388,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Upregulation of ERbeta-mediated human keratin 19 mRNA expression in human LNCaPLN3 cells at 1 uM,Other,17188490.0,
1438,297564,11,2,,103189263,5757,Active,544257.0,2099.0,0.0047,IC50,Binding affinity to human ERalpha,Confirmatory,17696335.0,
1439,297565,11,2,,103189263,5757,Active,6166154.0,2100.0,0.0167,IC50,Binding affinity to human ERbeta,Confirmatory,17696335.0,
1440,297577,3,3,,103189263,5757,Unspecified,,,,,Increase in ERK2 phosphorylation in rat hippocampal neurons at 10 nM after 30 mins by Western immunoblotting relative to control,Other,17696335.0,
1441,297578,3,3,,103189263,5757,Unspecified,,,,,Increase in Akt phosphorylation in rat hippocampal neurons at 10 nM after 30 mins by Western immunoblotting relative to control,Other,17696335.0,
1442,297581,3,3,,103189263,5757,Unspecified,,,,,Increase in Bcl2 expression in rat hippocampal neurons at 100 nM after 48 hrs by Western immunoblotting relative to control,Other,17696335.0,
1443,297582,3,3,,103189263,5757,Unspecified,,,,,Increase in Bcl-XL expression in rat hippocampal neurons at 100 nM after 48 hrs by Western immunoblotting relative to control,Other,17696335.0,
1444,297584,3,3,,103189263,5757,Unspecified,,,,,Increase in spinophilin expression in rat hippocampal neurons t 100 nM after 48 hrs by Western immunoblotting relative to control,Other,17696335.0,
1445,302805,3,4,,103189263,5757,Unspecified,,,,,Induction of ERalpha+ MCF7 cell growth at 1 nM,Other,17929798.0,
1446,304017,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human 320DM cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1447,304018,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human MLS cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1448,304019,3,4,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human A2780 cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1449,304020,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human H295R cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1450,304021,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human C4-2B cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1451,304022,3,3,,103189263,5757,Unspecified,,,,,Inhibition of DNA synthesis in human VSMC cells assessed as ratio of treated to untreated control at 30 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1452,304023,3,3,,103189263,5757,Unspecified,,,,,Stimulation of DNA synthesis in human MLS cells assessed as ratio of treated to untreated control at 300 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1453,304024,3,3,,103189263,5757,Unspecified,,,,,Stimulation of DNA synthesis in human 320DM cells assessed as ratio of treated to untreated control at 300 nM after 48 hrs by [3H]thymidine incorporation assay,Other,17990847.0,
1454,306462,8,5,,103189263,5757,Active,544257.0,2099.0,0.001,IC50,Displacement of [3H]estradiol from full length human recombinant ERalpha after 3 hrs by scintillation proximity assay,Confirmatory,17289385.0,
1455,306463,8,5,,103189263,5757,Active,6166154.0,2100.0,0.001,IC50,Displacement of [3H]estradiol from full length human recombinant ERbeta after 3 hrs by scintillation proximity assay,Confirmatory,17289385.0,
1456,306466,3,3,,103189263,5757,Unspecified,,,,,"Estrogenic activity in Sprague-Dawley rat assessed as effect on uterine weight at 1 ug/kg, sc",Other,17289385.0,
1457,306467,3,3,,103189263,5757,Unspecified,,,,,Selectivity for human recombinant ERalpha over human recombinant ERbeta,Other,17289385.0,
1458,307129,7,2,,103189263,5757,Active,,,0.012,Ki,Binding affinity to ERalpha,Confirmatory,17379515.0,
1459,307516,8,5,,103189263,5757,Active,544257.0,2099.0,0.0014,IC50,Binding affinity to human recombinant ERalpha by scintillation proximity assay,Confirmatory,17448656.0,
1460,307517,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity to human recombinant ERbeta by scintillation proximity assay,Confirmatory,17448656.0,
1461,307518,3,3,,103189263,5757,Unspecified,,,,,Ratio of IC50 for human ERalpha to IC50 for human ERbeta,Other,17448656.0,
1462,307519,5,6,,103189263,5757,Active,544257.0,2099.0,0.00075,EC50,Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay,Confirmatory,17448656.0,
1463,307520,5,6,,103189263,5757,Active,6166154.0,2100.0,0.0021,EC50,Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay,Confirmatory,17448656.0,
1464,307521,3,3,,103189263,5757,Unspecified,,,,,Ratio of EC50 for human ERalpha to EC50 for human ERbeta,Other,17448656.0,
1465,307522,7,3,,103189263,5757,Active,,,0.0191,IC50,Binding affinity to androgen receptor,Confirmatory,17448656.0,
1466,307523,3,3,,103189263,5757,Unspecified,,,,,Ratio of IC50 for androgen receptor to IC50 for human ERbeta,Other,17448656.0,
1467,307629,8,5,,103189263,5757,Active,215274146.0,2101.0,0.0036,IC50,Inhibition of human ERalpha,Confirmatory,17482813.0,
1468,307630,8,5,,103189263,5757,Active,374095385.0,2103.0,0.0032,IC50,Inhibition of human ERbeta,Confirmatory,17482813.0,
1469,307631,3,3,,103189263,5757,Unspecified,,,,,Selectivity for human ERalpha over ERbeta,Other,17482813.0,
1470,310108,8,5,,103189263,5757,Active,544257.0,2099.0,0.0014,IC50,Binding affinity at human recombinant ERalpha,Confirmatory,17890084.0,
1471,310109,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0012,IC50,Binding affinity at human recombinant ERbeta,Confirmatory,17890084.0,
1472,310110,5,6,,103189263,5757,Unspecified,544257.0,2099.0,,EC50,Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay,Confirmatory,17890084.0,
1473,310111,5,6,,103189263,5757,Unspecified,6166154.0,2100.0,,EC50,Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay,Confirmatory,17890084.0,
1474,310112,3,3,,103189263,5757,Unspecified,,,,,Selectivity for human recombinant ERbeta over ERalpha,Other,17890084.0,
1475,310113,3,3,,103189263,5757,Unspecified,,,,,Selectivity for ERbeta over ERalpha by transactivation assay,Other,17890084.0,
1476,310114,7,3,,103189263,5757,Active,,,0.026000000000000002,IC50,Binding affinity at AR,Confirmatory,17890084.0,
1477,310115,3,3,,103189263,5757,Unspecified,,,,,Selectivity for human recombinant ERbeta over AR,Other,17890084.0,
1478,311367,3,6,,103189263,5757,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
1479,318680,6,5,,103189263,5757,Active,134907.0,6462.0,0.00148,Kd,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,Confirmatory,18330978.0,
1480,320283,6,5,,103189263,5757,Active,,,0.03,Km,Activity of 17beta-HSD1,Confirmatory,18035543.0,
1481,323983,7,1,,103189263,5757,Active,,,,,Estrogenic potency in human MCF7 BUS cells assessed as drug level inducing maximal cell proliferation,Other,18242997.0,
1482,323984,3,4,,103189263,5757,Unspecified,,,,,Proliferative effect in human MCF7 BUS cells assessed as ratio of increase in cell number in drug treated to control,Other,18242997.0,
1483,324923,7,6,,103189263,5757,Active,74762624.0,151306.0,38.4,EC50,Agonist activity at human TGR5 expressed in CHO cells by luciferase assay,Confirmatory,18307294.0,
1484,324924,3,10,,103189263,5757,Unspecified,74762624.0,151306.0,,,Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid,Other,18307294.0,
1485,333508,11,2,,103189263,5757,Active,544257.0,2099.0,0.00037,EC50,Estrogenic activity at human estrogen receptor expressing Saccharomyces cerevisiae carrying estrogen responsive sequence containing plasmid assessed as metabolism of chlorophenol res beta-D-galactopyranoside,Confirmatory,15568770.0,
1486,333509,11,2,,103189263,5757,Active,544257.0,2099.0,4.7e-05,EC50,Estrogenic activity at estrogen receptor in human Ishikawa Var-1 cells assessed as stimulation of alkaline phosphatase activity measured by metabolism of p-nitrophenol phosphatase after 72 hrs,Confirmatory,15568770.0,
1487,348696,8,5,,103189263,5757,Active,544257.0,2099.0,0.004,IC50,Binding affinity to human recombinant ERalpha receptor by liquid scintillation counter,Confirmatory,18760603.0,
1488,348697,8,5,,103189263,5757,Active,6166154.0,2100.0,0.004,IC50,Binding affinity to human recombinant ERbeta receptor by liquid scintillation counter,Confirmatory,18760603.0,
1489,348700,10,1,,103189263,5757,Active,,,3.7000000000000006e-06,EC50,Estrogenic activity in human MCF7 cells assessed as cell proliferation after 6 days by WST8 assay,Confirmatory,18760603.0,
1490,350859,8,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity to full-length human estrogen receptor alpha,Confirmatory,19359182.0,
1491,350860,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity to full-length human estrogen receptor beta,Confirmatory,19359182.0,
1492,359098,3,3,,103189263,5757,Active,,,,,Antiapoptotic activity against osteoblasts in ovariectomized Wistar rat at 0.1 mg/kg after 10 weeks,Other,17513867.0,
1493,366229,3,3,,103189263,5757,Active,,,,,Stimulation of human T47C cell proliferation at 0.1 nM after 8 days by MTT assay,Other,18630892.0,
1494,367436,7,1,,103189263,5757,Unspecified,,,,,Antibone resorptive activity in sc dosed Sprague-Dawley rat assessed as inhibition of bilaterally ovariectomization-induced decrease in body weight normalized femoral mass administered 4 days after sugery at three times per week schedule for 6 weeks,Other,19117754.0,
1495,367437,7,1,,103189263,5757,Unspecified,,,,,Antibone resorptive activity in sc dosed Sprague-Dawley rat assessed as inhibition of bilaterally ovariectomization-induced decrease in body weight normalized uterine mass administered 4 days after sugery at three times per week schedule for 6 weeks,Other,19117754.0,
1496,367864,5,6,,103189263,5757,Active,6166154.0,2100.0,0.00013000000000000002,EC50,Agonist activity at full-length human estrogen receptor beta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay,Confirmatory,19128016.0,
1497,367865,5,6,,103189263,5757,Active,544257.0,2099.0,0.0007,EC50,Agonist activity at full-length human estrogen receptor alpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay,Confirmatory,19128016.0,
1498,367866,3,3,,103189263,5757,Unspecified,,,,,Ratio of transcriptional potency for full-length human estrogen receptor beta to transcriptional potency for full-length human estrogen receptor alpha relative to estradiol,Other,19128016.0,
1499,373496,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as calcium level in serum at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment by o-methyl-phenolphthalein method",Other,19004530.0,
1500,373497,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as phosphorous level in serum at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment by molybdenum blue method",Other,19004530.0,
1501,373498,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as weight of dry femur at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1502,373499,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as weight of femur ash at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1503,373500,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as length of femur at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1504,373501,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as calcium content in femur at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment by o-methyl-phenolphthalein",Other,19004530.0,
1505,373502,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as phosphorous content in femur at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment by molybdenum blue method",Other,19004530.0,
1506,373503,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity in ovariectomized ICR mouse assessed as mineral content in femur at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1507,373504,3,4,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as spleen weight at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1508,373505,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as lung weight at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1509,373506,3,4,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as kidney weight at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1510,373507,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as liver weight at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1511,373508,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as effect on tail bleeding time at 110.3 nmol/kg, po treated for 4 weeks measured after 30 mins of last treatment",Other,19004530.0,
1512,373509,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as effect on tail bleeding time at 110.3 nmol/kg, po treated for 4 weeks measured after 90 mins of last treatment",Other,19004530.0,
1513,373510,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as effect on uterine weight at 110.3 nmol/kg, po treated for 4 weeks measured after 1 day of last treatment",Other,19004530.0,
1514,377755,3,4,,103189263,5757,Unspecified,,,,,Estrogenic effect in human MCF7 cells assessed as stimulation of cell proliferation at 0.1 nM relative to control by [3H]hypoxanthine incorporation assay,Other,15787464.0,
1515,377756,3,4,,103189263,5757,Unspecified,,,,,Estrogenic effect in human MCF7 cells assessed as stimulation of cell proliferation at 1 nM relative to control by [3H]hypoxanthine incorporation assay,Other,15787464.0,
1516,377757,3,4,,103189263,5757,Unspecified,,,,,Estrogenic effect in human MCF7 cells assessed as stimulation of cell proliferation at 10 nM relative to control by [3H]hypoxanthine incorporation assay,Other,15787464.0,
1517,380095,3,5,,103189263,5757,Unspecified,,,,,Stimulation of cell proliferation in human MCF7 cells assessed as cell viability at 3.7 nM after 4 days relative to control,Other,16562825.0,
1518,385222,3,10,,103189263,5757,Unspecified,215274146.0,2101.0,,,Displacement of [3H]estradiol from human ERalpha receptor at 1 uM by radiometric binding assay,Other,18412324.0,
1519,385223,3,10,,103189263,5757,Unspecified,374095385.0,2103.0,,,Displacement of [3H]estradiol from human ERbeta receptor at 1 uM by radiometric binding assay,Other,18412324.0,
1520,386623,4,8,,103189263,5757,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1521,387083,8,5,,103189263,5757,Active,544257.0,2099.0,0.002,Ki,Displacement of [3H]estradiol from full length biotinylated human ERalpha by scintillation proximity assay,Confirmatory,18722117.0,
1522,387084,8,5,,103189263,5757,Active,6166154.0,2100.0,0.002,Ki,Displacement of [3H]estradiol from full length biotinylated human ERbeta by scintillation proximity assay,Confirmatory,18722117.0,
1523,397673,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Activity at ERbeta in human MCF7 cells assessed as change in c-myc protein level at 10 nM after 12 hrs by Western blot analysis relative to actin,Other,19356928.0,
1524,397674,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Activity at ERbeta in human MCF7 cells assessed as change in p21 protein level at 10 nM after 12 hrs by Western blot analysis relative to actin,Other,19356928.0,
1525,397675,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Activity at ERbeta in human MCF7 cells assessed as change in p27 protein level at 10 nM after 12 hrs by Western blot analysis relative to actin,Other,19356928.0,
1526,399373,8,1,,103189263,5757,Unspecified,,,,,Binding affinity to SHBG,Other,9461660.0,
1527,402359,3,11,,103189263,5757,Active,544257.0,2099.0,,,Activity at human estrogen receptor expressed in transgenic Arabidopsis plant at 1 uM by pER8-GFP reporter assay,Other,16038533.0,
1528,404304,3,10,,103189263,5757,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1529,404864,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Activation of human estrogen receptor beta expressed in HEK293 cells at 1 nM beta-galactosidase reporter gene assay relative to control,Other,18517258.0,
1530,404866,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Activation of human estrogen receptor alpha expressed in HEK293 cells at 1 nM in presence of ICI-182780 beta-galactosidase reporter gene assay relative to control,Other,18517258.0,
1531,404868,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Activation of human estrogen receptor alpha expressed in HEK293 cells at 1 nM beta-galactosidase reporter gene assay relative control,Other,18517258.0,
1532,404871,3,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Activation of human estrogen receptor beta expressed in HEK293 cells at 1 nM in presence of ICI-182781 beta-galactosidase reporter gene assay relative to control,Other,18517258.0,
1533,409954,4,9,,103189263,5757,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1534,409956,4,9,,103189263,5757,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
1535,417707,3,10,,103189263,5757,Unspecified,119600.0,24890.0,,,Binding affinity to rat uterus estrogen receptor at 0.01 uM,Other,18472187.0,
1536,417711,3,10,,103189263,5757,Unspecified,113832.0,24208.0,,,Binding affinity to rat ventral prostate androgen receptor at 0.01 uM,Other,18472187.0,
1537,417715,3,10,,103189263,5757,Unspecified,18202596.0,25154.0,,,Binding affinity to rat uterus progesterone receptor at 0.01 uM,Other,18472187.0,
1538,417719,3,10,,103189263,5757,Unspecified,1169883.0,24413.0,,,Binding affinity to rat liver glucocorticoid receptor at 0.01 uM,Other,18472187.0,
1539,424686,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum calcium level at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1540,424687,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum phosphorous level at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1541,424688,8,1,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum ALP activity at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1542,424689,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as dry femur weight at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1543,424690,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur ash weight at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1544,424691,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur length at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1545,424692,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur calcium content at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1546,424693,3,4,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur phosphorous content at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1547,424694,3,3,,103189263,5757,Unspecified,,,,,"Antiosteoporosis activity against ovariectomized ICR mouse assessed as mineral content at 110.3 nmol/kg, po after 30 mins",Other,19386502.0,
1548,424700,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as tail bleeding time at 110.3 nmol/kg, po for 30 mins",Other,19386502.0,
1549,424701,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as tail bleeding time at 110.3 nmol/kg, po for 90 mins",Other,19386502.0,
1550,424702,3,3,,103189263,5757,Unspecified,,,,,"Toxicity in ovariectomized ICR mouse assessed as change in uterine weight at 110.3 nmol/kg, po after 4 weeks",Other,19386502.0,
1551,424744,8,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity to full-length human estrogen receptor alpha,Confirmatory,19394231.0,
1552,424745,8,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity to full-length human estrogen receptor beta,Confirmatory,19394231.0,
1553,434955,1,2,,8139865,5757,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1554,434959,1,1,,85788274,5757,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1555,434962,1,2,,8139865,5757,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1556,434973,1,3,,8139865,5757,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1557,434989,1,1,,8139865,5757,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1558,435003,1,3,,8139865,5757,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1559,435005,1,1,,8139865,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1560,435022,2,2,,8139865,5757,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1561,435030,1,2,,8139865,5757,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1562,435030,1,2,,8139865,5757,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1563,436098,3,5,,103189263,5757,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 0.1 nM by MTT assay relative to control in presence of 17-beta-estradiol,Other,18986200.0,
1564,436101,3,5,,103189263,5757,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 0.1 nM by MTT assay relative to control in absence of 17-beta-estradiol,Other,18986200.0,
1565,436349,3,7,,103189263,5757,Active,,,0.0001,EC50,Agonist activity at ERalpha expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay,Confirmatory,19286283.0,
1566,436350,3,6,,103189263,5757,Active,,,0.0005,EC50,Agonist activity at ERbeta expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay,Confirmatory,19286283.0,
1567,436351,3,3,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for ERbeta to EC50 for ERalpha expressed in human HEC1 cells,Other,19286283.0,
1568,436352,7,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity to human full length ERalpha receptor,Confirmatory,19286283.0,
1569,436353,7,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity to human full length ERbeta receptor,Confirmatory,19286283.0,
1570,436354,3,3,,103189263,5757,Unspecified,,,,,Selectivity ratio of Kd for human full length ERbeta receptor to Kd for human full length ERalpha receptor,Other,19286283.0,
1571,446618,3,7,,103189263,5757,Unspecified,,,,,Displacement of estradiol-Alexa 633 from GFP-tagged ERalpha expressed in COS7 cells at 10 uM,Other,20041667.0,
1572,446619,3,6,,103189263,5757,Unspecified,,,,,Displacement of estradiol-Alexa 633 from GFP-tagged ERbeta expressed in COS7 cells at 10 uM,Other,20041667.0,
1573,446620,3,10,,103189263,5757,Unspecified,3023539.0,2852.0,,,"Displacement of 1-{2-[4-(6-bromobenzo[1,3]dioxol-5- yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethyl}- 3-(3-iodo(125)-phenyl)urea from GPR30 in human Hec50 cells",Other,20041667.0,
1574,446621,3,10,,103189263,5757,Unspecified,3023539.0,2852.0,,,Agonist activity at GPR30 in human SKBr3 cells assessed as stimulation of calcium mobilization at 10 uM relative to 200 nM estradiol,Other,20041667.0,
1575,446622,3,10,,103189263,5757,Unspecified,3023539.0,2852.0,,,Antagonist activity at GPR30 in human SKBr3 cells assessed as inhibition of estradiol-induced calcium mobilization at 10 uM,Other,20041667.0,
1576,446623,3,7,,103189263,5757,Unspecified,,,,,Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay relative to 10 nM estradiol,Other,20041667.0,
1577,446624,3,7,,103189263,5757,Unspecified,,,,,Antagonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as inhibition of estradiol-induced PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay,Other,20041667.0,
1578,446625,3,6,,103189263,5757,Unspecified,,,,,Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay relative to 10 nM estradiol,Other,20041667.0,
1579,446626,3,6,,103189263,5757,Unspecified,,,,,Antagonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as inhibition of estradiol-induced PI3K activation at 10 uM by PIP3 localization based PH-RFP reporter gene assay,Other,20041667.0,
1580,449728,1,2,,8139865,5757,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1581,449739,1,2,,8139865,5757,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1582,449762,1,2,,8139865,5757,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1583,449763,1,3,,8139865,5757,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1584,449768,1,1,,8139865,5757,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1585,455986,3,5,,103189263,5757,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
1586,459501,3,4,,103189263,5757,Active,,,,,"Estrogenic activity in uterus of ovariectomized Sprague-Dawley rat assessed as increase in uterus weight at 0.1 mg/kg, iv administered three times per week for 4 weeks on the first, second, and fifth days",Other,20071185.0,
1587,459502,3,3,,103189263,5757,Active,,,,,"Estrogenic activity in bone of ovariectomized Sprague-Dawley rat assessed as increase in bone mass at 0.1 mg/kg, iv administered three times per week for 4 weeks on the first, second, and fifth days",Other,20071185.0,
1588,463073,1,2,,8139865,5757,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1589,463075,1,1,,8139865,5757,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1590,463079,1,2,,8139865,5757,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1591,463082,1,1,,8139865,5757,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1592,463096,1,1,,50105619,5757,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1593,463097,1,1,,50105619,5757,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1594,463104,1,2,,8139865,5757,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1595,463106,1,2,,90341590,5757,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1596,463111,1,1,,8139865,5757,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1597,463115,1,1,,8139865,5757,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1598,463141,1,2,,8139865,5757,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1599,463165,1,1,,8139865,5757,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1600,463187,1,1,,8139865,5757,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1601,463189,1,1,,53777609,5757,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1602,463190,1,2,,8139865,5757,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1603,463193,1,1,,8139865,5757,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1604,463195,1,2,,8139865,5757,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1605,463210,1,2,,8139865,5757,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1606,463212,1,1,,8139865,5757,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1607,463254,1,1,,8139865,5757,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1608,467612,3,6,,103189263,5757,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1609,467613,5,3,,103189263,5757,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1610,467824,7,5,,103189263,5757,Active,544257.0,2099.0,0.0125,IC50,Displacement of [3H]17beta-estradiol from human ERalpha expressed in SF9 cells,Confirmatory,19836949.0,
1611,468381,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Agonist activity at ERalpha in human MCF7:D5L cells assessed as induction of ERE-dependent luciferase expression at 1 uM relative to control,Other,19845386.0,
1612,468387,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Agonist activity at estrogen receptor in human Ishikawa cells assessed as induction of ERE-dependent alkaline phosphatase level at 0.1 uM relative to control,Other,19845386.0,
1613,468984,4,10,,103189263,5757,Unspecified,8134404.0,51478.0,,,Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs,Other,19772289.0,
1614,468985,3,11,,103189263,5757,Unspecified,8134404.0,51478.0,,,Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs,Other,19772289.0,
1615,469725,6,1,,103189263,5757,Active,,,0.0032,EC50,Agonist activity at estrogen receptor alpha ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay,Confirmatory,19863083.0,
1616,469730,6,1,,103189263,5757,Active,,,0.011000000000000001,EC50,Agonist activity at estrogen receptor beta ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay,Confirmatory,19863083.0,
1617,471328,7,5,,103189263,5757,Active,544257.0,2099.0,0.0032,IC50,Displacement of fluorescent estrogen ES2 from human recombinant ERalpha by fluorescence polarization assay,Confirmatory,19705860.0,
1618,471329,7,5,,103189263,5757,Active,6166154.0,2100.0,0.0029,IC50,Displacement of fluorescent estrogen ES2 from human recombinant ERbeta by fluorescence polarization assay,Confirmatory,19705860.0,
1619,473401,3,11,,103189263,5757,Active,544257.0,2099.0,,,Activation of human ER in human MCF7:WS8 cells expressing estrogen responsive element by luciferase reporter gene assay,Other,20334368.0,
1620,473402,7,1,,103189263,5757,Active,,,1e-06,EC50,Estrogenic activity in human ERalpha expressing MCF7:WS8 cells assessed as stimulation of cell proliferation after 7 days,Confirmatory,20334368.0,
1621,473406,3,7,,103189263,5757,Active,,,,,Estrogenic activity at wild type ER alpha expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay,Other,20334368.0,
1622,473407,3,4,,103189263,5757,Active,,,,,Estrogenic activity at wild type ER alpha D351G mutant expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay,Other,20334368.0,
1623,478658,7,2,,103189263,5757,Active,,,0.01012,IC50,Binding affinity to ERalpha by fluorescence polarization-based competitive binding assay,Confirmatory,20408532.0,
1624,478659,7,2,,103189263,5757,Active,,,0.01135,IC50,Binding affinity to ERbeta by fluorescence polarization-based competitive binding assay,Confirmatory,20408532.0,
1625,478662,10,2,,103189263,5757,Active,544257.0,2099.0,6.459999999999998e-05,EC50,Transactivation of human ERalpha expressed in HEK293 cells after 18 hrs by luciferase reporter gene assay,Confirmatory,20408532.0,
1626,478663,10,2,,103189263,5757,Active,6166154.0,2100.0,6.17e-05,EC50,Transactivation of human ERbeta expressed in HEK293 cells after 18 hrs by luciferase reporter gene assay,Confirmatory,20408532.0,
1627,478669,3,3,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for human ERalpha to EC50 for human ERbeta,Other,20408532.0,
1628,480631,3,3,,103189263,5757,Unspecified,,,,,Selectivity ratio of relative binding affinity for human ERalpha to relative binding affinity for human ERbeta,Other,20430632.0,
1629,480632,3,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Induction of ERalpha-mediated pS2 gene expression in human MCF7 cells at 10 nM after 24 hrs by real-time quantitative PCR analysis relative to control,Other,20430632.0,
1630,482349,5,3,,103189263,5757,Active,,,0.00108,EC50,Agonist activity at ERbeta expressed in yeast assessed as alpha-galactosidase activity,Confirmatory,20553023.0,
1631,482350,3,6,,103189263,5757,Active,,,,,Agonist activity at ERbeta expressed in yeast assessed as alpha-galactosidase activity relative to E2,Other,20553023.0,
1632,482352,5,3,,103189263,5757,Active,,,0.00105,EC50,Agonist activity at ERalpha expressed in yeast assessed as alpha-galactosidase activity,Confirmatory,20553023.0,
1633,482353,3,7,,103189263,5757,Active,,,,,Agonist activity at ERalpha expressed in yeast assessed as alpha-galactosidase activity relative to E2,Other,20553023.0,
1634,482354,3,4,,103189263,5757,Unspecified,,,,,Selectivity ratio for ERalpha to ERbeta,Other,20553023.0,
1635,482355,5,3,,103189263,5757,Active,,,0.05,EC50,Agonist activity at ERalpha expressed in CHO-K1 cells by luciferase reporter gene transactivation assay,Confirmatory,20553023.0,
1636,482356,5,3,,103189263,5757,Active,,,0.03,EC50,Agonist activity at ERbeta expressed in CHO-K1 cells by luciferase reporter gene transactivation assay,Confirmatory,20553023.0,
1637,485270,1,1,,8139865,5757,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1638,485272,1,1,,8139865,5757,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1639,485273,2,1,,8139865,5757,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1640,485275,1,3,,8139865,5757,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1641,485281,1,1,,8139865,5757,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1642,485281,1,1,,26753050,5757,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1643,485281,1,1,,26753051,5757,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1644,485281,1,1,,29215116,5757,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1645,485281,1,1,,29215117,5757,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1646,485290,1,1,,8139865,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1647,485290,1,1,,17389898,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1648,485290,1,1,,26753050,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1649,485290,1,1,,26753051,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1650,485290,1,1,,29215116,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1651,485290,1,1,,29215117,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1652,485290,1,1,,50105619,5757,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1653,485294,1,1,,8139865,5757,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1654,485295,1,2,,90341590,5757,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1655,485297,1,1,,8139865,5757,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1656,485297,1,1,,90341590,5757,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1657,485298,1,1,,8139865,5757,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1658,485298,1,1,,90341590,5757,Active,,,23.1093,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1659,485313,1,2,,8139865,5757,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1660,485313,1,2,,90341590,5757,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1661,485314,1,1,,8139865,5757,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1662,485314,1,1,,50105619,5757,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1663,485341,1,1,,8139865,5757,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1664,485342,1,2,,90341590,5757,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1665,485344,1,1,,8139865,5757,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1666,485345,1,2,,90341590,5757,Inconclusive,,,25.929000000000002,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1667,485346,1,1,,8139865,5757,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1668,485346,1,1,,8139865,5757,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1669,485347,1,2,,8139865,5757,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1670,485349,1,1,,8139865,5757,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1671,485350,1,2,,92125448,5757,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1672,485350,1,2,,99300971,5757,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1673,485353,2,1,,8139865,5757,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1674,485358,1,1,,8139865,5757,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1675,485360,1,1,,8139865,5757,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1676,485364,1,1,,8139865,5757,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1677,485366,1,2,,90341590,5757,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1678,485367,1,2,,8139865,5757,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1679,485368,1,2,,90341590,5757,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1680,488745,1,4,,50105619,5757,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1681,488752,1,4,,50105619,5757,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1682,488772,1,1,,90341590,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1683,488773,1,2,,90341590,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1684,488806,1,2,,8139865,5757,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1685,488816,1,1,,90341590,5757,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1686,488837,1,1,,8139865,5757,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1687,488837,1,1,,90341590,5757,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1688,488839,1,1,,56422158,5757,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1689,488839,1,1,,56422158,5757,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1690,488847,1,3,,8139865,5757,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1691,488862,1,1,,56422158,5757,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1692,488890,1,2,,8139865,5757,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1693,488895,1,2,,56422158,5757,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1694,488896,1,1,,56422158,5757,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1695,488899,1,1,,56422158,5757,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1696,488922,1,2,,8139865,5757,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1697,488949,1,2,,50105619,5757,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1698,488949,1,2,,90341590,5757,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1699,488953,1,1,,90341590,5757,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1700,488965,1,2,,56422158,5757,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1701,488966,1,1,,56422158,5757,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1702,488975,1,2,,8139865,5757,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1703,488977,1,2,,8139865,5757,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1704,488978,1,1,,90341590,5757,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1705,488979,1,1,,50105619,5757,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1706,488980,1,1,,50105619,5757,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1707,488981,1,1,,90341590,5757,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1708,488982,1,1,,90341590,5757,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1709,488983,1,1,,90341590,5757,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1710,489030,2,1,,8139865,5757,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1711,489031,2,1,,8139865,5757,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1712,492947,1,1,,8139865,5757,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1713,492953,1,1,,56422158,5757,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1714,492956,1,1,,56422158,5757,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1715,492961,1,1,,29215116,5757,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1716,492967,1,2,,92125448,5757,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1717,492972,1,1,,56422158,5757,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1718,493005,1,1,,56422158,5757,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1719,493008,1,1,,56422158,5757,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1720,493008,1,1,,56422158,5757,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1721,493008,1,1,,56422158,5757,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1722,493008,1,1,,56422158,5757,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1723,493011,1,1,,8139865,5757,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1724,493012,1,1,,8139865,5757,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1725,493014,1,1,,8139865,5757,Inconclusive,,,16.3601,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1726,493027,1,2,,56422158,5757,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1727,493027,1,2,,56422158,5757,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1728,493033,1,2,,92125448,5757,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1729,493033,1,2,,99300971,5757,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1730,493035,1,2,,56422158,5757,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1731,493035,1,2,,56422158,5757,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1732,493036,1,2,,8139865,5757,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1733,493056,1,1,,8139865,5757,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1734,493084,1,1,,8139865,5757,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1735,493087,1,1,,56422158,5757,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1736,493091,1,1,,56422158,5757,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1737,493098,1,1,,56422158,5757,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1738,493106,1,1,,90341590,5757,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1739,493107,1,1,,90341590,5757,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1740,493127,1,1,,50105619,5757,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1741,493131,1,1,,56422158,5757,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1742,493140,1,1,,103913787,5757,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1743,493153,1,1,,90341590,5757,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1744,493153,1,1,,90341590,5757,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1745,493160,1,1,,56422158,5757,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1746,493162,1,2,,99302491,5757,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1747,493164,1,2,,90341590,5757,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1748,493164,1,2,,90341590,5757,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1749,493164,1,2,,90341590,5757,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1750,493187,1,2,,56422158,5757,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1751,493189,1,1,,50105619,5757,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1752,493244,1,1,,56422158,5757,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1753,493244,1,1,,56422158,5757,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1754,493244,1,1,,56422158,5757,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1755,493244,1,1,,56422158,5757,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1756,496817,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
1757,496818,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
1758,496819,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1759,496820,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
1760,496821,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
1761,496823,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1762,496824,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1763,496825,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
1764,496826,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
1765,496827,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
1766,496828,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
1767,496829,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
1768,496830,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
1769,496831,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1770,496832,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
1771,497005,4,2,,103189263,5757,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1772,497602,6,5,,103189263,5757,Active,544257.0,2099.0,0.00016,Ki,"Displacement of [2,4,6,7-3H]estradiol from human ERalpha expressed in HeLa cells after 18 hrs by liquid scintillation counting",Confirmatory,20621492.0,
1773,499038,2,11,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at human ERalpha ligand binding domain expressed in Escherichia coli BL21(DE3) cells assessed as induction of coactivator 53-protein binding by fluorescence assay,Other,19561619.0,
1774,499039,2,10,,103189263,5757,Active,6166154.0,2100.0,,,Agonist activity at human ERbeta ligand binding domain expressed in Escherichia coli BL21(DE3) cells assessed as induction of coactivator 53-protein binding by fluorescence assay,Other,19561619.0,
1775,499821,2,9,,103189263,5757,Unspecified,,,,,Displacement of fluorescent labeled ES2 from recombinant ERalpha relative to estradiol,Other,20669983.0,
1776,499828,2,5,,103189263,5757,Unspecified,,,,,Estrogenic activity in human MCF7 cells assessed as increase of estradiol-induced cell proliferation at 0.1 uM after 48 hrs by clonogenic assay relative to control,Other,20669983.0,
1777,501524,2,11,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at human wild type ERalpha expressed in human HeLa cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay,Other,20659801.0,
1778,501529,2,4,,103189263,5757,Active,,,0.0025,EC50,Agonist activity at human ERalpha E353A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay,Confirmatory,20659801.0,
1779,501530,2,4,,103189263,5757,Active,,,0.0104,EC50,Agonist activity at human ERbeta E305A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay,Confirmatory,20659801.0,
1780,501532,2,11,,103189263,5757,Active,544257.0,2099.0,,,Transactivation of human wild type ERalpha expressed in human HeLa cells co-expressing AP-1 by luciferase reporter gene assay,Other,20659801.0,
1781,501534,2,10,,103189263,5757,Active,6166154.0,2100.0,,,Agonist activity at human wild type ERbeta expressed in human HeLa cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay,Other,20659801.0,
1782,501537,3,6,,103189263,5757,Active,6166154.0,2100.0,,EC50,Antagonist activity at human wild type ERbeta expressed in human HeLa cells co-expressing AP-1 assessed as inhibition of transactivation activity by luciferase reporter gene assay,Confirmatory,20659801.0,
1783,503065,5,1,,103189263,5757,Active,,,0.0057,Ki,Displacement of E2-Alexa633 from GFP-tagged GPR30 expressed in COS7 cells by FACS,Confirmatory,16520733.0,
1784,503066,5,1,,103189263,5757,Active,,,0.0003,Ki,Displacement of E2-Alexa633 from GFP-tagged ERalpha expressed in COS7 cells by FACS,Confirmatory,16520733.0,
1785,503067,5,1,,103189263,5757,Active,,,0.00037999999999999997,Ki,Displacement of E2-Alexa633 from GFP-tagged ERbeta expressed in COS7 cells by FACS,Confirmatory,16520733.0,
1786,503070,4,3,,103189263,5757,Unspecified,,,,,Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level at 1 nM by spectrofluorimetry,Other,16520733.0,
1787,503072,2,7,,103189263,5757,Active,,,,,Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as increase in intracellular calcium level at 1 nM by spectrofluorimetry,Other,16520733.0,
1788,503073,2,6,,103189263,5757,Active,,,,,Agonist activity at GFP-tagged ERbeta expressed in COS7 cells assessed as increase in intracellular calcium level at 1 nM by spectrofluorimetry,Other,16520733.0,
1789,503076,2,6,,103189263,5757,Active,,,0.0003,EC50,Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level by spectrofluorimetry,Confirmatory,16520733.0,
1790,503077,2,7,,103189263,5757,Active,,,,,Agonist activity at GFP-tagged ERalpha expressed in COS7 cells assessed as PI3K activation at 1 nM by PIP3 nuclear accumulation assay,Other,16520733.0,
1791,503157,2,6,,103189263,5757,Active,,,,,Agonist activity at GFP-tagged ERbeta expressed in COS7 cells assessed as PI3K activation at 1 nM by PIP3 nuclear accumulation assay,Other,16520733.0,
1792,503158,2,6,,103189263,5757,Active,,,,,Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as PI3K activation at 1 nM by PIP3 nuclear accumulation assay,Other,16520733.0,
1793,503162,2,6,,103189263,5757,Active,,,,,Binding affinity to mRFP1-tagged GPR30 expressed in COS7 cells coexpressing GFP-tagged ERalpha assessed as inhibition of E2-Alexa633 binding in nucleus at 1 uM by FACS,Other,16520733.0,
1794,503163,2,7,,103189263,5757,Active,,,,,Binding affinity to GFP-tagged ERalpha expressed in COS7 cells coexpressing mRFP1-tagged GPR30 assessed as inhibition of E2-Alexa633 binding in nucleus at 1 uM by FACS,Other,16520733.0,
1795,503166,2,4,,103189263,5757,Active,,,0.0001,IC50,Inhibition of chemoattractant-induced cell migration of human SK-BR-3 cells after 48 hrs by transwell migration assay,Confirmatory,16520733.0,
1796,503167,2,4,,103189263,5757,Active,,,0.0004,IC50,Inhibition of chemoattractant-induced cell migration of human MCF7 cells after 48 hrs by transwell migration assay,Confirmatory,16520733.0,
1797,503305,2,5,,103189263,5757,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 500 nM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
1798,504326,1,2,,56422158,5757,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1799,504326,1,2,,56422158,5757,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1800,504327,1,1,,8139865,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1801,504327,1,1,,26753050,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1802,504327,1,1,,26753051,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1803,504327,1,1,,29215116,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1804,504327,1,1,,29215117,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1805,504327,1,1,,90341590,5757,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1806,504329,1,1,,56422158,5757,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1807,504332,1,1,,8139865,5757,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1808,504332,1,1,,26753050,5757,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1809,504332,1,1,,26753051,5757,Active,168985070.0,,19.9526,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1810,504332,1,1,,29215116,5757,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1811,504332,1,1,,50105619,5757,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1812,504332,1,1,,90341590,5757,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1813,504333,1,1,,8139865,5757,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1814,504339,1,1,,56422158,5757,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1815,504357,1,1,,56422158,5757,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1816,504357,1,1,,56422158,5757,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1817,504364,1,1,,50105619,5757,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1818,504406,1,1,,8139865,5757,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1819,504408,2,1,,8139865,5757,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1820,504411,1,1,,56422158,5757,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1821,504414,1,1,,56422158,5757,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1822,504414,1,1,,56422158,5757,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1823,504423,1,1,,56422158,5757,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1824,504441,1,1,,56422158,5757,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1825,504444,1,1,,56422158,5757,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1826,504454,1,3,,56422158,5757,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1827,504459,1,3,,8139865,5757,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1828,504462,1,1,,56422158,5757,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1829,504466,1,1,,8139865,5757,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1830,504467,1,1,,8139865,5757,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1831,504490,1,2,,56422158,5757,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1832,504523,1,1,,56422158,5757,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1833,504523,1,1,,56422158,5757,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1834,504536,1,1,,90341590,5757,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1835,504541,1,1,,8139865,5757,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1836,504547,1,1,,90341590,5757,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1837,504548,1,2,,90341590,5757,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1838,504558,1,1,,56422158,5757,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1839,504577,2,2,,56422158,5757,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1840,504582,2,1,,56422158,5757,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1841,504594,1,1,,56422158,5757,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1842,504600,1,2,,8139865,5757,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1843,504621,1,1,,56422158,5757,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1844,504634,1,1,,56422158,5757,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1845,504648,1,1,,56422158,5757,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1846,504651,1,1,,8139865,5757,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1847,504652,1,1,,8139865,5757,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1848,504660,1,1,,8139865,5757,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1849,504690,1,3,,56422158,5757,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1850,504692,2,2,,56422158,5757,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1851,504700,1,1,,56422158,5757,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1852,504700,1,1,,56422158,5757,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1853,504706,1,1,,8139865,5757,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1854,504707,1,1,,56422158,5757,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1855,504707,1,1,,56422158,5757,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1856,504720,1,1,,56422158,5757,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1857,504734,1,1,,56422158,5757,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1858,504749,1,3,,29215116,5757,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1859,504749,1,3,1.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1860,504749,1,3,2.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1861,504749,1,3,3.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1862,504749,1,3,4.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1863,504749,1,3,5.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1864,504749,1,3,6.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1865,504749,1,3,7.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1866,504749,1,3,8.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1867,504749,1,3,9.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1868,504749,1,3,10.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1869,504749,1,3,11.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1870,504749,1,3,12.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1871,504749,1,3,13.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1872,504749,1,3,14.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1873,504749,1,3,15.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1874,504749,1,3,16.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1875,504749,1,3,17.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1876,504749,1,3,18.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1877,504749,1,3,19.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1878,504749,1,3,20.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1879,504749,1,3,21.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1880,504749,1,3,22.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1881,504749,1,3,23.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1882,504749,1,3,24.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1883,504749,1,3,25.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1884,504749,1,3,26.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1885,504749,1,3,27.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1886,504749,1,3,28.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1887,504749,1,3,29.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1888,504749,1,3,30.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1889,504749,1,3,31.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1890,504749,1,3,32.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1891,504749,1,3,33.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1892,504749,1,3,34.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1893,504749,1,3,35.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1894,504749,1,3,36.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1895,504749,1,3,37.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1896,504749,1,3,38.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1897,504749,1,3,39.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1898,504749,1,3,40.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1899,504749,1,3,41.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1900,504749,1,3,42.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1901,504749,1,3,43.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1902,504749,1,3,44.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1903,504749,1,3,45.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1904,504749,1,3,46.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1905,504749,1,3,47.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1906,504749,1,3,48.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1907,504749,1,3,49.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1908,504749,1,3,50.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1909,504749,1,3,51.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1910,504749,1,3,52.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1911,504749,1,3,53.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1912,504749,1,3,54.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1913,504749,1,3,55.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1914,504749,1,3,56.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1915,504749,1,3,57.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1916,504749,1,3,58.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1917,504749,1,3,59.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1918,504749,1,3,60.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1919,504749,1,3,61.0,29215116,5757,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1920,504766,2,1,,56422158,5757,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1921,504775,1,1,,56422158,5757,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1922,504803,1,1,,56422158,5757,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1923,504810,1,2,,8139865,5757,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1924,504810,1,2,,90341590,5757,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1925,504812,1,2,,8139865,5757,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1926,504812,1,2,,90341590,5757,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1927,504821,1,1,,50105619,5757,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1928,504832,1,1,,8139865,5757,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1929,504832,1,1,,29215116,5757,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1930,504834,1,1,,8139865,5757,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1931,504834,1,1,,29215116,5757,Inconclusive,,,6.7456,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1932,504836,1,2,,90341590,5757,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1933,504842,1,1,,8139865,5757,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1934,504845,1,1,,26753050,5757,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1935,504845,1,1,,26753051,5757,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1936,504845,1,1,,56422158,5757,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1937,504845,1,1,,90341590,5757,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1938,504847,1,1,,26753050,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1939,504847,1,1,,26753051,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1940,504847,1,1,,29215116,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1941,504847,1,1,,29215117,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1942,504847,1,1,,56422158,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1943,504847,1,1,,90341590,5757,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1944,504865,1,1,,29215116,5757,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1945,504865,1,1,,90341590,5757,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1946,504884,1,2,,56422158,5757,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1947,504891,1,1,,56422158,5757,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1948,504894,1,1,,56422158,5757,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1949,504937,1,2,,56422158,5757,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1950,517024,5,6,,103189263,5757,Active,544257.0,2099.0,0.00277,EC50,Agonist activity at ERalpha-LBD in human U2OS cells transfected with Gal4-DBD assessed as increase of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1951,517025,5,6,,103189263,5757,Active,6166154.0,2100.0,0.000458,EC50,Agonist activity at ERbeta-LBD in human U2OS cells transfected with Gal4-DBD assessed as increase of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1952,517031,5,6,,103189263,5757,Active,544257.0,2099.0,0.02104,IC50,Antagonist activity at ERalpha-LBD in human U2OS cells transfected with Gal4-DBD assessed as inhibition of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1953,517032,5,6,,103189263,5757,Active,6166154.0,2100.0,0.010740000000000001,IC50,Antagonist activity at ERbeta-LBD in human U2OS cells transfected with Gal4-DBD assessed as inhibition of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1954,521220,3,3,,103189263,5757,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1955,539436,1,4,,103189263,5757,Unspecified,,,,,Binding affinity to hydroxyapatite at 10 nM by UV-spectroscopy relative to tetracycline,Other,21055931.0,
1956,540209,4,3,,103189263,5757,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1957,540210,4,3,,103189263,5757,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1958,540211,2,5,,103189263,5757,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1959,540212,4,3,,103189263,5757,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1960,540213,4,3,,103189263,5757,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1961,540253,1,1,,56422158,5757,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1962,540253,1,1,,56422158,5757,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1963,540253,1,1,,56422158,5757,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1964,540256,1,2,,8139865,5757,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1965,540256,1,2,,50105619,5757,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1966,540256,1,2,,90341590,5757,Inconclusive,,,25.9185,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1967,540263,1,1,,56422158,5757,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1968,540263,1,1,,56422158,5757,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1969,540267,1,1,,56422158,5757,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1970,540275,1,1,,8139865,5757,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1971,540276,1,2,,8139865,5757,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1972,540276,1,2,,17389898,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1973,540276,1,2,,26753050,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1974,540276,1,2,,26753051,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1975,540276,1,2,,29215115,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1976,540276,1,2,,29215116,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1977,540276,1,2,,29215117,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1978,540276,1,2,,50105619,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1979,540276,1,2,,50105620,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1980,540276,1,2,,50124031,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1981,540276,1,2,,56422158,5757,Inconclusive,420597.0,,0.7943,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1982,540276,1,2,,90341590,5757,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1983,540277,1,1,,8139865,5757,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1984,540295,1,1,,56422158,5757,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1985,540299,1,2,,92125448,5757,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1986,540299,1,2,,99302491,5757,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1987,540303,1,1,,56422158,5757,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1988,540303,1,1,,56422158,5757,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1989,540303,1,1,,56422158,5757,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1990,540308,1,1,,56422158,5757,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1991,540317,1,1,,56422158,5757,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1992,540336,1,1,,56422158,5757,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1993,540336,1,1,,56422158,5757,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1994,540364,1,2,,56422158,5757,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1995,547838,4,7,,103189263,5757,Active,215273968.0,316.0,0.08,IC50,Inhibition of human aldehyde oxidase,Confirmatory,20853847.0,
1996,547840,4,7,,103189263,5757,Active,20978407.0,54349.0,,IC50,Inhibition of rat aldehyde oxidase,Confirmatory,20853847.0,
1997,547842,4,7,,103189263,5757,Active,20981678.0,100008601.0,40.0,IC50,Inhibition of rabbit aldehyde oxidase,Confirmatory,20853847.0,
1998,547843,4,7,,103189263,5757,Active,586830439.0,102131116.0,12.0,IC50,Inhibition of monkey aldehyde oxidase,Confirmatory,20853847.0,
1999,549847,2,3,,103189263,5757,Unspecified,,,,,"Selectivity ratio, ratio of RBA for human recombinant ERbeta to RBA for human recombinant ERalpha",Other,21129978.0,
2000,549848,2,10,,103189263,5757,Unspecified,6166154.0,2100.0,,,Displacement of fluorescent estrogen ES2 from human recombinant ERbeta by fluorescence polarization assay relative to estradiol,Other,21129978.0,
2001,549849,2,11,,103189263,5757,Unspecified,544257.0,2099.0,,,Displacement of fluorescent estrogen ES2 from human recombinant ERalpha by fluorescence polarization assay relative to estradiol,Other,21129978.0,
2002,551432,7,2,,103189263,5757,Unspecified,,,300.0,IC50,Inhibition of recombinant SHP2,Confirmatory,21193311.0,
2003,566276,6,5,,103189263,5757,Active,544257.0,2099.0,0.046,IC50,Inhibition of human estrogen receptor beta,Confirmatory,20875743.0,
2004,566843,4,5,,103189263,5757,Unspecified,,,400.0,LC50,Hepatotoxicity in Sprague-Dawley rat hepatocyte after 2 hrs,Confirmatory,21190382.0,
2005,569810,6,1,,103189263,5757,Active,,,0.0059,EC50,Agonist activity at 6his-tagged ERRalpha LBD assessed as recruitment of GST-labeled coactivator Scr2 by TR-FRET assay,Confirmatory,21218783.0,
2006,569812,6,1,,103189263,5757,Active,,,0.0046,EC50,Agonist activity at ZFP-fused ERRbeta LBD expressed in HEK293 cells by TR-FRET assay,Confirmatory,21218783.0,
2007,569824,7,2,,103189263,5757,Active,544257.0,2099.0,0.01,EC50,Agonist activity at human ERalpha LBD in human MCF7 cells assessed as induction of cell proliferation after up to 6 days by celltiter-glo assay,Confirmatory,21218783.0,
2008,569825,7,2,,103189263,5757,Active,6166154.0,2100.0,0.0014,EC50,Agonist activity at human ERbeta LBD by cell based luciferase reporter gene assay,Confirmatory,21218783.0,
2009,578354,3,2,,103189263,5757,Active,,,0.0023,IC50,Displacement of [3H]17-beta-estradiol from rabbit ER by liquid scintillation counting,Confirmatory,21349712.0,
2010,588209,2,3,,103189263,5757,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2011,588210,2,4,,103189263,5757,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2012,588211,2,3,,103189263,5757,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2013,588212,2,3,,103189263,5757,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2014,588213,2,3,,103189263,5757,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2015,588214,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2016,588215,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2017,588216,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2018,588217,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2019,588218,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2020,588219,2,3,,103189263,5757,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2021,588334,1,1,,56422158,5757,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2022,588335,1,1,,56422158,5757,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2023,588342,1,1,,8139865,5757,Inconclusive,160794.0,,26.8545,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2024,588349,1,1,,90341590,5757,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2025,588352,1,2,,56422158,5757,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2026,588354,1,1,,56422158,5757,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2027,588358,1,2,,56422158,5757,Active,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2028,588368,1,2,,8139865,5757,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2029,588378,1,1,,90341590,5757,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2030,588391,1,1,,56422158,5757,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2031,588405,1,1,,56422158,5757,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2032,588413,1,2,,56422158,5757,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2033,588436,1,1,,56422158,5757,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2034,588453,1,1,,50105619,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2035,588453,1,1,,56422158,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2036,588453,1,1,,90341590,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2037,588456,1,1,,56422158,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2038,588456,1,1,,90341590,5757,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2039,588458,1,1,,56422158,5757,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2040,588459,1,2,,8139865,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2041,588459,1,2,,8139865,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2042,588459,1,2,,8139865,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2043,588460,1,2,,8139865,5757,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2044,588460,1,2,,8139865,5757,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2045,588460,1,2,,8139865,5757,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2046,588461,1,2,,8139865,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2047,588461,1,2,,8139865,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2048,588461,1,2,,8139865,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2049,588466,1,1,,56422158,5757,Inactive,,,,,"HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies, using Cherry Pick 1 compounds",Screening,,
2050,588473,1,1,,56422158,5757,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2051,588473,1,1,,56422158,5757,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2052,588475,1,2,,56422158,5757,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2053,588475,1,2,,56422158,5757,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2054,588478,1,2,,124801447,5757,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2055,588489,1,1,,56422158,5757,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2056,588492,1,1,,56422158,5757,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2057,588493,1,2,,56422158,5757,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2058,588497,1,2,,56422158,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2059,588497,1,2,,56422158,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2060,588497,1,2,,56422158,5757,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2061,588499,1,3,,56422158,5757,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2062,588499,1,3,,56422158,5757,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2063,588499,1,3,,56422158,5757,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2064,588501,1,2,,56422158,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2065,588501,1,2,,56422158,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2066,588501,1,2,,56422158,5757,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2067,588506,1,2,,8139865,5757,Active,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2068,588511,1,2,,8139865,5757,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2069,588513,1,1,,17389898,5757,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2070,588514,1,1,,17389898,5757,Inconclusive,348019627.0,2099.0,31.6228,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2071,588515,1,1,,17389898,5757,Inconclusive,124375976.0,367.0,0.631,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2072,588516,1,1,,17389898,5757,Inconclusive,124375976.0,367.0,25.1189,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2073,588519,1,2,,92125448,5757,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2074,588519,1,2,,99300971,5757,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2075,588519,1,2,,99302491,5757,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2076,588526,1,1,,17389898,5757,Inconclusive,325495553.0,9971.0,39.8107,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2077,588527,1,1,,17389898,5757,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2078,588532,1,1,,17389898,5757,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2079,588533,1,1,,17389898,5757,Active,311348376.0,2908.0,7.0795,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2080,588534,1,1,,17389898,5757,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2081,588535,1,1,,17389898,5757,Inconclusive,216409690.0,5467.0,15.8489,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2082,588536,1,1,,17389898,5757,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2083,588537,1,1,,17389898,5757,Active,216409692.0,5468.0,39.8107,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2084,588541,1,1,,17389898,5757,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2085,588543,1,1,,17389898,5757,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2086,588544,1,1,,17389898,5757,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2087,588545,1,1,,17389898,5757,Inconclusive,189491771.0,7068.0,15.8489,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2088,588546,1,1,,17389898,5757,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2089,588547,1,1,,17389898,5757,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2090,588549,1,1,,56422158,5757,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2091,588550,1,1,,8139865,5757,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2092,588579,1,1,,26753050,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2093,588579,1,1,,26753051,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2094,588579,1,1,,29215116,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2095,588579,1,1,,29215117,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2096,588579,1,1,,56422158,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2097,588579,1,1,,90341590,5757,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2098,588590,1,1,,50105619,5757,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2099,588590,1,1,,56422158,5757,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2100,588591,1,1,,50105619,5757,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2101,588591,1,1,,56422158,5757,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2102,588621,1,1,,56422158,5757,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2103,588627,1,1,,8139865,5757,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2104,588664,1,2,,56422158,5757,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2105,588664,1,2,,56422158,5757,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2106,588674,1,2,,56422158,5757,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2107,588675,1,1,,8139865,5757,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2108,588676,1,1,,8139865,5757,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2109,588685,1,1,,8139865,5757,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2110,588689,1,1,,56422158,5757,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2111,588692,2,1,,56422158,5757,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2112,588726,1,2,,56422158,5757,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2113,588727,1,1,,56422158,5757,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2114,588795,1,1,,56422158,5757,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2115,588795,1,1,,90341590,5757,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2116,588812,1,1,,17389898,5757,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2117,588812,1,1,1.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2118,588812,1,1,2.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2119,588812,1,1,3.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2120,588812,1,1,4.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2121,588812,1,1,5.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2122,588812,1,1,6.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2123,588812,1,1,7.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2124,588812,1,1,8.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2125,588812,1,1,9.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2126,588812,1,1,10.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2127,588812,1,1,11.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2128,588812,1,1,12.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2129,588812,1,1,13.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2130,588812,1,1,14.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2131,588812,1,1,15.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2132,588812,1,1,16.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2133,588812,1,1,17.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2134,588812,1,1,18.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2135,588812,1,1,19.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2136,588812,1,1,20.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2137,588812,1,1,21.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2138,588812,1,1,22.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2139,588812,1,1,23.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2140,588812,1,1,24.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2141,588812,1,1,25.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2142,588812,1,1,26.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2143,588812,1,1,27.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2144,588812,1,1,28.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2145,588812,1,1,29.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2146,588812,1,1,30.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2147,588812,1,1,31.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2148,588812,1,1,32.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2149,588812,1,1,33.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2150,588812,1,1,34.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2151,588812,1,1,35.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2152,588812,1,1,36.0,17389898,5757,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2153,588812,1,1,37.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2154,588812,1,1,38.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2155,588812,1,1,39.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2156,588812,1,1,40.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2157,588812,1,1,41.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2158,588812,1,1,42.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2159,588812,1,1,43.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2160,588812,1,1,44.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2161,588812,1,1,45.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2162,588812,1,1,46.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2163,588812,1,1,47.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2164,588812,1,1,48.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2165,588812,1,1,49.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2166,588812,1,1,50.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2167,588812,1,1,51.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2168,588812,1,1,52.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2169,588812,1,1,53.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2170,588812,1,1,54.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2171,588812,1,1,55.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2172,588812,1,1,56.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2173,588812,1,1,57.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2174,588812,1,1,58.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2175,588812,1,1,59.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2176,588812,1,1,60.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2177,588812,1,1,61.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2178,588812,1,1,62.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2179,588812,1,1,63.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2180,588812,1,1,64.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2181,588812,1,1,65.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2182,588812,1,1,66.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2183,588812,1,1,67.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2184,588812,1,1,68.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2185,588812,1,1,69.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2186,588812,1,1,70.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2187,588812,1,1,71.0,17389898,5757,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2188,588812,1,1,72.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2189,588812,1,1,73.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2190,588812,1,1,74.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2191,588812,1,1,75.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2192,588812,1,1,76.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2193,588812,1,1,77.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2194,588812,1,1,78.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2195,588812,1,1,79.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2196,588812,1,1,80.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2197,588812,1,1,81.0,17389898,5757,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2198,588813,1,1,,17389898,5757,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2199,588813,1,1,1.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2200,588813,1,1,2.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2201,588813,1,1,3.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2202,588813,1,1,4.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2203,588813,1,1,5.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2204,588813,1,1,6.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2205,588813,1,1,7.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2206,588813,1,1,8.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2207,588813,1,1,9.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2208,588813,1,1,10.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2209,588813,1,1,11.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2210,588813,1,1,12.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2211,588813,1,1,13.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2212,588813,1,1,14.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2213,588813,1,1,15.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2214,588813,1,1,16.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2215,588813,1,1,17.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2216,588813,1,1,18.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2217,588813,1,1,19.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2218,588813,1,1,20.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2219,588813,1,1,21.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2220,588813,1,1,22.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2221,588813,1,1,23.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2222,588813,1,1,24.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2223,588813,1,1,25.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2224,588813,1,1,26.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2225,588813,1,1,27.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2226,588813,1,1,28.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2227,588813,1,1,29.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2228,588813,1,1,30.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2229,588813,1,1,31.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2230,588813,1,1,32.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2231,588813,1,1,33.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2232,588813,1,1,34.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2233,588813,1,1,35.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2234,588813,1,1,36.0,17389898,5757,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2235,588813,1,1,37.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2236,588813,1,1,38.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2237,588813,1,1,39.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2238,588813,1,1,40.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2239,588813,1,1,41.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2240,588813,1,1,42.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2241,588813,1,1,43.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2242,588813,1,1,44.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2243,588813,1,1,45.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2244,588813,1,1,46.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2245,588813,1,1,47.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2246,588813,1,1,48.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2247,588813,1,1,49.0,17389898,5757,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2248,588813,1,1,50.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2249,588813,1,1,51.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2250,588813,1,1,52.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2251,588813,1,1,53.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2252,588813,1,1,54.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2253,588813,1,1,55.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2254,588813,1,1,56.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2255,588813,1,1,57.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2256,588813,1,1,58.0,17389898,5757,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2257,588813,1,1,59.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2258,588813,1,1,60.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2259,588813,1,1,61.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2260,588813,1,1,62.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2261,588813,1,1,63.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2262,588813,1,1,64.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2263,588813,1,1,65.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2264,588813,1,1,66.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2265,588813,1,1,67.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2266,588813,1,1,68.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2267,588813,1,1,69.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2268,588813,1,1,70.0,17389898,5757,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2269,588813,1,1,71.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2270,588813,1,1,72.0,17389898,5757,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2271,588813,1,1,73.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2272,588813,1,1,74.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2273,588813,1,1,75.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2274,588813,1,1,76.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2275,588813,1,1,77.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2276,588813,1,1,78.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2277,588813,1,1,79.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2278,588813,1,1,80.0,17389898,5757,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2279,588813,1,1,81.0,17389898,5757,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2280,588814,1,3,,56422158,5757,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2281,588819,1,4,,56422158,5757,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2282,588834,2,1,,17389898,5757,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2283,588834,2,1,,50105619,5757,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2284,588834,2,1,,144204699,5757,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2285,588850,1,1,,56422158,5757,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2286,588852,1,3,,56422158,5757,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2287,588855,1,1,,56422158,5757,Inactive,18418623.0,4088.0,3.1623,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2288,588856,1,1,,56422158,5757,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2289,588994,1,10,,103189263,5757,Unspecified,67462103.0,9429.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, BCRP",Other,20190787.0,
2290,589057,1,10,,103189263,5757,Unspecified,313104286.0,6817.0,,,Major substrate of human cytosolic sulfotransferase SULT1A1,Other,,
2291,589063,1,10,,103189263,5757,Unspecified,1711604.0,6783.0,,,Major substrate of human cytosolic sulfotransferase SULT1E1,Other,,
2292,589064,1,10,,103189263,5757,Unspecified,1711591.0,6822.0,,,Major substrate of human cytosolic sulfotransferase SULT2A1,Other,,
2293,589069,1,10,,103189263,5757,Unspecified,549152.0,54659.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A3,Other,,
2294,589082,1,10,,103189263,5757,Unspecified,20140759.0,54490.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B28,Other,,
2295,591391,5,4,,103189263,5757,Active,544257.0,2099.0,0.13,EC50,Agonist activity at human N-terminal His6-tagged ERalpha receptor LBD expressed in Escherichia coli BL21 (DE3) assessed as induction of SRC1 peptide recruitment after 1 hr by fluorescence polarization assay,Confirmatory,21381753.0,
2296,591392,5,4,,103189263,5757,Active,6166154.0,2100.0,0.28,EC50,Agonist activity at human N-terminal His6-tagged ERbeta receptor LBD expressed in Escherichia coli BL21 (DE3) assessed as induction of SRC1 peptide recruitment after 1 hr by fluorescence polarization assay,Confirmatory,21381753.0,
2297,591393,1,4,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for human N-terminal His6-tagged ERalpha to EC50 for N-terminal His6-tagged ERbeta,Other,21381753.0,
2298,592681,1,4,,103189263,5757,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2299,592937,1,4,,103189263,5757,Active,,,,,Cytotoxicity against human MCF7 cells at 4 uM after 24 hrs by MTT assay,Other,21459581.0,
2300,593069,1,4,,103189263,5757,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0 phase using propidium iodide staining at 4 uM after 24 hrs by flow cytometry,Other,21459581.0,
2301,593070,1,4,,103189263,5757,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase using propidium iodide staining at 4 uM after 24 hrs by flow cytometry,Other,21459581.0,
2302,593071,1,4,,103189263,5757,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase using propidium iodide staining at 4 uM after 24 hrs by flow cytometry,Other,21459581.0,
2303,593072,1,4,,103189263,5757,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase using propidium iodide staining at 4 uM after 24 hrs by flow cytometry,Other,21459581.0,
2304,593074,1,4,,103189263,5757,Active,,,,,Reduction in Cdk1 protein level in human MCF7 cells at 4 uM after 24 hrs by Western blot analysis,Other,21459581.0,
2305,601684,2,6,,103189263,5757,Active,544257.0,2099.0,9e-05,EC50,Agonist activity at human full-length ERalpha receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay,Confirmatory,21481497.0,
2306,601686,2,6,,103189263,5757,Active,6166154.0,2100.0,0.00072,EC50,Agonist activity at human full-length ERbeta receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay,Confirmatory,21481497.0,
2307,601688,1,4,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for human full-length ERbeta receptor to EC50 for human full-length ERalpha receptor,Other,21481497.0,
2308,601690,5,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity to human full-length ERalpha receptor,Confirmatory,21481497.0,
2309,601691,5,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity to human full-length ERbeta receptor,Confirmatory,21481497.0,
2310,602053,1,8,,103189263,5757,Unspecified,,,,,Inhibition of fluorescence-labeled 17beta-estradiol binding to ERalpha receptor at 0.1 microM after 2 hrs by fluorometric analysis,Other,21510635.0,
2311,602054,8,1,,103189263,5757,Active,,,0.018000000000000002,IC50,Inhibition of fluorescence-labeled 17beta-estradiol binding to ERalpha receptor after 2 hrs by fluorometric analysis,Confirmatory,21510635.0,
2312,602123,1,1,,56422158,5757,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2313,602141,1,1,,56422158,5757,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2314,602162,1,1,,56422158,5757,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2315,602163,1,1,,56422158,5757,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2316,602179,1,2,,56422158,5757,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2317,602229,1,1,,56422158,5757,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2318,602233,1,1,,56422158,5757,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2319,602244,1,2,,56422158,5757,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2320,602247,1,2,,56422158,5757,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2321,602248,1,2,,56422158,5757,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2322,602250,1,2,,56422158,5757,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2323,602252,1,1,,56422158,5757,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2324,602252,1,1,,56422158,5757,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2325,602261,1,1,,56422158,5757,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2326,602274,1,2,,56422158,5757,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2327,602281,1,1,,56422158,5757,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2328,602281,1,1,,56422158,5757,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2329,602310,1,2,,56422158,5757,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2330,602313,1,1,,56422158,5757,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2331,602314,1,2,,92125448,5757,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2332,602314,1,2,,99300971,5757,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2333,602329,1,1,,56422158,5757,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2334,602332,1,1,,26753050,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2335,602332,1,1,,26753051,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2336,602332,1,1,,29215116,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2337,602332,1,1,,29215117,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2338,602332,1,1,,56422158,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2339,602332,1,1,,90341590,5757,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2340,602340,1,2,,56422158,5757,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2341,602342,2,1,,56422158,5757,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2342,602346,1,1,,56422158,5757,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2343,602363,1,1,,56422158,5757,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2344,602393,1,1,,56422158,5757,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2345,602396,1,2,,56422158,5757,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2346,602399,1,2,,56422158,5757,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2347,602405,1,1,,56422158,5757,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2348,602410,1,1,,56422158,5757,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2349,602429,1,1,,56422158,5757,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2350,602438,1,1,,56422158,5757,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2351,602440,1,1,,56422158,5757,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2352,602449,1,2,,56422158,5757,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2353,602481,1,1,,56422158,5757,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2354,614197,3,2,,103189263,5757,Active,,,0.00057,IC50,Binding affinity to estrogen receptor-alpha after 2 hrs by TR-FRET assay,Confirmatory,21839641.0,
2355,622835,1,5,,103189263,5757,Active,,,0.00025,EC50,Agonist activity at ERbeta expressed in UAS cells co-expressing beta-lactamase after 18 hrs by beta-lactamase reporter gene assay,Confirmatory,21885279.0,
2356,622837,1,6,,103189263,5757,Active,,,4.6e-05,EC50,Agonist activity at ERalpha expressed in HEK cells co-expressing beta-lactamase after 18 hrs by beta-lactamase reporter gene assay,Confirmatory,21885279.0,
2357,623870,1,1,,56422158,5757,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2358,623870,1,1,,56422158,5757,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2359,623877,1,1,,56422158,5757,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2360,623901,1,1,,56422158,5757,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2361,624030,1,2,,29215116,5757,Inconclusive,160794.0,,36.1254,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2362,624031,1,2,,29215116,5757,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2363,624032,1,2,,29215116,5757,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2364,624037,1,3,,56422158,5757,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2365,624038,1,3,,56422158,5757,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2366,624040,1,3,,56422158,5757,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2367,624044,1,2,,29215116,5757,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2368,624101,1,2,,85788274,5757,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2369,624125,1,4,,56422158,5757,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2370,624126,1,3,,56422158,5757,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2371,624127,1,2,,56422158,5757,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2372,624137,1,1,,85788274,5757,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
2373,624146,1,1,,90341590,5757,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2374,624147,1,1,,90341590,5757,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2375,624148,1,2,,90341590,5757,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2376,624149,1,1,,90341590,5757,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2377,624151,1,1,,85788274,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
2378,624156,1,1,,85788274,5757,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2379,624168,1,1,,56422158,5757,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2380,624169,1,1,,56422158,5757,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2381,624170,1,1,,29215116,5757,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2382,624170,1,1,,56422158,5757,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2383,624171,1,1,,56422158,5757,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2384,624172,1,1,,29215116,5757,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2385,624172,1,1,,56422158,5757,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2386,624173,1,3,,29215116,5757,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2387,624173,1,3,,56422158,5757,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2388,624178,1,1,,56422158,5757,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2389,624202,1,1,,56422158,5757,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2390,624204,1,2,,56422158,5757,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2391,624246,1,1,,56422158,5757,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2392,624256,1,2,,56422158,5757,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2393,624260,1,1,,85788274,5757,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2394,624263,1,1,,56422158,5757,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2395,624263,1,1,,56422158,5757,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2396,624267,1,2,,56422158,5757,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2397,624267,1,2,,56422158,5757,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2398,624268,1,3,,56422158,5757,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2399,624288,1,1,,56422158,5757,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2400,624296,1,1,,8139865,5757,Inconclusive,7705682.0,51053.0,32.6427,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2401,624296,1,1,,29215116,5757,Inconclusive,7705682.0,51053.0,26.6086,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2402,624296,1,1,,56422158,5757,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2403,624297,1,1,,8139865,5757,Inconclusive,7705682.0,51053.0,25.929000000000002,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2404,624297,1,1,,29215116,5757,Inconclusive,7705682.0,51053.0,33.4983,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2405,624297,1,1,,56422158,5757,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2406,624304,1,2,,56422158,5757,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2407,624330,1,2,,56422158,5757,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2408,624349,1,2,,92125448,5757,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2409,624349,1,2,,92308287,5757,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2410,624349,1,2,,92309094,5757,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2411,624349,1,2,,121363119,5757,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2412,624352,1,1,,56422158,5757,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2413,624354,1,1,,56422158,5757,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2414,624377,1,1,,8139865,5757,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2415,624414,1,1,,56422158,5757,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2416,624415,1,2,,56422158,5757,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2417,624416,1,1,,8139865,5757,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2418,624417,1,1,,56422158,5757,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2419,624418,1,1,,56422158,5757,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2420,624455,1,1,,90341590,5757,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2421,624463,1,1,,56422158,5757,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2422,624464,1,1,,56422158,5757,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2423,624465,1,1,,56422158,5757,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2424,624466,1,3,,8139865,5757,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2425,624467,1,1,,8139865,5757,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2426,624483,1,1,,56422158,5757,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2427,624606,1,9,,103189263,5757,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
2428,624608,3,2,,103189263,5757,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
2429,624609,1,9,,103189263,5757,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
2430,624610,1,9,,103189263,5757,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
2431,624612,1,9,,103189263,5757,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
2432,624613,1,9,,103189263,5757,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
2433,624614,1,8,,103189263,5757,Unspecified,296452854.0,10941.0,,,Specific activity of expressed human recombinant UGT2A1,Other,10836148.0,
2434,624616,1,8,,103189263,5757,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
2435,624617,1,8,,103189263,5757,Unspecified,6136104.0,7367.0,,,Specific activity of expressed human recombinant UGT2B17,Other,10836148.0,
2436,624618,3,2,,103189263,5757,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
2437,624619,3,2,,103189263,5757,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
2438,624639,1,8,,103189263,5757,Unspecified,20140759.0,54490.0,,,Drug glucuronidation reaction catalyzed by human recombinant UGT2B28,Other,15781124.0,
2439,625144,5,5,,103189263,5757,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2440,625145,4,7,,103189263,5757,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2441,625146,5,5,,103189263,5757,Active,126397.0,100009114.0,11.295,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2442,625147,4,7,,103189263,5757,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2443,625148,4,7,,103189263,5757,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2444,625149,4,7,,103189263,5757,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2445,625150,5,5,,103189263,5757,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2446,625151,4,7,,103189263,5757,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2447,625152,4,7,,103189263,5757,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2448,625153,4,7,,103189263,5757,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2449,625154,4,7,,103189263,5757,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2450,625155,4,7,,103189263,5757,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2451,625156,1,9,,103189263,5757,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2452,625157,6,2,,103189263,5757,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2453,625158,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2454,625159,5,5,,103189263,5757,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2455,625160,1,9,,103189263,5757,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2456,625161,4,7,,103189263,5757,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2457,625162,4,7,,103189263,5757,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2458,625163,4,7,,103189263,5757,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2459,625164,1,6,,103189263,5757,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2460,625165,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2461,625166,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2462,625167,5,5,,103189263,5757,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2463,625168,4,7,,103189263,5757,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2464,625169,1,6,,103189263,5757,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2465,625170,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2466,625171,4,7,,103189263,5757,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2467,625172,4,7,,103189263,5757,Active,75071465.0,,32.559,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2468,625173,5,5,,103189263,5757,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2469,625174,5,5,,103189263,5757,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2470,625175,5,5,,103189263,5757,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2471,625176,1,9,,103189263,5757,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2472,625177,5,5,,103189263,5757,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2473,625178,5,5,,103189263,5757,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2474,625179,1,9,,103189263,5757,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2475,625180,5,5,,103189263,5757,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2476,625181,5,5,,103189263,5757,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2477,625182,5,5,,103189263,5757,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2478,625183,5,5,,103189263,5757,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2479,625184,5,5,,103189263,5757,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2480,625185,5,5,,103189263,5757,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2481,625186,5,5,,103189263,5757,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2482,625187,5,5,,103189263,5757,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2483,625188,1,9,,103189263,5757,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2484,625189,1,7,,103189263,5757,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2485,625190,4,5,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2486,625191,4,7,,103189263,5757,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2487,625192,4,7,,103189263,5757,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2488,625193,5,5,,103189263,5757,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2489,625194,4,7,,103189263,5757,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2490,625195,4,7,,103189263,5757,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2491,625196,5,6,,103189263,5757,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2492,625197,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2493,625198,4,7,,103189263,5757,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2494,625199,4,7,,103189263,5757,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2495,625200,4,7,,103189263,5757,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2496,625201,4,7,,103189263,5757,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2497,625202,4,7,,103189263,5757,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2498,625203,4,7,,103189263,5757,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2499,625204,4,7,,103189263,5757,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2500,625205,4,7,,103189263,5757,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2501,625206,4,7,,103189263,5757,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2502,625207,4,7,,103189263,5757,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2503,625208,5,5,,103189263,5757,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2504,625209,4,7,,103189263,5757,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2505,625210,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2506,625211,1,6,,103189263,5757,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2507,625212,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2508,625213,4,7,,103189263,5757,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2509,625214,1,9,,103189263,5757,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2510,625215,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2511,625216,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2512,625217,4,7,,103189263,5757,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2513,625218,4,7,,103189263,5757,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2514,625219,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2515,625220,4,7,,103189263,5757,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2516,625221,4,7,,103189263,5757,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2517,625222,4,7,,103189263,5757,Active,400630.0,6532.0,10.755,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2518,625223,4,7,,103189263,5757,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2519,625224,3,4,,103189263,5757,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2520,625225,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2521,625226,4,7,,103189263,5757,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2522,625227,4,7,,103189263,5757,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2523,625228,4,7,,103189263,5757,Active,113832.0,24208.0,0.353,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2524,625229,5,5,,103189263,5757,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2525,625230,1,6,,103189263,5757,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2526,625231,4,7,,103189263,5757,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2527,625232,1,9,,103189263,5757,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2528,625233,4,7,,103189263,5757,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2529,625234,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2530,625235,4,7,,103189263,5757,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2531,625236,5,5,,103189263,5757,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2532,625237,4,7,,103189263,5757,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2533,625238,4,7,,103189263,5757,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2534,625239,4,7,,103189263,5757,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2535,625240,1,9,,103189263,5757,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2536,625241,4,7,,103189263,5757,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2537,625242,4,7,,103189263,5757,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2538,625243,5,5,,103189263,5757,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2539,625244,5,5,,103189263,5757,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2540,625245,5,5,,103189263,5757,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2541,625246,1,9,,103189263,5757,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2542,625247,5,5,,103189263,5757,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2543,625248,5,5,,103189263,5757,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2544,625249,5,5,,103189263,5757,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2545,625250,5,5,,103189263,5757,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2546,625251,5,5,,103189263,5757,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2547,625252,4,7,,103189263,5757,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2548,625253,4,7,,103189263,5757,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2549,625254,4,7,,103189263,5757,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2550,625255,4,7,,103189263,5757,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2551,625256,4,7,,103189263,5757,Active,266667.0,6531.0,14.911,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2552,625257,4,7,,103189263,5757,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2553,625258,4,7,,103189263,5757,Active,544257.0,2099.0,0.00161,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2554,625259,4,7,,103189263,5757,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2555,625260,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2556,625261,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2557,625262,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2558,625263,4,7,,103189263,5757,Active,121069.0,2908.0,41.422,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2559,625264,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2560,625265,1,6,,103189263,5757,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2561,625266,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2562,625267,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2563,625268,4,2,,103189263,5757,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2564,625268,4,2,,103189263,5757,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2565,625268,4,2,,103189263,5757,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2566,625268,4,2,,103189263,5757,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2567,625269,4,7,,103189263,5757,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2568,625270,4,7,,103189263,5757,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2569,625271,5,5,,103189263,5757,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2570,625272,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2571,625273,4,6,,103189263,5757,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2572,625274,1,6,,103189263,5757,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2573,625275,3,4,,103189263,5757,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2574,625277,1,3,,103189263,5757,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2575,625279,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2576,625280,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2577,625281,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2578,625282,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2579,625283,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2580,625284,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2581,625285,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2582,625286,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2583,625287,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2584,625288,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2585,625289,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2586,625290,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2587,625291,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2588,625292,1,3,,103189263,5757,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2589,626475,2,2,,103189263,5757,Active,,,0.0023,IC50,Displacement of [3H]E2 from estrogen receptor in JW rabbit uterus after 2 hrs by liquid scintillation counting,Confirmatory,21944856.0,
2590,628250,1,4,,103189263,5757,Unspecified,,,,,Estrogenic activity in transgenic Arabidopsis thaliana transfected with pER8:GUS plasmid assessed as beta-glucuronidase expression after 48 hrs using 4-methylumbelliferyl-beta-D-glucuronide by fluorometric assay,Other,21800859.0,
2591,628344,1,4,,103189263,5757,Active,,,,,Estrogenic activity in human ER-positive MCF7 cells assessed as secreted alkaline phosphatase activity at 0.01 nM after 48 hrs by phospha-light reporter chemiluminescence assay,Other,21800859.0,
2592,640215,1,4,,103189263,5757,Active,,,0.0009,EC50,Agonist activity at estrogen receptor in human Ishikawa cells assessed as increase of alkaline phosphatase level after 3 days using P-nitrophenyl phosphate as substrate,Confirmatory,22178552.0,
2593,643982,1,4,,103189263,5757,Unspecified,,,,,Estrogenic activity in ER expressing human Ishikawa cells assessed as induction of ALP activity at 100 pM relative to control,Other,22212722.0,
2594,644916,4,5,,103189263,5757,Unspecified,6166154.0,2100.0,,EC50,Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERbeta ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay,Confirmatory,22122563.0,
2595,644918,4,5,,103189263,5757,Unspecified,544257.0,2099.0,,EC50,Agonist activity at human N-His6-tagged terbium-labelled NRID-SRC3 of ERalpha ligand binding domain expressed in Escherichia coli BL21 cells after 1 hr by TR-FRET assay,Confirmatory,22122563.0,
2596,644921,4,5,,103189263,5757,Unspecified,6166154.0,2100.0,,EC50,Agonist activity at human N-His6-tagged terbium-labelled ERbeta ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay,Confirmatory,22122563.0,
2597,644923,4,5,,103189263,5757,Unspecified,544257.0,2099.0,,EC50,Agonist activity at human N-His6-tagged terbium-labelled ERalpha ligand binding domain expressed in Escherichia coli BL21 cells assessed as recruitment of fluorescein-labelled SRC3 after 1 hr by TR-FRET assay,Confirmatory,22122563.0,
2598,644926,2,6,,103189263,5757,Active,6166154.0,2100.0,0.0002,EC50,Agonist activity at human ERbeta expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay,Confirmatory,22122563.0,
2599,644928,2,6,,103189263,5757,Active,544257.0,2099.0,0.000123,EC50,Agonist activity at human ERalpha expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay,Confirmatory,22122563.0,
2600,645557,2,6,,103189263,5757,Active,6166154.0,2100.0,0.0004,EC50,Agonist activity at human ERbeta expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay,Confirmatory,22122563.0,
2601,645559,2,6,,103189263,5757,Active,544257.0,2099.0,0.00015,EC50,Agonist activity at human ERalpha expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay,Confirmatory,22122563.0,
2602,651548,1,1,,85788274,5757,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2603,651550,1,1,,56422158,5757,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2604,651560,1,1,,56422158,5757,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2605,651572,1,2,,8139865,5757,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2606,651582,1,1,,56422158,5757,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2607,651602,1,1,,8139865,5757,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2608,651602,1,1,,8139865,5757,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2609,651602,1,1,,8139865,5757,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2610,651610,2,1,,8139865,5757,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2611,651631,4,1,,144204699,5757,Active,269849759.0,7157.0,13.3332,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2612,651631,4,1,,144209255,5757,Active,269849759.0,7157.0,19.2919,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2613,651631,4,1,,144210608,5757,Active,269849759.0,7157.0,9.6885,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2614,651632,4,1,,144204699,5757,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2615,651632,4,1,,144209255,5757,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2616,651632,4,1,,144210608,5757,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2617,651633,4,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2618,651633,4,1,,144209255,5757,Inactive,,,0.0193,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2619,651633,4,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2620,651634,4,1,,144204699,5757,Inconclusive,,,23.7101,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2621,651634,4,1,,144209255,5757,Inconclusive,,,30.5756,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2622,651634,4,1,,144210608,5757,Inconclusive,,,48.5577,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2623,651635,1,3,,56422158,5757,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2624,651635,1,3,,90341590,5757,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2625,651636,1,1,,56422158,5757,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2626,651640,1,1,,8139865,5757,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2627,651644,1,1,,56422158,5757,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2628,651647,1,1,,56422158,5757,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2629,651654,1,1,,56422158,5757,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2630,651658,1,1,,8139865,5757,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2631,651661,2,1,,8139865,5757,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2632,651687,1,1,,56422158,5757,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2633,651699,1,1,,56422158,5757,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2634,651699,1,1,,56422158,5757,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2635,651702,1,2,,56422158,5757,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2636,651704,2,1,,8139865,5757,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2637,651710,1,1,,8139865,5757,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2638,651711,2,1,,8139865,5757,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2639,651718,1,2,,8139865,5757,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2640,651723,1,1,,56422158,5757,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2641,651724,1,1,,56422158,5757,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2642,651725,1,1,,56422158,5757,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2643,651741,1,1,,17389898,5757,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2644,651743,1,1,,17389898,5757,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2645,651749,1,1,,17389898,5757,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2646,651751,1,1,,17389898,5757,Inconclusive,5702233.0,84385.0,50.1187,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2647,651754,1,1,,17389898,5757,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2648,651755,1,1,,17389898,5757,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2649,651757,1,1,,17389898,5757,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2650,651758,1,1,,17389898,5757,Inconclusive,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2651,651768,1,2,,56422158,5757,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2652,651777,1,1,,17389898,5757,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2653,651778,1,1,,17389898,5757,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2654,651800,1,1,,8139865,5757,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2655,651802,1,1,,17389898,5757,Active,49066040.0,6097.0,33.4915,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2656,651819,1,1,,56422158,5757,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2657,651820,1,1,,8139865,5757,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2658,651820,1,1,,56422158,5757,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2659,651821,2,4,,8139865,5757,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2660,651828,1,2,,92308287,5757,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2661,651828,1,2,,92309094,5757,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2662,651828,1,2,,121361231,5757,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2663,651838,1,1,,17389898,5757,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2664,651838,1,1,1.0,17389898,5757,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2665,651838,1,1,2.0,17389898,5757,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2666,651838,1,1,3.0,17389898,5757,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2667,651838,1,1,4.0,17389898,5757,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2668,651838,1,1,5.0,17389898,5757,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2669,651838,1,1,6.0,17389898,5757,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2670,651838,1,1,7.0,17389898,5757,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2671,651838,1,1,8.0,17389898,5757,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2672,651957,1,1,,8139865,5757,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2673,651958,1,1,,8139865,5757,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2674,651965,1,1,,56422158,5757,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2675,651999,1,1,,56422158,5757,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2676,652010,1,1,,8139865,5757,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2677,652017,1,1,,8139865,5757,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2678,652025,1,1,,56422158,5757,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2679,652039,1,1,,8139865,5757,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2680,652048,1,2,,56422158,5757,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2681,652048,1,2,,144204699,5757,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2682,652051,1,1,,56422158,5757,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2683,652051,1,1,,144204699,5757,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2684,652054,1,1,,56422158,5757,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2685,652067,1,4,,8139865,5757,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2686,652104,1,1,,56422158,5757,Inconclusive,20140568.0,23435.0,3.1623,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2687,652105,1,1,,56422158,5757,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2688,652106,1,1,,56422158,5757,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2689,652106,1,1,,90341590,5757,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2690,652115,1,1,,8139865,5757,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2691,652126,1,3,,8139865,5757,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2692,652154,1,1,,8139865,5757,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2693,652162,2,1,,8139865,5757,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2694,652163,1,1,,8139865,5757,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2695,652163,1,1,,56422158,5757,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2696,652197,1,1,,8139865,5757,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2697,652257,1,1,,8139865,5757,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2698,657937,1,5,,103189263,5757,Unspecified,,,,,Relative binding affinity to estrogen receptor,Other,22405286.0,
2699,658133,1,3,,103189263,5757,Inactive,,,,IC50,Antiproliferative activity against human MCF7 cells,Confirmatory,22405286.0,
2700,658144,1,5,,103189263,5757,Unspecified,,,,,Displacement of [3H]-raloxifene from estrogen receptor,Other,22405286.0,
2701,658145,1,8,,103189263,5757,Unspecified,1706709.0,443228.0,,,Relative binding affinity to estrogen receptor in lamb uterine tissue,Other,22405286.0,
2702,658146,1,8,,103189263,5757,Unspecified,544257.0,2099.0,,,Relative binding affinity to human ERalpha,Other,22405286.0,
2703,658147,1,8,,103189263,5757,Unspecified,6166154.0,2100.0,,,Relative binding affinity to human ERbeta,Other,22405286.0,
2704,658953,1,5,,103189263,5757,Unspecified,,,,,Displacement of fluorescent estrogen ES2 from recombinant ERalpha receptor by fluorescence polarization assay relative to estradiol,Other,22464681.0,
2705,658954,1,5,,103189263,5757,Unspecified,,,,,Displacement of fluorescent estrogen ES2 from recombinant ERbeta receptor by fluorescence polarization assay relative to estradiol,Other,22464681.0,
2706,658955,4,1,,103189263,5757,Active,,,1.9600000000000002e-05,EC50,Estrogenic activity at estrogen receptor in human MCF7:D5L cells co-expressing ERE assessed as induction of luciferase gene expression after 16 hrs by microplate reader,Confirmatory,22464681.0,
2707,658956,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human MCF7:D5L cells co-expressing ERE assessed as induction of luciferase gene expression at 1 micoM after 16 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2708,658957,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human MCF7:D5L cells co-expressing ERE assessed as induction of luciferase gene expression at 10 micoM after 16 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2709,658958,4,1,,103189263,5757,Active,,,6.4e-06,EC50,Antiproliferative activity against estrogen-deficient human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22464681.0,
2710,658959,1,3,,103189263,5757,Unspecified,,,,,Antiproliferative activity against estrogen-deficient human MCF7 cells at 1 uM after 72 hrs by MTT assay relative to untreated vehicle control,Other,22464681.0,
2711,658960,1,3,,103189263,5757,Unspecified,,,,,Antiproliferative activity against estrogen-deficient human MCF7 cells at 10 uM after 72 hrs by MTT assay relative to untreated vehicle control,Other,22464681.0,
2712,658961,4,1,,103189263,5757,Active,,,2.46e-05,EC50,Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression after 72 hrs by microplate reader,Confirmatory,22464681.0,
2713,658962,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression at 1 uM after 72 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2714,658963,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression at 10 uM after 72 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2715,658965,1,3,,103189263,5757,Inactive,,,,,Estrogenic activity at estrogen receptor in human MCF7:D5L cells co-expressing ERE assessed as induction of luciferase gene expression at => 0.1 nM after 16 hrs by microplate reader in presence of 100 nM ER destabilizer fulvestrant,Other,22464681.0,
2716,658966,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human MCF7:D5L cells co-expressing ERE assessed as induction of luciferase gene expression at => 0.1 nM after 16 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2717,658972,1,3,,103189263,5757,Unspecified,,,,,Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression at => 0.1 nM after 72 hrs by microplate reader relative to untreated vehicle control,Other,22464681.0,
2718,658973,1,3,,103189263,5757,Inactive,,,,,Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression at => 0.1 nM after 72 hrs by microplate reader relative to untreated vehicle control in presence of 100 nM ER destabilizer fulvestrant,Other,22464681.0,
2719,659104,1,3,,103189263,5757,Active,,,,,Effect on cell proliferation of human Ishikawa cells at 0.1 nM after 72 hrs by MTT assay,Other,22464681.0,
2720,661596,2,6,,103189263,5757,Active,544257.0,2099.0,0.0022,EC50,Agonist activity at human ERalpha expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay,Confirmatory,22283328.0,
2721,661598,2,6,,103189263,5757,Active,6166154.0,2100.0,0.011000000000000001,EC50,Agonist activity at human ERbeta expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay,Confirmatory,22283328.0,
2722,677847,3,1,,103189263,5757,Active,544257.0,2099.0,0.00105,EC50,Agonist activity at ERalpha receptor LBD expressed in yeast AH109 cells assessed as interaction with SRC1 after 24 hrs by alpha-galactosidase assay,Confirmatory,22647217.0,
2723,677848,3,1,,103189263,5757,Active,6166154.0,2100.0,0.00108,EC50,Agonist activity at ERbeta receptor LBD expressed in yeast AH109 cells assessed as interaction with SRC1 after 24 hrs by alpha-galactosidase assay,Confirmatory,22647217.0,
2724,677851,1,5,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at ERalpha receptor LBD expressed in yeast AH109 cells assessed as compound concentration at which 10% agonist activity of the maximum activity of E2 after 24 hrs by alpha-galactosidase assay,Other,22647217.0,
2725,677852,1,5,,103189263,5757,Active,6166154.0,2100.0,,,Agonist activity at ERbeta receptor LBD expressed in yeast AH109 cells assessed as compound concentration at which 10% agonist activity of the maximum activity of E2 after 24 hrs by alpha-galactosidase assay,Other,22647217.0,
2726,677853,1,3,,103189263,5757,Unspecified,,,,,Selectivity ratio of REC10 for ERalpha receptor LBD expressed in yeast AH109 cells to REC10 for ERbeta receptor LBD expressed in yeast AH109 cells,Other,22647217.0,
2727,677855,1,3,,103189263,5757,Inconclusive,,,,,Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability at 100 uM after 24 hrs by MTT assay,Other,22647217.0,
2728,677856,4,1,,103189263,5757,Active,544257.0,2099.0,5e-05,EC50,Transcriptional activation of ERalpha receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay,Confirmatory,22647217.0,
2729,677857,7,1,,103189263,5757,Active,6166154.0,2100.0,3.6e-05,EC50,Transcriptional activation of ERbeta receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay,Confirmatory,22647217.0,
2730,678712,1,8,,103189263,5757,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2731,678713,1,8,,103189263,5757,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2732,678714,1,8,,103189263,5757,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2733,678715,1,8,,103189263,5757,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2734,678716,1,8,,103189263,5757,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2735,678717,1,8,,103189263,5757,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2736,678718,1,5,,103189263,5757,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2737,678722,1,5,,103189263,5757,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2738,678784,3,6,,103189263,5757,Unspecified,24212062.0,29504.0,1.1,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells,Confirmatory,9830022.0,
2739,678964,1,8,,103189263,5757,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: uptake in BCRP-expressing Lactococcus lactis cells,Other,12668685.0,
2740,679208,1,7,,103189263,5757,Unspecified,81872095.0,24904.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, beta-Estradiol: 100 uM) in OCT1-expressing HRPE cells",Other,9830022.0,
2741,679219,1,8,,103189263,5757,Unspecified,74756298.0,89845.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, beta-Estradiol: 100 uM) in membrane vesicles from MRP7-expressing HEK293 cells",Other,12527806.0,
2742,679439,1,8,,103189263,5757,Unspecified,313104012.0,11309.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.04 uM, beta-Estradiol: 100 uM) in OATP-B-expressing HEK293 cells",Other,11683238.0,
2743,680183,1,7,,103189263,5757,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, beta-Estradiol: 500 uM) in Xenopus laevis oocytes",Other,10660625.0,
2744,680432,1,8,,103189263,5757,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, beta-Estradiol: 100 uM) in Xenopus laevis oocytes",Other,8786566.0,
2745,680650,1,8,,103189263,5757,Unspecified,1171883.0,50572.0,,,TP_TRANSPORTER: Northern blot,Other,8779895.0,
2746,680751,1,8,,103189263,5757,Unspecified,12643959.0,10599.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.04 uM, beta-Estradiol: 100 uM) in OATP-C-expressing HEK293 cells",Other,11683238.0,
2747,680985,1,8,,103189263,5757,Unspecified,67462103.0,9429.0,,,"TP_TRANSPORTER: inhibition of Topotecan efflux (Topotecan: 20 uM, beta-Estradiol: 100 uM) in BCRP-expressing K562 cells: flow cytometric analysis",Other,11927002.0,
2748,681136,1,8,,103189263,5757,Unspecified,27735248.0,80899.0,,,TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells,Other,10101033.0,
2749,681147,2,7,,103189263,5757,Unspecified,1171883.0,50572.0,4.7,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing HeLa cells,Confirmatory,8779894.0,
2750,681176,1,8,,103189263,5757,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: inhibition of E1S uptake by 17beta-estradiol at a concentration of 30uM in membrane vesicle from BCRP-expressing K562 cells,Other,12920197.0,
2751,681359,1,8,,103189263,5757,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,7914405.0,
2752,681560,3,6,,103189263,5757,Unspecified,313104181.0,6580.0,5.73,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells,Confirmatory,12110607.0,
2753,681561,3,6,,103189263,5757,Unspecified,313104182.0,6582.0,30.0,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells,Confirmatory,12110607.0,
2754,681588,1,8,,103189263,5757,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: ATPase assay in membrane vesicle from BCRP-expressing Lactococcus lactis cells,Other,12668685.0,
2755,681591,3,6,,103189263,5757,Unspecified,81872789.0,29503.0,84.8,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells,Confirmatory,9830022.0,
2756,681612,1,8,,103189263,5757,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells,Other,15290871.0,
2757,682023,1,3,,103189263,5757,Unspecified,,,,,"TP_TRANSPORTER: Northern blot in vivo, kidney of SD rat",Other,11076394.0,
2758,682144,3,6,,103189263,5757,Unspecified,24212063.0,6581.0,2.88,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells,Confirmatory,12110607.0,
2759,686940,1,1,,8139865,5757,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2760,686964,1,1,,8139865,5757,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2761,686970,1,2,,56422158,5757,Inconclusive,49168486.0,3417.0,29.0929,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2762,686971,1,2,,56422158,5757,Inconclusive,,,18.3564,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2763,686977,2,1,,49698496,5757,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2764,686978,1,1,,26753050,5757,Active,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2765,686978,1,1,,26753051,5757,Inconclusive,79154014.0,55775.0,31.6228,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2766,686978,1,1,,56422158,5757,Inconclusive,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2767,686978,1,1,,144204699,5757,Active,79154014.0,55775.0,16.7889,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2768,686979,1,1,,26753050,5757,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2769,686979,1,1,,26753051,5757,Inconclusive,79154014.0,55775.0,56.2341,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2770,686979,1,1,,56422158,5757,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2771,686979,1,1,,144204699,5757,Inconclusive,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2772,686992,2,1,,8139865,5757,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2773,686996,1,1,,8139865,5757,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2774,687014,1,1,,8139865,5757,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2775,687016,1,1,,8139865,5757,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2776,687035,1,1,,163564457,5757,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2777,687037,1,3,,163564457,5757,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2778,699539,1,7,,103189263,5757,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2779,699540,1,7,,103189263,5757,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2780,699541,1,7,,103189263,5757,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2781,700857,2,3,,103189263,5757,Active,544257.0,2099.0,0.001,ED50,Agonist activity at human cloned estrogen receptor,Confirmatory,21354674.0,
2782,707058,1,2,,103189263,5757,Active,,,,,Down regulation of ERalpha human MCF7 cells at 1 uM by Western blotting,Other,23043242.0,
2783,707063,3,5,,103189263,5757,Active,544257.0,2099.0,4e-06,EC50,Activation of human ERalpha expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control,Confirmatory,23043242.0,
2784,707064,1,7,,103189263,5757,Unspecified,544257.0,2099.0,,,Intrinsic activation of human ERalpha expressed in human U2-OS cells at 1 uM by luciferase reporter gene assay relative to untreated control,Other,23043242.0,
2785,707065,3,5,,103189263,5757,Active,544257.0,2099.0,0.0001,EC50,Activation of ERalpha in human MCF7/2a cells by luciferase reporter gene assay relative to untreated control,Confirmatory,23043242.0,
2786,707066,1,7,,103189263,5757,Unspecified,544257.0,2099.0,,,Intrinsic activation of ERalpha in human MCF7/2a cells at 1 uM by luciferase reporter gene assay relative to untreated control,Other,23043242.0,
2787,707067,1,2,,103189263,5757,Unspecified,,,,,"Selectivity index, ratio of RBA to human recombinant ERalpha to RBA human recombinant ERbeta",Other,23043242.0,
2788,707068,1,7,,103189263,5757,Unspecified,6166154.0,2100.0,,,Displacement of [3H]E2 from human recombinant ERbeta ligand binding domain by hydroxylapatite assay relative to untreated control,Other,23043242.0,
2789,707069,1,7,,103189263,5757,Unspecified,544257.0,2099.0,,,Displacement of [3H]E2 from human recombinant ERalpha ligand binding domain by hydroxylapatite assay relative to untreated control,Other,23043242.0,
2790,707071,1,7,,103189263,5757,Unspecified,6166154.0,2100.0,,,Intrinsic activation of human ERbeta expressed in human U2-OS cells at 1 uM by luciferase reporter gene assay relative to untreated control,Other,23043242.0,
2791,707072,3,5,,103189263,5757,Active,6166154.0,2100.0,1e-05,EC50,Activation of human ERbeta expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control,Confirmatory,23043242.0,
2792,720504,1,1,,56422158,5757,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2793,720508,1,1,,8139865,5757,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2794,720509,1,1,,8139865,5757,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2795,720511,1,1,,8139865,5757,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2796,720516,2,1,,144204699,5757,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2797,720516,2,1,,144209255,5757,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2798,720516,2,1,,144210608,5757,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2799,720532,1,1,,26753050,5757,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2800,720532,1,1,,26753051,5757,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2801,720532,1,1,,29215117,5757,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2802,720532,1,1,,144204699,5757,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2803,720533,1,1,,26753050,5757,Inconclusive,,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2804,720533,1,1,,26753051,5757,Active,,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2805,720533,1,1,,29215117,5757,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2806,720533,1,1,,144204699,5757,Inconclusive,,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2807,720538,1,2,,90341590,5757,Inconclusive,220983390.0,410.0,2.3934,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2808,720542,1,2,,56422158,5757,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2809,720543,1,1,,8139865,5757,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2810,720551,1,2,,56422158,5757,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2811,720552,2,1,,144204699,5757,Active,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2812,720552,2,1,,144209255,5757,Active,269849759.0,7157.0,22.4927,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2813,720552,2,1,,144210608,5757,Active,269849759.0,7157.0,11.7379,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2814,720553,1,2,,56422158,5757,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2815,720554,1,3,,92308287,5757,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2816,720559,1,2,,90341590,5757,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2817,720572,1,2,,90341590,5757,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2818,720573,1,2,,90341590,5757,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2819,720579,2,1,,26753050,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2820,720579,2,1,,26753051,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2821,720579,2,1,,56422158,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2822,720580,1,1,,26753050,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2823,720580,1,1,,26753051,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2824,720580,1,1,,56422158,5757,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2825,720582,1,1,,8139865,5757,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2826,720596,1,1,,8139865,5757,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2827,720634,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2828,720634,2,1,,144209255,5757,Inconclusive,,,61.0063,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2829,720634,2,1,,144210608,5757,Inconclusive,,,61.1306,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2830,720635,2,1,,144204699,5757,Active,,,26.6032,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2831,720635,2,1,,144209255,5757,Active,,,30.5756,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2832,720635,2,1,,144210608,5757,Active,,,17.2289,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2833,720636,1,1,,17389898,5757,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2834,720637,2,1,,144204699,5757,Active,,,26.6032,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2835,720637,2,1,,144209255,5757,Active,,,34.3063,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2836,720637,2,1,,144210608,5757,Active,,,13.6854,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2837,720641,1,2,,92308287,5757,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2838,720641,1,2,,92309094,5757,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2839,720648,1,1,,8139865,5757,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2840,720652,1,1,,17389898,5757,Inconclusive,,,37.578,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2841,720653,1,1,,17389898,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2842,720659,1,1,,17389898,5757,Inconclusive,325495557.0,8856.0,12.5893,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2843,720674,2,2,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2844,720674,2,2,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2845,720674,2,2,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2846,720675,2,2,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2847,720675,2,2,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2848,720675,2,2,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2849,720678,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2850,720678,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2851,720678,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2852,720679,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2853,720679,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2854,720679,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2855,720680,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2856,720680,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2857,720680,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2858,720681,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2859,720681,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2860,720681,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2861,720682,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2862,720682,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2863,720682,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2864,720683,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2865,720683,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2866,720683,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2867,720684,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2868,720684,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2869,720684,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2870,720685,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2871,720685,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2872,720685,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2873,720686,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2874,720686,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2875,720686,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2876,720687,2,2,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2877,720687,2,2,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2878,720687,2,2,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2879,720691,4,1,,144204699,5757,Inconclusive,311348376.0,2908.0,0.0425,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2880,720691,4,1,,144209255,5757,Inconclusive,311348376.0,2908.0,0.2183,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2881,720691,4,1,,144210608,5757,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2882,720692,3,1,,144204699,5757,Active,311348376.0,2908.0,4.2527,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2883,720692,3,1,,144209255,5757,Active,311348376.0,2908.0,2.1827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2884,720692,3,1,,144210608,5757,Inconclusive,311348376.0,2908.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2885,720693,3,1,,144204699,5757,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2886,720693,3,1,,144209255,5757,Active,,,24.4902,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2887,720693,3,1,,144210608,5757,Inconclusive,,,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2888,720700,1,4,,8139865,5757,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2889,720702,1,1,,8139865,5757,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2890,720704,1,4,,8139865,5757,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2891,720706,1,2,,8139865,5757,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2892,720707,1,2,,56422158,5757,Inactive,317373593.0,10411.0,125.89299999999999,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2893,720708,1,2,,56422158,5757,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2894,720709,1,2,,56422158,5757,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2895,720711,1,2,,56422158,5757,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2896,720717,1,3,,92125448,5757,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2897,720717,1,3,,92308287,5757,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2898,720717,1,3,,92309094,5757,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2899,720717,1,3,,92310059,5757,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2900,720719,2,1,,144204699,5757,Inconclusive,311348376.0,2908.0,4.77156,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2901,720719,2,1,,144209255,5757,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2902,720719,2,1,,144210608,5757,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2903,720725,2,1,,144204699,5757,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2904,720725,2,1,,144209255,5757,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2905,720725,2,1,,144210608,5757,Active,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2906,721574,1,2,,103189263,5757,Unspecified,,,,,Estrogenic activity in human MCF7 cells by luciferase reporter gene assay,Other,23237974.0,
2907,728179,1,6,,103189263,5757,Active,215274146.0,2101.0,,,Agonist activity at ERalpha receptor in human HeLa cells assessed as activation of ERalpha-based transcription at 1 nM after 20 to 24 hrs by luciferase reporter gene assay,Other,23448346.0,
2908,728181,1,6,,103189263,5757,Active,215274146.0,2101.0,,,Agonist activity at ERalpha receptor in human MCF7 cells assessed as activation of ERalpha-based transcription at 1 nM after 20 to 24 hrs by luciferase reporter gene assay,Other,23448346.0,
2909,728189,2,5,,103189263,5757,Active,374095385.0,2103.0,0.0087,IC50,Displacement of [3H]E2 from human recombinant ERbeta receptor after overnight incubation by liquid scintillation counting analysis,Confirmatory,23448346.0,
2910,728190,2,5,,103189263,5757,Active,215274146.0,2101.0,0.006,IC50,Displacement of [3H]E2 from human recombinant ERalpha receptor after overnight incubation by liquid scintillation counting analysis,Confirmatory,23448346.0,
2911,736239,2,5,,103189263,5757,Active,6166154.0,2100.0,0.0005,Kd,Binding affinity to human full length estrogen receptor beta by Scatchard plot analysis,Confirmatory,23586645.0,
2912,736240,2,5,,103189263,5757,Active,544257.0,2099.0,0.0002,Kd,Binding affinity to human full length estrogen receptor alpha by Scatchard plot analysis,Confirmatory,23586645.0,
2913,743012,3,1,,144204699,5757,Active,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2914,743012,3,1,,144209255,5757,Inconclusive,,,68.4501,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2915,743012,3,1,,144210608,5757,Active,,,61.1306,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2916,743014,3,1,,144204699,5757,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2917,743014,3,1,,144209255,5757,Active,,,54.3719,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2918,743014,3,1,,144210608,5757,Active,,,54.4827,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2919,743015,3,1,,144204699,5757,Active,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2920,743015,3,1,,144209255,5757,Inconclusive,,,68.4501,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2921,743015,3,1,,144210608,5757,Active,,,54.4827,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2922,743033,3,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2923,743033,3,1,,144209255,5757,Inconclusive,,,38.8144,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2924,743033,3,1,,144210608,5757,Inconclusive,,,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2925,743035,2,1,,144204699,5757,Inconclusive,124375976.0,367.0,0.0674,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2926,743035,2,1,,144209255,5757,Inconclusive,124375976.0,367.0,48.8644,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2927,743035,2,1,,144210608,5757,Inconclusive,124375976.0,367.0,38.8952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2928,743036,2,1,,144204699,5757,Active,124375976.0,367.0,2.1314,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2929,743036,2,1,,144209255,5757,Active,124375976.0,367.0,2.449,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2930,743036,2,1,,144210608,5757,Active,124375976.0,367.0,1.23,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2931,743040,3,1,,144204699,5757,Active,124375976.0,367.0,3.3491,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2932,743040,3,1,,144209255,5757,Active,124375976.0,367.0,1.5324,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2933,743040,3,1,,144210608,5757,Active,124375976.0,367.0,1.3685,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2934,743041,3,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2935,743041,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2936,743041,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2937,743042,3,1,,144204699,5757,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2938,743042,3,1,,144209255,5757,Inconclusive,124375976.0,367.0,76.8023,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2939,743042,3,1,,144210608,5757,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2940,743053,2,1,,144204699,5757,Active,124375976.0,367.0,2.8973,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2941,743053,2,1,,144209255,5757,Active,124375976.0,367.0,2.77116,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2942,743053,2,1,,144210608,5757,Active,124375976.0,367.0,1.7373900000000002,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2943,743054,2,1,,144204699,5757,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2944,743054,2,1,,144209255,5757,Active,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2945,743054,2,1,,144210608,5757,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2946,743063,2,1,,144204699,5757,Active,124375976.0,367.0,0.06007040000000001,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2947,743063,2,1,,144209255,5757,Inconclusive,124375976.0,367.0,41.1143,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2948,743063,2,1,,144210608,5757,Active,124375976.0,367.0,51.8676,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2949,743064,3,1,,144204699,5757,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2950,743064,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2951,743064,3,1,,144210608,5757,Inconclusive,,,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2952,743065,3,1,,144204699,5757,Inconclusive,399498506.0,24831.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2953,743065,3,1,,144209255,5757,Active,399498506.0,24831.0,27.2505,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2954,743065,3,1,,144210608,5757,Active,399498506.0,24831.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2955,743066,3,1,,144204699,5757,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2956,743066,3,1,,144209255,5757,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2957,743066,3,1,,144210608,5757,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2958,743067,2,1,,144204699,5757,Inconclusive,399498506.0,24831.0,25.1151,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2959,743067,2,1,,144209255,5757,Active,399498506.0,24831.0,35.6485,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2960,743067,2,1,,144210608,5757,Inconclusive,399498506.0,24831.0,36.4132,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2961,743069,2,1,,144204699,5757,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2962,743069,2,1,,144209255,5757,Inconclusive,348019627.0,2099.0,38.8144,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2963,743069,2,1,,144210608,5757,Inconclusive,348019627.0,2099.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2964,743074,2,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2965,743074,2,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2966,743074,2,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2967,743075,2,1,,144204699,5757,Active,348019627.0,2099.0,0.0008,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2968,743075,2,1,,144209255,5757,Active,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2969,743075,2,1,,144210608,5757,Active,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2970,743077,2,1,,144204699,5757,Active,348019627.0,2099.0,0.0005147169999999999,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2971,743077,2,1,,144209255,5757,Active,348019627.0,2099.0,0.001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2972,743077,2,1,,144210608,5757,Active,348019627.0,2099.0,0.001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2973,743078,2,1,,144204699,5757,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2974,743078,2,1,,144209255,5757,Inconclusive,348019627.0,2099.0,23.1202,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2975,743078,2,1,,144210608,5757,Inconclusive,348019627.0,2099.0,21.8724,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2976,743079,3,1,,144204699,5757,Active,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2977,743079,3,1,,144209255,5757,Active,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2978,743079,3,1,,144210608,5757,Active,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2979,743080,3,1,,144204699,5757,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2980,743080,3,1,,144209255,5757,Active,348019627.0,2099.0,61.0063,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2981,743080,3,1,,144210608,5757,Inconclusive,348019627.0,2099.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2982,743081,3,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2983,743081,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2984,743081,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2985,743083,3,1,,144204699,5757,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2986,743083,3,1,,144209255,5757,Inconclusive,119597822.0,1588.0,43.1891,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2987,743083,3,1,,144210608,5757,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2988,743084,3,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2989,743084,3,1,,144209255,5757,Inconclusive,,,61.0063,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2990,743084,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2991,743085,3,1,,144204699,5757,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2992,743085,3,1,,144209255,5757,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2993,743085,3,1,,144210608,5757,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2994,743086,3,1,,144204699,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2995,743086,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2996,743086,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2997,743091,2,1,,144204699,5757,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2998,743091,2,1,,144209255,5757,Active,348019627.0,2099.0,65.873,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2999,743091,2,1,,144210608,5757,Inconclusive,348019627.0,2099.0,61.1306,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3000,743094,3,1,,144204699,5757,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3001,743094,3,1,,144209255,5757,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3002,743094,3,1,,144210608,5757,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3003,743122,2,1,,144204699,5757,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3004,743122,2,1,,144209255,5757,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3005,743122,2,1,,144210608,5757,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3006,743126,1,1,,8139865,5757,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3007,743139,2,1,,144204699,5757,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3008,743139,2,1,,144209255,5757,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3009,743139,2,1,,144210608,5757,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3010,743140,2,1,,144204699,5757,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3011,743140,2,1,,144209255,5757,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3012,743140,2,1,,144210608,5757,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3013,743191,3,1,,144209255,5757,Inconclusive,216409692.0,5468.0,21.8269,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3014,743191,3,1,,144210608,5757,Inconclusive,216409692.0,5468.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3015,743194,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3016,743194,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3017,743199,2,1,,144209255,5757,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3018,743199,2,1,,144210608,5757,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3019,743202,4,1,,144209255,5757,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3020,743202,4,1,,144210608,5757,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3021,743203,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3022,743203,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3023,743205,1,1,,90341590,5757,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3024,743205,1,1,,90341590,5757,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3025,743206,1,1,,90341590,5757,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3026,743206,1,1,,90341590,5757,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3027,743207,1,1,,90341590,5757,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3028,743207,1,1,,90341590,5757,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3029,743209,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3030,743209,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3031,743210,4,1,,144209255,5757,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3032,743210,4,1,,144210608,5757,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3033,743211,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3034,743211,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3035,743212,3,1,,144209255,5757,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3036,743212,3,1,,144210608,5757,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3037,743213,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3038,743213,3,1,,144210608,5757,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3039,743215,3,1,,144209255,5757,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3040,743215,3,1,,144210608,5757,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3041,743217,3,1,,144209255,5757,Inconclusive,325495553.0,9971.0,27.4785,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3042,743217,3,1,,144210608,5757,Inconclusive,325495553.0,9971.0,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3043,743218,3,1,,144209255,5757,Inconclusive,,,5.4827,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3044,743218,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3045,743219,3,1,,144209255,5757,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3046,743219,3,1,,144210608,5757,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3047,743220,3,1,,144209255,5757,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3048,743220,3,1,,144210608,5757,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3049,743221,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3050,743221,3,1,,144210608,5757,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3051,743222,3,1,,144209255,5757,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3052,743222,3,1,,144210608,5757,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3053,743223,3,1,,144209255,5757,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3054,743223,3,1,,144210608,5757,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3055,743224,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3056,743224,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3057,743225,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3058,743225,3,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3059,743226,2,1,,144209255,5757,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3060,743226,2,1,,144210608,5757,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3061,743227,2,1,,144209255,5757,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3062,743227,2,1,,144210608,5757,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3063,743228,3,1,,144209255,5757,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3064,743228,3,1,,144210608,5757,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3065,743238,1,1,,8139865,5757,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3066,743239,2,1,,144209255,5757,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3067,743239,2,1,,144210608,5757,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3068,743240,2,1,,144209255,5757,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3069,743240,2,1,,144210608,5757,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3070,743241,2,1,,144209255,5757,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3071,743241,2,1,,144210608,5757,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3072,743242,2,1,,144209255,5757,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3073,743242,2,1,,144210608,5757,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3074,743244,1,1,,90341590,5757,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3075,743244,1,1,,144204699,5757,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3076,743247,1,2,,8139865,5757,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3077,743255,1,1,,56422158,5757,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3078,743266,1,2,,56422158,5757,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3079,743268,1,1,,172080181,5757,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3080,743269,1,1,,8139865,5757,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3081,743269,1,1,,8139865,5757,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3082,743270,1,1,,172080181,5757,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3083,743271,1,1,,172080181,5757,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3084,743272,1,1,,172080181,5757,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3085,743279,1,2,,56422158,5757,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3086,743288,1,1,,17389898,5757,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3087,743292,1,1,,17389898,5757,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3088,743397,1,1,,8139865,5757,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3089,743398,1,1,,8139865,5757,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3090,747467,2,3,,103189263,5757,Active,6166154.0,2100.0,0.00105,EC50,Agonist activity at human estrogen receptor-beta by yeast two-hybrid assay in presence of SRC1,Confirmatory,23608764.0,
3091,747468,2,3,,103189263,5757,Active,544257.0,2099.0,0.00108,EC50,Agonist activity at human estrogen receptor-alpha by yeast two-hybrid assay in presence of SRC1,Confirmatory,23608764.0,
3092,756452,1,1,,103189263,5757,Unspecified,,,,,Agonist activity at estrogen receptor in mouse HC11 cells at 10 nM after 24 hrs by luciferase reporter gene assay,Other,23735829.0,
3093,759300,1,1,,103189263,5757,Inconclusive,,,,IC50,Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23786452.0,
3094,759301,1,1,,103189263,5757,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23786452.0,
3095,759307,1,5,,103189263,5757,Unspecified,544257.0,2099.0,,,Agonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells at 10 uM after 40 hrs by luciferase reporter gene assay relative to control,Other,23786452.0,
3096,759309,1,1,,103189263,5757,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23786452.0,
3097,759311,1,1,,103189263,5757,Inconclusive,,,,IC50,Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23786452.0,
3098,769552,2,3,,103189263,5757,Active,3023539.0,2852.0,0.0057,Ki,Inhibition of estrogen binding to GPR30 (unknown origin),Confirmatory,23672690.0,
3099,769553,3,1,,103189263,5757,Active,3023539.0,2852.0,0.0003,EC50,Agonist activity at GPR30 (unknown origin) by calcium mobilization assay,Confirmatory,23672690.0,
3100,927191,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
3101,927192,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
3102,927193,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
3103,927194,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
3104,927195,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
3105,927196,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
3106,927197,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
3107,927198,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
3108,927199,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
3109,927200,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
3110,927201,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
3111,927202,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
3112,927203,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
3113,927204,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
3114,927833,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
3115,927834,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
3116,927835,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
3117,927836,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
3118,927837,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
3119,928776,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
3120,928777,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
3121,928778,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
3122,928779,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
3123,928780,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
3124,928781,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
3125,928782,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
3126,928783,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
3127,928784,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
3128,928785,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
3129,928786,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
3130,928787,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
3131,928788,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
3132,928789,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
3133,928790,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
3134,928791,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
3135,928792,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
3136,928793,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
3137,928794,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
3138,939030,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
3139,939031,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
3140,939032,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
3141,939033,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
3142,939034,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
3143,939035,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
3144,939036,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
3145,939037,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
3146,939038,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
3147,939039,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
3148,939040,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
3149,939041,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
3150,939042,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
3151,939043,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
3152,939044,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
3153,939045,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
3154,939046,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
3155,939047,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
3156,939048,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
3157,939049,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
3158,939050,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
3159,939051,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
3160,939052,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
3161,939053,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
3162,941701,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
3163,941702,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
3164,941703,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
3165,941704,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
3166,941705,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
3167,941706,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
3168,941707,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
3169,941708,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
3170,941709,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
3171,941710,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
3172,941711,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
3173,941712,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
3174,941713,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
3175,941714,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
3176,960700,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3177,960701,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3178,960702,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3179,960703,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3180,966058,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3181,966059,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3182,966060,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3183,966061,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3184,966062,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3185,966063,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3186,966064,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3187,966065,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3188,966066,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3189,966067,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3190,966068,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3191,966069,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3192,966070,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3193,966503,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3194,966504,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3195,967129,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3196,967130,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3197,967131,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3198,967132,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3199,967133,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3200,967134,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3201,967135,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3202,967136,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3203,967137,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3204,967768,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3205,967769,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3206,967770,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3207,967771,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3208,967772,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3209,967773,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3210,967774,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3211,967775,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3212,967776,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3213,967777,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3214,970078,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3215,970079,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3216,970710,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3217,970711,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3218,970712,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3219,970713,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3220,970714,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3221,970715,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3222,970716,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3223,970717,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3224,970718,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3225,972740,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3226,972741,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3227,972742,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3228,972743,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3229,972744,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3230,972745,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3231,972746,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3232,972747,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3233,972748,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3234,972749,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3235,972750,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3236,972751,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3237,972752,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3238,972753,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3239,972754,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3240,972755,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3241,972756,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3242,972757,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3243,972758,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3244,972759,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3245,972760,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3246,972761,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3247,972762,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3248,972763,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3249,972764,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3250,972765,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3251,972766,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3252,977599,1,1,,103189263,5757,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3253,977602,1,2,,103189263,5757,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3254,977608,3,1,,208012019,5757,Active,,,0.0017,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,15456246.0,
3255,977610,3,1,,46394036,5757,Active,82408297.0,,83.2,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,16221673.0,
3256,977610,3,1,,208011806,5757,Active,,,0.000138,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,9216828.0,
3257,977611,3,1,,46392276,5757,Active,16975338.0,,0.002,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,11451948.0,
3258,977611,3,1,,46392276,5757,Active,16975339.0,,0.002,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,11451948.0,
3259,977611,3,1,,46393010,5757,Active,10120873.0,,0.0009199999999999999,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,,
3260,977611,3,1,,53812544,5757,Active,10120874.0,,0.00026000000000000003,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,11278577.0,
3261,977611,3,1,,208011870,5757,Active,,,0.53,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,15771445.0,
3262,977611,3,1,,208011873,5757,Active,,,0.00148,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,18330978.0,
3263,990566,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011113",Other,,
3264,990567,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011113",Other,,
3265,990568,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011113,Other,,
3266,990569,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3267,990570,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011113",Other,,
3268,990571,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011113",Other,,
3269,990572,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011113",Other,,
3270,990573,1,4,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: S011113",Other,,
3271,990574,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011113,Other,,
3272,990575,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3273,990576,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011113",Other,,
3274,990577,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3275,990578,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3276,990579,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3277,990580,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011113",Other,,
3278,990581,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011113",Other,,
3279,992415,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3280,992416,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011113",Other,,
3281,992996,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3282,992997,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3283,992998,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011113",Other,,
3284,992999,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3285,993000,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011113",Other,,
3286,993001,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011113",Other,,
3287,993002,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011113",Other,,
3288,993003,1,4,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Nuclear Proliferation; Study_ID: S011113",Other,,
3289,993004,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011113,Other,,
3290,993005,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011113,Other,,
3291,993006,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011113",Other,,
3292,993007,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3293,993008,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3294,993009,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011113",Other,,
3295,993010,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011113",Other,,
3296,993011,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011113",Other,,
3297,993012,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011113",Other,,
3298,993013,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011113",Other,,
3299,993014,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011113,Other,,
3300,993015,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011113",Other,,
3301,993016,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3302,993017,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3303,993018,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3304,993019,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011113",Other,,
3305,993020,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011113,Other,,
3306,993021,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3307,993022,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011113",Other,,
3308,993023,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011113",Other,,
3309,993024,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011113,Other,,
3310,993025,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011113",Other,,
3311,993026,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011113",Other,,
3312,993027,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3313,993028,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011113",Other,,
3314,993029,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011113",Other,,
3315,993030,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011113",Other,,
3316,993031,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011113",Other,,
3317,993032,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011113",Other,,
3318,993033,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011113",Other,,
3319,994230,1,4,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: S011113",Other,,
3320,994231,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011113,Other,,
3321,994232,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3322,994233,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011113",Other,,
3323,994234,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011113",Other,,
3324,994235,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011113",Other,,
3325,994236,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3326,994237,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3327,994815,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011113",Other,,
3328,994816,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011113",Other,,
3329,994817,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011113",Other,,
3330,994818,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011113",Other,,
3331,994819,1,4,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: S011113",Other,,
3332,994820,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011113,Other,,
3333,994821,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011113",Other,,
3334,994822,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011113,Other,,
3335,994823,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011113",Other,,
3336,994824,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3337,994825,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011113",Other,,
3338,994826,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011113",Other,,
3339,994827,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3340,994828,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011113",Other,,
3341,994829,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3342,994830,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011113",Other,,
3343,994831,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011113",Other,,
3344,994832,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3345,994833,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011113",Other,,
3346,994834,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3347,994835,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3348,994836,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3349,994837,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3350,994838,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3351,1019170,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3352,1019171,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011113",Other,,
3353,1019172,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011113",Other,,
3354,1019173,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011113",Other,,
3355,1019174,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3356,1019175,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3357,1019176,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011113,Other,,
3358,1019177,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011113",Other,,
3359,1019178,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011113,Other,,
3360,1019179,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011113",Other,,
3361,1019180,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3362,1019181,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011113",Other,,
3363,1019182,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011113",Other,,
3364,1019183,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3365,1019184,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011113",Other,,
3366,1019185,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011113",Other,,
3367,1019186,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3368,1019187,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3369,1019188,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3370,1019189,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3371,1019190,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3372,1019191,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3373,1019192,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3374,1021061,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3375,1021062,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011113",Other,,
3376,1021063,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3377,1021064,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3378,1021065,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011113",Other,,
3379,1021066,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3380,1021067,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011113,Other,,
3381,1021068,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011113,Other,,
3382,1021069,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011113",Other,,
3383,1021070,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3384,1021071,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3385,1021072,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011113",Other,,
3386,1021656,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011113,Other,,
3387,1021657,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3388,1021658,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3389,1021659,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3390,1021660,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011113",Other,,
3391,1021661,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011113",Other,,
3392,1021662,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011113,Other,,
3393,1021663,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3394,1021664,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011113",Other,,
3395,1021665,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011113",Other,,
3396,1021666,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3397,1021667,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011113",Other,,
3398,1021668,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011113",Other,,
3399,1021669,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011113",Other,,
3400,1021670,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011113,Other,,
3401,1021671,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3402,1021672,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011113",Other,,
3403,1021673,1,3,,103189263,5757,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011113,Other,,
3404,1021674,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3405,1021675,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011113",Other,,
3406,1021676,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3407,1021677,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3408,1021678,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3409,1021679,1,3,,103189263,5757,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011113",Other,,
3410,1053197,1,1,,8139865,5757,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3411,1061128,2,3,,103189263,5757,Active,6166154.0,2100.0,4.6e-05,IC50,Antagonist activity at ERbeta (unknown origin) by cell-based assay,Confirmatory,24315190.0,
3412,1061130,2,3,,103189263,5757,Active,544257.0,2099.0,0.0013,IC50,Agonist activity at ERalpha (unknown origin) by cell-based assay,Confirmatory,24315190.0,
3413,1061131,2,3,,103189263,5757,Active,544257.0,2099.0,0.003,Kd,Displacement of fluorescein-labeled ES2 from human recombinant ERalpha receptor after 2 hrs by fluorescence polarization assay,Confirmatory,24315190.0,
3414,1061132,1,4,,103189263,5757,Inactive,544257.0,2099.0,,,Antagonist activity at ERalpha (unknown origin) assessed as inhibition of E2-induced receptor activation after 22 hrs by cell-based luciferase reporter gene assay,Other,24315190.0,
3415,1061133,2,3,,103189263,5757,Inactive,6166154.0,2100.0,,IC50,Antagonist activity at ERbeta (unknown origin) assessed as inhibition of E2-induced receptor activation after 22 hrs by cell-based luciferase reporter gene assay,Confirmatory,24315190.0,
3416,1077856,1,2,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for ER-alpha (unknown origin) to EC50 for ER-beta (unknown origin),Other,,
3417,1077858,2,3,,103189263,5757,Active,6166154.0,2100.0,3.98e-05,EC50,Agonist activity at ER-beta (unknown origin) transfected in HEK293T cells after 24 hrs by Steady-Glo luciferase reporter gene assay,Confirmatory,,
3418,1077859,2,3,,103189263,5757,Active,544257.0,2099.0,0.0001,EC50,Agonist activity at ER-alpha (unknown origin) transfected in HEK293T cells after 24 hrs by Steady-Glo luciferase reporter gene assay,Confirmatory,,
3419,1079708,1,2,,103189263,5757,Unspecified,,,,,Estrogenic activity in human MCF7 cells assessed as cell proliferation at 0.1 nM by MTS assay relative to basal level,Other,,
3420,1079709,1,2,,103189263,5757,Unspecified,,,,,Estrogenic activity in human Saos2 cells assessed as increase in alkaline phosphatase activity at 1 nM,Other,,
3421,1079710,1,2,,103189263,5757,Unspecified,,,,,Estrogenic activity in human Saos2 cells assessed as cell proliferation at 1 uM,Other,,
3422,1079931,1,1,,103189263,5757,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3423,1079932,1,1,,103189263,5757,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3424,1079933,1,1,,103189263,5757,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3425,1079934,1,1,,103189263,5757,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3426,1079935,1,1,,103189263,5757,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3427,1079936,1,1,,103189263,5757,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3428,1079937,1,1,,103189263,5757,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3429,1079938,1,1,,103189263,5757,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3430,1079939,1,1,,103189263,5757,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3431,1079940,1,1,,103189263,5757,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3432,1079941,1,1,,103189263,5757,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3433,1079942,1,1,,103189263,5757,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3434,1079943,1,1,,103189263,5757,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3435,1079944,1,1,,103189263,5757,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3436,1079945,1,1,,103189263,5757,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3437,1079946,1,1,,103189263,5757,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3438,1079947,1,1,,103189263,5757,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3439,1079948,1,1,,103189263,5757,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3440,1079949,1,1,,103189263,5757,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3441,1096272,1,2,,103189263,5757,Inactive,,,,,Growth inhibition of Homo sapiens (human) MCF-7 cell growth at 10'-6 M after 48 hr by MTT assay,Other,,
3442,1096273,1,2,,103189263,5757,Unspecified,,,,,Induction of Homo sapiens (human) MCF7 cell growth at 10'-6 M after 48 hr by MTT assay,Other,,
3443,1096274,1,2,,103189263,5757,Unspecified,,,,,Growth inhibition of Homo sapiens (human) MCF-7 cells at 10'-12 to 10'-7 M after 48 hr by MTT assay,Other,,
3444,1096276,1,2,,103189263,5757,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HT-29 cells at 10'-12 to 10'-6 M after 48 hr by MTT assay,Other,,
3445,1096280,1,2,,103189263,5757,Active,,,,,Growth inhibition of Homo sapiens (human) MDA-MB-231 cells at 10'-12 to 10'-6 M after 48 hr by MTT assay,Other,,
3446,1117319,1,2,,8139865,5757,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3447,1117319,1,2,,8139865,5757,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3448,1120280,1,1,,103189263,5757,Unspecified,,,,,Induction of rat UMR106 cell proliferation after 24 hrs by MTS assay,Other,,
3449,1120282,1,1,,103189263,5757,Active,,,,,Induction of rat UMR106 cell proliferation assessed as increase in cell number at 10'-8 M after 24 hrs by MTS assay,Other,,
3450,1120283,1,1,,103189263,5757,Inactive,,,,,"Induction of rat UMR106 cell proliferation at 10'-8 M after 24 hrs by MTS assay in presence of estrogen receptor antagonist ICI 182,780",Other,,
3451,1120286,1,1,,103189263,5757,Active,,,,,Induction of rat UMR106 cell differentiation at 10'-8 M after 24 hrs by ALP assay relative to control,Other,,
3452,1120288,1,1,,103189263,5757,Active,,,,,"Induction of rat UMR106 cell differentiation after 24 hrs by ALP assay in presence of estrogen receptor antagonist ICI 182,780",Other,,
3453,1120289,1,3,,103189263,5757,Active,544257.0,2099.0,,,Transactivation of human ER-alpha transfected in rat UMR106 cells at 10'-8 M after 24 hrs by dual luciferase reporter gene assay,Other,,
3454,1120290,1,3,,103189263,5757,Active,6166154.0,2100.0,,,Transactivation of human ER-beta transfected in rat UMR106 cells at 10'-8 M after 24 hrs by dual luciferase reporter gene assay,Other,,
3455,1152694,3,2,,103189263,5757,Unspecified,544257.0,2099.0,,EC50,Agonist activity at ER in human MCF7:WS8 cells assessed as increase in cell growth by measuring DNA level after 7 days by fluorescence analysis,Confirmatory,24805199.0,
3456,1152702,1,3,,103189263,5757,Unspecified,119600.0,24890.0,,,Agonist activity at ER in rat GH3 cells assessed as increase in prolactin mRNA level after 48 hrs by RT-PCR analysis,Other,24805199.0,
3457,1152706,1,3,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at ER in human MCF7:WS8 cells assessed as increase in pS2 gene expression at 10'-10 M after 48 hrs by RT-PCR analysis,Other,24805199.0,
3458,1152707,1,3,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at ER in human MCF7:WS8 cells assessed as increase in GREB1 gene expression at 10'-10 M after 48 hrs by RT-PCR analysis,Other,24805199.0,
3459,1152708,1,3,,103189263,5757,Active,544257.0,2099.0,,,Agonist activity at ER in human MCF7:WS8 cells assessed as increase in PgR gene expression at 10'-10 M after 48 hrs by RT-PCR analysis,Other,24805199.0,
3460,1152715,1,1,,103189263,5757,Unspecified,,,,,Effect on ER-alpha protein level in human MCF7:WS8 cells at 1 nM after 24 hrs by Western blot analysis,Other,24805199.0,
3461,1152716,1,1,,103189263,5757,Unspecified,,,,,Effect on ER-alpha protein level in human MCF7:WS8 cells after 24 hrs by Western blot analysis relative to control,Other,24805199.0,
3462,1159387,1,2,,103189263,5757,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3463,1159509,1,1,,144209255,5757,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3464,1159509,1,1,,144210608,5757,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3465,1159515,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3466,1159515,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3467,1159516,1,1,,144209255,5757,Inconclusive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3468,1159516,1,1,,144210608,5757,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3469,1159517,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3470,1159517,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3471,1159518,1,1,,144209255,5757,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3472,1159518,1,1,,144210608,5757,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3473,1159519,1,1,,144209255,5757,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3474,1159519,1,1,,144210608,5757,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3475,1159520,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3476,1159520,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3477,1159521,1,1,,144209255,5757,Inconclusive,15928672.0,19885.0,38.4923,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3478,1159521,1,1,,144210608,5757,Active,15928672.0,19885.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3479,1159523,1,1,,144209255,5757,Inconclusive,15928672.0,19885.0,43.1891,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3480,1159523,1,1,,144210608,5757,Active,15928672.0,19885.0,40.0798,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3481,1159524,1,1,,26753050,5757,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3482,1159524,1,1,,26753051,5757,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3483,1159524,1,1,,56422158,5757,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3484,1159525,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3485,1159525,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3486,1159526,1,1,,144209255,5757,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3487,1159526,1,1,,144210608,5757,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3488,1159527,1,1,,144209255,5757,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3489,1159527,1,1,,144210608,5757,Inconclusive,325495497.0,6256.0,4.3641,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3490,1159528,1,1,,144209255,5757,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3491,1159528,1,1,,144210608,5757,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3492,1159529,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3493,1159529,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3494,1159531,1,1,,144209255,5757,Inconclusive,325495497.0,6256.0,24.4902,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3495,1159531,1,1,,144210608,5757,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3496,1159550,3,1,,252402126,5757,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3497,1159551,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3498,1159551,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3499,1159552,1,1,,144209255,5757,Inconclusive,325495463.0,5914.0,15.3241,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3500,1159552,1,1,,144210608,5757,Inconclusive,325495463.0,5914.0,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3501,1159553,2,1,,144209255,5757,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3502,1159553,2,1,,144210608,5757,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3503,1159555,1,1,,144209255,5757,Inconclusive,325495463.0,5914.0,15.3241,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3504,1159555,1,1,,144210608,5757,Active,325495463.0,5914.0,10.2626,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3505,1159580,2,1,,268738127,5757,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3506,1159606,1,1,,56422158,5757,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3507,1159607,2,1,,312309814,5757,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3508,1159620,1,1,,103189263,5757,Active,,,,,Summary of drug indications.,Other,,
3509,1164490,1,1,,103189263,5757,Active,,,27.35,IC50,Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay,Confirmatory,25222876.0,
3510,1164491,1,1,,103189263,5757,Active,,,33.46,IC50,Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay,Confirmatory,25222876.0,
3511,1164492,1,1,,103189263,5757,Active,,,39.81,IC50,Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay,Confirmatory,25222876.0,
3512,1164493,1,1,,103189263,5757,Active,,,42.93,IC50,Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay,Confirmatory,25222876.0,
3513,1164494,1,1,,103189263,5757,Unspecified,,,100.0,IC50,Antiproliferative activity against CHO cells after 2 days by MTT assay,Confirmatory,25222876.0,
3514,1164495,1,1,,103189263,5757,Unspecified,,,100.0,IC50,Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay,Confirmatory,25222876.0,
3515,1167634,1,1,,103189263,5757,Unspecified,,,,,Blood brain permeability of the compound at donor and acceptor by PAMPA assay,Other,25282654.0,
3516,1168711,1,2,,103189263,5757,Active,544257.0,2099.0,2.4e-05,EC50,Agonist activity at human ERalpha expressed in HEK293 cells by luciferase reporter gene assay,Confirmatory,25305688.0,
3517,1168712,1,2,,103189263,5757,Active,6166154.0,2100.0,8.499999999999999e-05,EC50,Agonist activity at human ERbeta expressed in HEK293 cells by luciferase reporter gene assay,Confirmatory,25305688.0,
3518,1170536,1,1,,103189263,5757,Inconclusive,,,,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25369367.0,
3519,1170537,1,2,,103189263,5757,Active,544257.0,2099.0,0.0057,IC50,Displacement of fluorescein-labeled estrogen from human recombinant ERalpha by fluorescence polarization based competitive binding affinity assay,Confirmatory,25369367.0,
3520,1170538,1,2,,103189263,5757,Active,6166154.0,2100.0,0.0056,IC50,Displacement of fluorescein-labeled estrogen from human recombinant ERbeta by fluorescence polarization based competitive binding affinity assay,Confirmatory,25369367.0,
3521,1183872,1,2,,103189263,5757,Unspecified,544257.0,2099.0,,,Binding affinity to ERalpha (unknown origin) relative to estradiol,Other,25027938.0,
3522,1183873,1,2,,103189263,5757,Unspecified,6166154.0,2100.0,,,Binding affinity to ERbeta (unknown origin) relative to estradiol,Other,25027938.0,
3523,1190185,1,1,,103189263,5757,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25542589.0,
3524,1196500,1,2,,103189263,5757,Active,544257.0,2099.0,0.00016,EC50,Agonist activity at human ERalpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay,Confirmatory,25559213.0,
3525,1196501,1,2,,103189263,5757,Unspecified,544257.0,2099.0,,,Agonist activity at human ERalpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay relative to estradiol,Other,25559213.0,
3526,1196502,1,2,,103189263,5757,Active,6166154.0,2100.0,0.00037999999999999997,EC50,Agonist activity at human ERbeta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay,Confirmatory,25559213.0,
3527,1196503,1,2,,103189263,5757,Unspecified,6166154.0,2100.0,,,Agonist activity at human ERbeta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay relative to estradiol,Other,25559213.0,
3528,1196504,1,1,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for human ERbeta in to EC50 for human ERalpha in ERE-luciferase reporter gene transfection assay,Other,25559213.0,
3529,1196505,1,1,,103189263,5757,Unspecified,,,,,Selectivity ratio of RTP for human ERbeta in to RTP for human ERalpha in ERE-luciferase reporter gene transfection assay,Other,25559213.0,
3530,1196506,1,2,,103189263,5757,Active,544257.0,2099.0,8.400000000000001e-06,EC50,Agonist activity at human ERalpha in human MCF7 cells assessed as progesterone receptor endogenous genes activation after 24 hrs by qPCR,Confirmatory,25559213.0,
3531,1196507,1,2,,103189263,5757,Unspecified,544257.0,2099.0,,,Agonist activity at human ERalpha in human MCF7 cells assessed as progesterone receptor endogenous genes activation after 24 hrs by qPCR relative to estradiol,Other,25559213.0,
3532,1196508,1,2,,103189263,5757,Active,6166154.0,2100.0,0.0003,EC50,Agonist activity at human ERbeta in human MCF7 cells assessed as otubain 2 endogenous genes activation after 24 hrs by qPCR,Confirmatory,25559213.0,
3533,1196509,1,2,,103189263,5757,Unspecified,6166154.0,2100.0,,,Agonist activity at human ERbeta in human MCF7 cells assessed as otubain 2 endogenous genes activation after 24 hrs by qPCR relative to estradiol,Other,25559213.0,
3534,1196510,1,1,,103189263,5757,Unspecified,,,,,Selectivity ratio of EC50 for human ERbeta in to EC50 for human ERalpha in endogenous genes activation after 24 hrs by qPCR,Other,25559213.0,
3535,1196511,1,1,,103189263,5757,Unspecified,,,,,Selectivity ratio of RTP for human ERbeta in to RTP for human ERalpha in endogenous genes activation after 24 hrs by qPCR,Other,25559213.0,
3536,1198140,1,1,,103189263,5757,Unspecified,,,,,Permeability of the compound in PBS and EtOH by PAMPA method,Other,25656088.0,
3537,1200946,1,1,,103189263,5757,Unspecified,,,,,Estrogenic activity in human T47D cells assessed as cell proliferation at 0.1 uM incubated for 7 days with replacement of media in every 2 days by CellTitre-Glo assay,Other,25728028.0,
3538,1200947,1,1,,103189263,5757,Unspecified,,,,,Estrogenic activity in human T47D cells assessed as cell proliferation at 0.5 uM incubated for 7 days with replacement of media in every 2 days by CellTitre-Glo assay,Other,25728028.0,
3539,1201746,1,1,,103189263,5757,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25812965.0,
3540,1201747,1,1,,103189263,5757,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25812965.0,
3541,1207648,1,2,,103189263,5757,Unspecified,308153651.0,775.0,50.0,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
3542,1210064,1,1,,103189263,5757,Active,,,1.9,EC50,Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method,Confirmatory,22815312.0,
3543,1210065,1,1,,103189263,5757,Unspecified,,,,,Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method relative to untreated control,Other,22815312.0,
3544,1210066,1,2,,103189263,5757,Active,117205.0,1555.0,4.1,EC50,Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method,Confirmatory,22815312.0,
3545,1210067,1,2,,103189263,5757,Unspecified,117205.0,1555.0,,,Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method relative to untreated control,Other,22815312.0,
3546,1210791,1,2,,103189263,5757,Active,215273968.0,316.0,0.87,Ki,Competitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as free enzyme by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
3547,1210792,1,2,,103189263,5757,Active,215273968.0,316.0,4.4,Ki,Uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate assessed as enzyme-substrate complex by Lineweaver-Burk plot analysis,Confirmatory,22996261.0,
3548,1210793,1,2,,103189263,5757,Unspecified,215273968.0,316.0,,,Ratio of Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase to Ki for competitive inhibition of human liver cytosolic aldehyde oxidase,Other,22996261.0,
3549,1210796,1,2,,103189263,5757,Unspecified,215273968.0,316.0,,,Selectivity ratio Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase using DACA as substrate to Ki for uncompetitive inhibition of human liver cytosolic aldehyde oxidase using phthalazine as substrate,Other,22996261.0,
3550,1222377,1,2,,103189263,5757,Unspecified,313104286.0,6817.0,,Km,Activity of human SULT1A1 expressed in Escherichia coli at 20 uM by Michaelis-Menten equation analysis,Confirmatory,22593037.0,
3551,1222378,1,2,,103189263,5757,Active,313104286.0,6817.0,0.36,Km,Activity of human SULT1A1 expressed in Escherichia coli at 20 uM by Michaelis-Menten equation analysis in presence of PAPS,Confirmatory,22593037.0,
3552,1222381,1,2,,103189263,5757,Active,313104286.0,6817.0,2.3,Kd,Binding affinity to human SULT1A1 expressed in Escherichia coli assessed as change in intrinsic fluorescence,Confirmatory,22593037.0,
3553,1222382,1,2,,103189263,5757,Active,313104286.0,6817.0,1.2,Kd,"Binding affinity to human SULT1A1 expressed in Escherichia coli assessed as change in intrinsic fluorescence in presence of 3',5'-phosphoadenosine",Confirmatory,22593037.0,
3554,1222387,1,2,,103189263,5757,Active,1711604.0,6783.0,0.004,Km,Activity of SULT1E1 (unknown origin),Confirmatory,22593037.0,
3555,1222795,1,2,,103189263,5757,Unspecified,296452854.0,10941.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2A1-mediated estradiol-3-glucuronide/estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3556,1222796,1,2,,103189263,5757,Unspecified,296452854.0,10941.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2A2-mediated estradiol-3-glucuronide/estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3557,1222797,1,2,,103189263,5757,Unspecified,332278237.0,7366.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B15-mediated estradiol-3-glucuronide/estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3558,1222800,1,2,,103189263,5757,Unspecified,6175083.0,7363.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B4-mediated estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3559,1222801,1,2,,103189263,5757,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B7-mediated estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3560,1222803,1,2,,103189263,5757,Unspecified,6136104.0,7367.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B17-mediated estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3561,1222806,1,1,,103189263,5757,Unspecified,,,,,Drug metabolism assessed as human UGT1A10 F93G mutant-mediated estradiol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3562,1222840,1,2,,103189263,5757,Unspecified,136729.0,54658.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A1-mediated estradiol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3563,1222841,1,2,,103189263,5757,Unspecified,549152.0,54659.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A3-mediated estradiol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3564,1222842,1,2,,103189263,5757,Unspecified,29839637.0,54576.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A8-mediated estradiol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3565,1222844,1,2,,103189263,5757,Unspecified,136731.0,54657.0,,,Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A4-mediated estradiol-17-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA,Other,23288867.0,
3566,1224818,1,1,,312344628,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3567,1224819,1,1,,312344628,5757,Inconclusive,325495545.0,2101.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3568,1224820,1,1,,312344628,5757,Inactive,325495545.0,2101.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3569,1224821,1,1,,312344628,5757,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3570,1224822,1,1,,312344628,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3571,1224823,1,1,,312344628,5757,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3572,1224834,3,1,,144209255,5757,Active,,,30.5756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3573,1224834,3,1,,144210608,5757,Active,,,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3574,1224835,1,1,,144209255,5757,Active,160794.0,,39.8498,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3575,1224835,1,1,,144210608,5757,Active,160794.0,,79.6407,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3576,1224836,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3577,1224836,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3578,1224837,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3579,1224837,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3580,1224838,1,1,,144209255,5757,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3581,1224838,1,1,,144210608,5757,Inactive,66775687.0,9970.0,6.859,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3582,1224839,1,1,,144209255,5757,Active,66775687.0,9970.0,9.6688,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3583,1224839,1,1,,144210608,5757,Active,66775687.0,9970.0,10.8707,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3584,1224840,3,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3585,1224840,3,1,,144210608,5757,Inconclusive,,,38.5708,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3586,1224841,3,1,,144209255,5757,Inconclusive,325495545.0,2101.0,68.4501,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3587,1224841,3,1,,144210608,5757,Inconclusive,325495545.0,2101.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3588,1224842,3,1,,144209255,5757,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3589,1224842,3,1,,144210608,5757,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3590,1224843,1,1,,144209255,5757,Inconclusive,119601739.0,7253.0,3.8492,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3591,1224843,1,1,,144210608,5757,Inconclusive,119601739.0,7253.0,7.6959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3592,1224844,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3593,1224844,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3594,1224845,1,1,,144209255,5757,Inconclusive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3595,1224845,1,1,,144210608,5757,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3596,1224846,1,1,,144209255,5757,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3597,1224846,1,1,,144210608,5757,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3598,1224847,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3599,1224847,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3600,1224848,3,1,,144209255,5757,Active,325495545.0,2101.0,27.2505,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3601,1224848,3,1,,144210608,5757,Active,325495545.0,2101.0,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3602,1224849,3,1,,144209255,5757,Inactive,325495545.0,2101.0,30.5756,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3603,1224849,3,1,,144210608,5757,Inactive,325495545.0,2101.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3604,1224857,2,1,,312344628,5757,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3605,1224859,2,1,,90341590,5757,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3606,1224863,1,1,,176484349,5757,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3607,1224863,1,1,,176484679,5757,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3608,1224864,1,2,,316935231,5757,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3609,1224865,1,2,,56422158,5757,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3610,1224867,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3611,1224867,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3612,1224868,1,1,,144209255,5757,Active,,,17.3377,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3613,1224868,1,1,,144210608,5757,Active,,,21.8724,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3614,1224869,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3615,1224869,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3616,1224870,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3617,1224870,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3618,1224871,1,1,,144209255,5757,Inconclusive,,,61.5166,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3619,1224871,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3620,1224872,1,1,,144209255,5757,Inconclusive,,,21.8269,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3621,1224872,1,1,,144210608,5757,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3622,1224873,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3623,1224873,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3624,1224874,1,1,,144209255,5757,Active,,,17.3377,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3625,1224874,1,1,,144210608,5757,Active,,,21.8724,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3626,1224875,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3627,1224875,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3628,1224876,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3629,1224876,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3630,1224877,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3631,1224877,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3632,1224878,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3633,1224878,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3634,1224879,1,1,,144209255,5757,Active,,,34.5933,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3635,1224879,1,1,,144210608,5757,Inconclusive,,,38.8952,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3636,1224880,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3637,1224880,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3638,1224881,1,1,,144209255,5757,Inconclusive,,,61.5166,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3639,1224881,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3640,1224882,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3641,1224882,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3642,1224883,1,1,,144209255,5757,Active,,,43.5504,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3643,1224883,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3644,1224884,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3645,1224884,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3646,1224885,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3647,1224885,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3648,1224886,1,1,,144209255,5757,Active,,,19.4533,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3649,1224886,1,1,,144210608,5757,Inconclusive,,,21.8724,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3650,1224887,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3651,1224887,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3652,1224888,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3653,1224888,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3654,1224889,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3655,1224889,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3656,1224890,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3657,1224890,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3658,1224892,1,1,,144209255,5757,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3659,1224892,1,1,,144210608,5757,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3660,1224893,1,1,,144209255,5757,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3661,1224893,1,1,,144210608,5757,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3662,1224894,1,1,,144209255,5757,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3663,1224894,1,1,,144210608,5757,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3664,1224895,1,1,,144209255,5757,Inconclusive,119601739.0,7253.0,5.035480000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3665,1224895,1,1,,144210608,5757,Inconclusive,119601739.0,7253.0,6.475280000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3666,1224896,1,1,,144209255,5757,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3667,1224896,1,1,,144210608,5757,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3668,1224905,2,1,,92309094,5757,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3669,1224905,2,1,,92309094,5757,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3670,1224905,2,1,,121361231,5757,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3671,1224905,2,1,,121361231,5757,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3672,1228242,1,1,,103189263,5757,Active,544257.0,2099.0,,,Induction of estrogen receptor-alpha degradation in human MCF7 cells at 10 nM after 20 hrs by Western blot analysis,Other,25879485.0,
3673,1236032,1,1,,103189263,5757,Active,544257.0,2099.0,0.0009,IC50,Inhibition of estrogen receptor alpha (unknown origin)-SRC1 coactivator interaction incubated for 1 hr by receptor cofactor assay system based method,Confirmatory,26183544.0,
3674,1258858,1,1,,103189263,5757,Active,544257.0,2099.0,0.00021,Ki,"BindingDB_Patents: Binding Assay. The method employed was adapted from the scientific literature and described in detail by Osbourn et al. (1993, Biochemistry, 32, 6229-6236). Recombinant human ERalpha and ERR proteins were purified from transfected Sf9-cells. The in vitro assays involved the use of either ERalpha or ERbeta proteins and [3H]E2, at a fixed concentration of 0.5 nM, as the labeled ligand. Recombinant human ERalpha or ERbeta proteins were dissolved in binding buffer (10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA) and duplicate aliquots were then incubated with [3H]E2 at a final concentration of 0.5 nM, together with a vehicle control (0.4% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 2 h at 25 C., the unbound ligands were removed and the amounts of [3H]E2 bound to either ERalpha or ERbeta proteins were measured.",Confirmatory,,
3675,1258859,1,1,,103189263,5757,Active,6166154.0,2100.0,1.4999999999999999e-05,Ki,"BindingDB_Patents: Binding Assay. The method employed was adapted from the scientific literature and described in detail by Osbourn et al. (1993, Biochemistry, 32, 6229-6236). Recombinant human ERalpha and ERR proteins were purified from transfected Sf9-cells. The in vitro assays involved the use of either ERalpha or ERbeta proteins and [3H]E2, at a fixed concentration of 0.5 nM, as the labeled ligand. Recombinant human ERalpha or ERbeta proteins were dissolved in binding buffer (10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA) and duplicate aliquots were then incubated with [3H]E2 at a final concentration of 0.5 nM, together with a vehicle control (0.4% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 2 h at 25 C., the unbound ligands were removed and the amounts of [3H]E2 bound to either ERalpha or ERbeta proteins were measured.",Confirmatory,,
3676,1258884,1,1,,103189263,5757,Active,544257.0,2099.0,0.00021,Ki,"BindingDB_Patents: Inhibition Assay. The method employed was adapted from the scientific literature and described in detail by Osboum et al. (1993, Biochemistry, 32, 6229-6236). Recombinant human ERalpha and ERbeta proteins were purified from transfected Sf9-cells. The in vitro assays involved the use of either ERalpha or ERbeta proteins and [3H]E2, at a fixed concentration of 0.5 nM, as the labeled ligand. Recombinant human ERalpha or ERbeta proteins were dissolved in binding buffer (10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA) and duplicate aliquots were then incubated with [3H]E2 at a final concentration of 0.5 nM, together with a vehicle control (0.4% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 2 h at 25 C., the unbound ligands were removed and the amounts of [3H]E2 bound to either ERalpha or ERbeta proteins were measured.",Confirmatory,,
3677,1258885,1,1,,103189263,5757,Active,6166154.0,2100.0,1.4999999999999999e-05,Ki,"BindingDB_Patents: Inhibition Assay. The method employed was adapted from the scientific literature and described in detail by Osboum et al. (1993, Biochemistry, 32, 6229-6236). Recombinant human ERalpha and ERbeta proteins were purified from transfected Sf9-cells. The in vitro assays involved the use of either ERalpha or ERbeta proteins and [3H]E2, at a fixed concentration of 0.5 nM, as the labeled ligand. Recombinant human ERalpha or ERbeta proteins were dissolved in binding buffer (10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA) and duplicate aliquots were then incubated with [3H]E2 at a final concentration of 0.5 nM, together with a vehicle control (0.4% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 2 h at 25 C., the unbound ligands were removed and the amounts of [3H]E2 bound to either ERalpha or ERbeta proteins were measured.",Confirmatory,,
3678,1259241,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3679,1259241,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3680,1259242,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3681,1259242,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3682,1259243,1,1,,144209255,5757,Inactive,124375976.0,367.0,4.3189,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3683,1259243,1,1,,144210608,5757,Inactive,124375976.0,367.0,6.859,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3684,1259244,1,1,,144209255,5757,Inconclusive,348019627.0,2099.0,48.458999999999996,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3685,1259244,1,1,,144210608,5757,Inconclusive,348019627.0,2099.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3686,1259247,1,1,,144209255,5757,Inconclusive,124375976.0,367.0,7.68023,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3687,1259247,1,1,,144210608,5757,Inconclusive,124375976.0,367.0,9.68854,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3688,1259248,1,1,,144209255,5757,Active,348019627.0,2099.0,50.3548,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3689,1259248,1,1,,144210608,5757,Active,348019627.0,2099.0,50.4574,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3690,1259310,1,1,,321942377,5757,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3691,1259310,1,1,,332950186,5757,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3692,1259310,1,1,,333473078,5757,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3693,1259313,1,1,,56422158,5757,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3694,1259318,1,1,,8139865,5757,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3695,1259325,1,2,,336955328,5757,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3696,1259344,1,1,,144204699,5757,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3697,1259354,1,1,,348417862,5757,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3698,1259355,1,1,,144204699,5757,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3699,1259356,1,1,,144204699,5757,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3700,1259364,1,1,,144209255,5757,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3701,1259364,1,1,,144210608,5757,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3702,1259365,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3703,1259365,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3704,1259366,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3705,1259366,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3706,1259367,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3707,1259367,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3708,1259368,1,1,,144209255,5757,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3709,1259368,1,1,,144210608,5757,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3710,1259369,1,1,,144209255,5757,Active,109731339.0,2737.0,3.0576,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3711,1259369,1,1,,144210608,5757,Active,109731339.0,2737.0,5.4483,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3712,1259370,2,2,,124658823,5757,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3713,1259370,2,2,,124658823,5757,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3714,1259370,2,2,,124658823,5757,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3715,1259377,1,1,,144209255,5757,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3716,1259377,1,1,,144210608,5757,Active,54288833.0,2100.0,0.0005,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3717,1259378,1,1,,144209255,5757,Inconclusive,54288833.0,2100.0,0.0024,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3718,1259378,1,1,,144210608,5757,Inconclusive,54288833.0,2100.0,0.0022,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3719,1259379,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3720,1259379,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3721,1259380,1,1,,144209255,5757,Active,,,12.1723,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3722,1259380,1,1,,144210608,5757,Active,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3723,1259381,1,1,,144209255,5757,Active,124375976.0,367.0,2.725,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3724,1259381,1,1,,144210608,5757,Active,124375976.0,367.0,2.7306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3725,1259382,1,1,,144209255,5757,Inconclusive,,,15.3241,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3726,1259382,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3727,1259383,1,1,,144209255,5757,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3728,1259383,1,1,,144210608,5757,Active,348019627.0,2099.0,0.0017,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3729,1259384,1,1,,144209255,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3730,1259384,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3731,1259385,1,1,,144209255,5757,Inconclusive,119601739.0,7253.0,54.3719,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3732,1259385,1,1,,144210608,5757,Inconclusive,119601739.0,7253.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3733,1259386,1,1,,144209255,5757,Inconclusive,,,76.8023,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3734,1259386,1,1,,144210608,5757,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3735,1259387,1,1,,144209255,5757,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3736,1259387,1,1,,144210608,5757,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3737,1259388,1,1,,144209255,5757,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3738,1259388,1,1,,144210608,5757,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3739,1259389,1,1,,124658823,5757,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3740,1259390,1,1,,144209255,5757,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3741,1259390,1,1,,144210608,5757,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3742,1259391,1,1,,144209255,5757,Active,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3743,1259391,1,1,,144210608,5757,Active,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3744,1259392,1,1,,144209255,5757,Active,109731339.0,2737.0,3.56485,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3745,1259392,1,1,,144210608,5757,Active,109731339.0,2737.0,5.44827,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3746,1259393,1,1,,144209255,5757,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3747,1259393,1,1,,144210608,5757,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3748,1259394,1,1,,144209255,5757,Active,54288833.0,2100.0,0.001198,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3749,1259394,1,1,,144210608,5757,Active,54288833.0,2100.0,0.00101743,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3750,1259395,1,1,,144209255,5757,Active,119601739.0,7253.0,27.2505,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3751,1259395,1,1,,144210608,5757,Active,119601739.0,7253.0,58.82899999999999,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3752,1259396,1,1,,144209255,5757,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3753,1259396,1,1,,144210608,5757,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3754,1259401,1,1,,144209255,5757,Inconclusive,325495545.0,2101.0,68.4501,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3755,1259401,1,1,,144210608,5757,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3756,1259402,1,1,,144209255,5757,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3757,1259402,1,1,,144210608,5757,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3758,1259403,1,1,,144209255,5757,Active,325495545.0,2101.0,27.2505,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3759,1259403,1,1,,144210608,5757,Inconclusive,325495545.0,2101.0,35.7211,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3760,1259404,1,1,,144209255,5757,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3761,1259404,1,1,,144210608,5757,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3762,1259406,1,1,,363920499,5757,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3763,1259406,1,1,1.0,363920499,5757,Inactive,26638650.0,3778.0,0.0248919,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3764,1259406,1,1,3.0,363920499,5757,Inactive,5031823.0,10242.0,-0.05810459999999999,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3765,1259406,1,1,5.0,363920499,5757,Inactive,160410009.0,389816.0,0.07197769999999999,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3766,1259406,1,1,6.0,363920499,5757,Inactive,26638650.0,3778.0,0.020986599999999998,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3767,1259406,1,1,7.0,363920499,5757,Inactive,4758626.0,3779.0,0.022152,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3768,1259406,1,1,8.0,363920499,5757,Inactive,5031823.0,10242.0,-0.029402099999999997,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3769,1259407,1,1,,363898230,5757,Active,,,,,CCRIS mutagenicity studies,Other,,
3770,1259408,1,1,,363894754,5757,Active,,,,,GENE-TOX mutagenicity studies,Other,,
3771,1259409,1,1,,363898230,5757,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3772,1259410,1,1,,363898230,5757,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
3773,1259411,1,1,,363898230,5757,Active,,,,,CCRIS carcinogenicity studies,Other,,
3774,1259415,1,1,,8139865,5757,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3775,1259416,1,2,,144089058,5757,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3776,1259416,1,2,,340080762,5757,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3777,1259416,1,2,,375190311,5757,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3778,1259421,1,1,,340080762,5757,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3779,1259421,1,1,,375190311,5757,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3780,1259423,1,2,,354780382,5757,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3781,1259423,1,2,,354913739,5757,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3782,1259423,1,2,,355002713,5757,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
